CTCAE_v3_to_v4_Detailed_Conversion_List - Excel

Document Sample
CTCAE_v3_to_v4_Detailed_Conversion_List - Excel Powered By Docstoc
					                             Lead              Lead
Protocol                     Organization Organization
Number     Title             CTEP ID           Name              PI               Current Status
639                          NY045             Montefiore Medical Center
                                                                  Thalidomide Plus Fludarabine for & Treatment
           Randomized Phase II Study of Thalidomide VersusFurman, RichardClosed to AccrualPatients with Chronic Ly
5375                         MD017             Johns Hopkins University Maura Closed to Accrual & Treatment
                                                                 Gillison,
           A Phase I Study of OSI-774 in Combination with Standard Fractionation Radiation Therapy in Patients with Or
5599                         MN026             Mayo Clinic Rochester Philip
                                                                 Philip,          Closed to Accrual & Treatment
           Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 with Docetaxel and Capecitabine f
5633                         OH007             Ohio State University Medical Center
                                                                 Carson, William Active
           A Phase I Study of Sequential Vaccinations with Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM/LFA3) and Vaccinia-
5736       A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin™) in Combination with Bortezomib (PS-341, Ve
                             NY045                               Hochster,        C
                                               Montefiore Medical Center Howard losed to Accrual & Treatment
5785                         PA086             Fox Chase Cancer Center
                                                                 Hudes, Gary      Active
           A Phase I Study of Intravenous CCI-779 in Combination with Bryostatin-1 in Solid Tumors (10038414)
5876                         MN026             Mayo Clinic Rochester Keith
                                                                 Bible,           Active
           Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas
5906                         NY016             Memorial Sloan Kettering Miguel-Angel
                                                                 Perales, Cancer Closed
                                                                                   Multi-Epitope Peptide Vaccine Using GM
           Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients with aCenter to Accrual
5917                         Preoperative Chemotherapy with Kettering Cancer Centerfor Advanced, but Resectable Gast
           An Evaluation of NY016                                Shah, Manish Closed
                                               Memorial Sloan Irinotecan and Cisplatin to Accrual
5926                         NCIMET            National Cancer Morris, Metabolism Branch
                                                                  Tyrosine KinaseClosed toGefitinib (Iressa®) Combined wi
           A Pilot Phase I Dose Escalation Study of the EGFRInstituteJohn         Inhibitor Accrual & Treatment
5941                          of PS-341 Alone Montefiore Medicalwith Irinotecan in PatientsAccrual & Treatment of the G
           A Phase II Study NY045                                Ocean, Allyson Closed to with Adenocarcinoma
                                                or in Combination Center
5943                         NCILMB            National Cancer Institute Lab of Molecular Biology
                                                                 Kreitman, RobertActive
           A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneou
5954                          Decitabine in Patients with Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer
           Phase II Study ofTX035                                Sherman, Steven
                                               M D Anderson Cancer Center         Closed to Accrual & Treatment
5987                          Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus,
           Phase I Study of NCISB                                Schrump, David Active
                                               National Cancer Institute Surgery Branch
5996                          of Depsipeptide in Relapsed/Refractory Multiple Myeloma to Accrual & Treatment
           A Phase 2 Study NY045                                 Niesvizky-Iszaevich, Ruben
                                               Montefiore Medical Center          Closed
6012                          of ZD1839 and Radiation in Patients with Squamous Cell Carcinoma of the Skin
           A Phase II Study TX035                                Weber, Randal Closed to Accrual
                                               M D Anderson Cancer Center
6014                         MN026             Mayo Clinic Rochester Julian Closed to Accrual
                                                                 Molina,
           Phase I Trial of R115777 and OSI-774 in Patients with Advanced Solid Tumors
6070                          UCN-01           National Cancer Institute WyndhamBranch
                                                                 Wilson, MedicineActive
           Phase II Study ofNCIMB in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymph
6074                         NCILMB            National Cancer Institute Lab of Molecular Biology
                                                                 Kreitman, RobertActive
           A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic L
6113                         MN026             Mayo Clinic Rochester
                                                                 Hobday, TimothyClosed
           A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors to Accrual
6132                          of Bortezomib in M D Anderson Cancer Center
           A Phase 2 Study TX035                                 Sherman, Carcinoma orto Accrual Thyroid Carcinoma
                                               Metastatic Papillary ThyroidSteven Closed Follicular
6139                         MN026             Mayo Hepatocellular Carcinoma Closed to Accrual & Treatment
                                                                 Kim,
           Phase II Trial of PS-341 in Patients with Clinic RochesterGeorge
6156                         MN026              Soft Clinic Sarcoma
                                                                 Okuno,
           A Trial of CCI-779 in Patients with MayoTissue Rochester Scott         Closed to Accrual & Treatment
6171                          of CCI-779 in Metastatic Neuroendocrine CarcinomasConsortium
           A Phase II Study PMHC                                 Siu, Lillian      2
                                               Princess Margaret Hospital PhaseClosed to Accrual & Treatment
6204                         NY016             Memorial Sloan Kettering Supplied Agent,
                                                                 D'Adamo, David Active
           Phase I Trial of Doxorubicin and Alvocidib (Flavopiridol; NCI Cancer Center NSC 649890) in the Treatment o
6236                         OH007             Ohio State with Valproic Acid in Patients to Accrual & Treatment
                                                                 Blum, Kristie
           A Phase I Study of Decitabine in CombinationUniversity Medical Center  Closed with Selected Hematologic Malign
6237                         OH007             Ohio State with Valproic Acid in Patients to Accrual & Treatment Cancer
                                                                 Otterson, Gregory losed with Non-Small Cell Lung
           A Phase I Study of Decitabine in CombinationUniversity Medical Center  C
6240                         MN026             Mayo Clinic Rochester Matthew Closed to Accrual & Treatment
                                                                 Goetz,
           A Phase I and Pharmacogenetic Study of CPT-11, Oxaliplatin, and Capecitabine in Patients with Solid Tumors
6241                         Trial of          Moffitt Cancer Center and Research Pulsed
                                                                 Weber, Jeffrey Active
           A Dose Ranging FL065 MART-1/gp100/Tyrosinase/NY-ESO-1 PeptideInstitute Dendritic Cells Matured Using
6246                         MN026             Mayo Treatment Witzig,
                                                                 of Relapsed and Refractory Lymphoma
           Phase II Evaluation of FTI (R115777) in Clinic Rochester Thomas Closed to Accrual
6254                          of Triapine in Combination with Gemcitabine in Adenocarcinoma of the Treatment and Gal
           A Phase II Study NY045                                Ocean, Allyson Closed to Accrual & Biliary Ducts
                                               Montefiore Medical Center
6297                          of Trastuzumab in Combination with BMS-247550 in WomenAccrual & Treatment Cancer
           A Phase II Study MA036                                Bunnell, Craig Closed to with Metastatic Breast
                                               Dana-Farber Cancer Institute
6304                         WI020             University in Subjects with Advanced Melanoma
                                                                 Sondel, Paul     Active
           Phase II Trial of Hu14.18-IL2 (EMD 273063) of Wisconsin Hospital and Clinics
6307                         MN026             Combination with 17-Allylaminogeldanamycin (17-AAG) in Advanced Epithe
                                                                 Haluska, Paul Closed to Accrual
           A Phase II Trial of Gemcitabine in Mayo Clinic Rochester
6317                          of Oxaliplatin Combined with Continuous Infusion Topotecan Accrual & Treatment Patients w
           A Phase II Study NY045                                Tiersten,
                                               Montefiore Medical CenterAmy Closed to as Chemotherapy for
6319                          of Single        Wake Forest University Metastatic or Unresectable & Treatment
                                                                 Savage, Paul     Closed
           A Phase II Study NC002 Agent Depsipeptide (FK228) in Health Sciences to AccrualSoft Tissue Sarcomas
6335                          of Single        Montefiore Medical Center MissakClosed to Accrual & Treatment
                                                                 Haigentz,
           A Phase II Study NY045 Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients with Unresectab
6359                         MN026             Mayo Clinic Rochester Stephen Closed to Accrual & Lymphoma
                                                                 Ansell,
           Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin'sTreatment
6383                         MN026             Mayo Clinic Rochester
                                                                 Kaufmann, Scott Closed to Accrual & Treatment
           A Phase I and Pharmacological Trial of 17-Allylamino-17demethoxygeldanamycin (17-AAG) and Cytarabine in
6413                         FL065             Moffitt Cancer Center Alvocidib Active
                                                                  and and Research Institute
           Phase I Trial of Bortezomib (PS-341; NSC 681239)Grant, Steven (Flavopiridol NSC 649890) in Patients with R
6432                         MI020             of PS-341 in University
                                                                 LoRusso, PatriciaActive
           A Phase I Pharmacokinetic Study Wayne State Patients with Advanced Malignancies and Varying Degrees of
6438                         FL065             Moffitt then SubcutaneousMayer Closedin Metastatic Renal Cancer
                                                                 Fishman, Interleukin-2 to Accrual
           Phase 2 Trial of Sequential BevacizumabCancer Center and Research Institute
6446                         FL065             Moffitt Cancer Center and Research Institute
                                                                 Weber, Jeffrey Closed to Accrual
           An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination with Tyrosinase/gp100
6482                         MN026             Mayo Clinic (17-AAG) Advanced Medullary and Differentiated Thyroid Ca
                                                                 Moley,
           A Phase II Trial of 17-Allylaminogeldanamycin Rochester inJeffrey Closed to Accrual
6485                          of Rituximab-CHOP with Pegylated Liposomal Doxorubicinto Accrual Older than 60 Years o
           A Phase II Study MDA                                  Rodriguez, MariaClosed in Patients
                                               M D Anderson Cancer Center
6490                         NY045             Montefiore Medical Center
                                                                 Ocean, Allyson Closed to Accrual
           Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients with Colorectal Cancer
6500                         25036             The Royal Marsden 17-demethoxygeldanamycin (17-AAG) in Patients with
                                                                 Eisen, Timothy Closed to
           A Phase II Trial to Assess the Activity of 17-allylamino,NHS Foundation Trust Accrual & Treatment
6528                         CA011             University of Southern California
                                                                 Mohrbacher, AnnActive
           Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies
6536                         NCIMB             National Cancer InstituteJames Closed to Accrual
                                                                 Gulley, Medicine Branch
           An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC(TM)V (Vaccinia) and PANVAC (
6537                      OR010              Oregon Health and Science Imaging
                                                                Neuwelt, EdwardClosed to Accrual
       NCI-Sponsored Multi-Disciplinary Study for Initial Timing of MRUniversityof Intravenous Superparamagnetic Cr
6542                       17-dimethylaminoethylamino-17-demethoxygeldanamycin to Accrual & NSC #707545) in Pat
       Phase 1 Study ofNY016                                    Solit, David      Closed
                                             Memorial Sloan Kettering Cancer Center (17-DMAG, Treatment
6547                      25094              Royal Evaluate the Safety, Tolerability and Accrual
                                                                Judson, Ian        Research
       A Cancer Research UK Phase 1 Trial to Marsden Institute of CancerClosed toPharmacokinetics of 17-Dimethy
6552                      MI020              Wayne State University Elaina Closed to Accrual & Treatment
                                                                Gartner,
       A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory M
6555                       of BAY            Vanderbilt University
                                                                Sosman, Jeffrey in Patients with Advanced Renal Cancer
       A Phase I/II Trial TN008 43-9006 in Combination with Bevacizumab Active
6557                      OH029              Case Western Reserve UniversityActive
                                                                Waggoner, Steven
       A Phase II Trial of BAY 43-9006, a Novel Raf Kinase Inhibitor, Plus Paclitaxel/Carboplatin in Women with Rec
6565                       of BAY            Princess Margaret Hospital PhaseClosed to Accrual & Treatment
                                                                Oza, Amit          2 Consortium
       A Phase 2 Study PMHC 43-9006 in Combination with Gemcitabine in Recurrent Epithelial Ovarian Cancer
6567                       of BAY            University of for Advanced Pancreatic Cancer
       A Phase II Study IL057 43-9006/Gemcitabine Chicago       Kindler, Hedy     Closed to Accrual & Treatment
6569                       of BAY            University of Chicago
                                                                Fleming, Gini     Closed to Accrual & Treatment
       A Phase II Study IL057 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma
6576                      CA043              City of Hope       Lenz, Heinz-Josef Closed to Accrual & Treatment
       A Randomized Phase II Study of BAY 43-9006 in Combination with Gemcitabine in Metastatic Pancreatic Carc
6580                      IL057              University of (NSC# 704865) and Closed to Accrual & Treatment Either C
       A Randomized Phase II Study of Bevacizumab Chicago       Kindler, Hedy     Gemcitabine in Combination with
6581                      CA043              City of Hope       Kirschbaum, or High Risk Accrual & Treatment
                                                                                  C
       Phase I Trial of R115777 (NSC 702818) in Relapsed, RefractoryMark losed to Myeloid Leukemia
6584                       of BAY            Georgetown University Hospital Closed to in Patients with Metastatic Brea
                                                                Isaacs, Claudine
       A Phase I/II Trial DC005 43-9006 (Sorafenib) in Combination with Anastrozole Accrual & Treatment
6591                      MD017              Johns Hopkins University
                                                                Gore, MS-275 Closed to Accrual & Treatment
       A Dose-Finding Trial of the Histone Deacetylase Inhibitor Steven (NSC 706995) in Combination with 5-Azacit
6608                       BAY 43-9006 in Ohio State University Medical Center
       Phase II Study ofOH007                                   Shah, Thyroid Closed to
                                             Patients with MetastaticManisha Carcinoma Accrual
6617                       of BAY            Montefiore Medical Center
                                                                Unresectable Closed to IV Melanoma (IND 69,869)
       A Phase II Study NY045 43-9006 (NCS 724772) in Pavlick, Anna Stage III and Accrual & Treatment
6619                      CA088              University of California Mesylate in Chronic Myelogenous Leukemia
       A Phase I Study of CCI-779 in Combination with ImatinibS.                  Active
                                                                Ong, Medical Center At Irvine-Orange Campus
6620                      NCIMB              National Cancer Institute MedicineActive
                                                                Fojo, Antonio      Branch
       A Phase II Clinical Trial of Ixabepilone (Ixempra®, BMS-247550, NSC 710428), an Epothilone B Analog, in Ce
6629                      TX035              M D Efficacy Cancer Center
                                                                Jonasch, Eric      or without Low Dose Interferon in Metasta
       A Phase II Clinical Trial to Evaluate theAndersonof BAY43-9006 withClosed to Accrual
6634                        the CombinationSaint Jude Children's266046, IND Active Ifosfamide, and Etoposide in Rec
       A Phase I Trial ofTN024                                  McGregor, Lisa 57004),
                                              of Oxaliplatin (NSC Research Hospital
6654                       BAY 43-9006 (Sorafenib)Cancer Institute of Giuseppe Oncology in Patients with Relapsed N
       Phase II Study ofNCINAV                                  Giaccone, RAS Signal
                                                                                  Active
                                             National with Evaluation Navy Medical Pathway Branch
6718                       of GW572016 in University of Chicago
       A Phase II Study IL057                                   Cohen, Ezra       Head to Accrual & Treatment
                                              Squamous Cell Carcinoma of the Closedand Neck (SCCHN)
6724                       of GW572016 and Tamoxifen University with Metastatic Breast Cancer Resistant to Single-A
       A Phase II Study MI020                                   Gartner,
                                             Wayne State in Patients Elaina Active
6735                      MI213              University of Michigan Comprehensive Cancer Center
                                                                Cilengitide) in Patients with Non-Metastatic Androgen Inde
       Phase II Evaluation of EMD 121974 (NSC 707544, Hussain, Maha Closed to Accrual & Treatment
6742                      BAY 43-9006 (NSCD Anderson Patients Center
       Phase I Study of TX035                                   Cortes, Jorge
                                             M 724772) in Cancer with Acute ActiveLeukemias, Myelodysplastic Syndromes a
6745                      MD017              Johns Kinase Inhibitor BAY
                                                                Smith, B.         Closed to 724772) Treatment
       Phase I Dose Escalation Trial of the Raf Hopkins University 43-9006 (NSC #Accrual &as Single Agent for Ad
6750                        BAY 43-9006 (Sorafenib)Cancer Institute MedicineClosed to Accrual
       A Phase I Trial ofNCIMB                                  Kohn, Elise        Branch
                                             National and Bevacizumab in Refractory Solid Tumors with Biologic and Pr
6785                      MI020              Wayne State University
                                                                LoRusso, Administered to Accrualof a 21-Day Cycle in Pat
       A Phase I, Open-Label, Dose-Escalation Study of SB-715992Patricia          Closed Days 1-3 & Treatment
6789                      NY158              Roswell Park Cancer Institute
                                                                Fakih, Marwan Active
       A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination with 5-Fluorouracil, Leucovor
6800                      CA043              City of Hope        SB-715992        Closed to Accrual Three Weeks
       A Randomized Phase II Non-Comparative Study of Iqbal, Syma Given Weekly or Every& Treatment in Advan
6803   A Phase 2 Study PMHC                  Recurrent or Metastatic Squamous2Cell Carcinoma & Treatment
                                                                Winquist, Phase Consortium
                           of SB-715992 in Princess Margaret HospitalEric Closed to Accrual of the Head and Neck
6813                      TX098              Cancer Therapy Sarantopoulos, John
                                                                 Study of Temsirolimus The UT Health Science Center at
                                                                                  Closed to Accrual
       A Phase I Pharmacokinetic and Pharmacodynamicand Research Center at(CCI-779) in Patients with Advance
6814                       of Decitabine in Myelofibrosis Chicago
       A Phase II Study IL057                University of      Odenike, OlatoyosiClosed to Accrual
6816                      TN008              Vanderbilt Intravenous
                                                                Puzanov, Igor Closed to with Advanced Solid
       A Phase I Dose Escalation Study of Daily x 3University SJG-136 in Patients Accrual & Treatment Tumors
6825                      IDD                Institute for Drug Sarantopoulos, John
                                                                 Development Closed to Hydroxamic Acid (SAHA) in Pa
       A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Accrual & Treatment
6829                      MD015              University of Maryland Greenebaum Cancer Center
                                                                Ross, Douglas Active
       A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination with Cytosine Arab
6837                        5Azacitidine andJohns Hopkins Singapore International Medical Center
       A Phase I Trial of47006                                  Hydroxamic Acid in Patients with Metastatic or Locally Rec
                                              Suberoylanilide Hsieh, Wen-Son Active
6865                       of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Gemcitabine in Patients wit
       A Phase 1 Study TX035                                    Varadhachary, Closed to Accrual & Treatment
                                             M D Anderson Cancer Center Gauri
6869   A Phase 1 Study PMHC                  Princess Margaret Hospital PhaseClosed to Accrual
                                                                Yee, Karen         2 Consortium
                           of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination with Decitabine in Pa
6879                       Oral Suberoylanilide of Hope
       Phase II Study ofCA043                                   Acid (SAHA)       Closed to Accrual & Treatment
                                             City Hydroxamic Quinn, David in Recurrent or Metastatic Transitional Cell C
6884                      MD017               Hydroxamic Acid (SAHA) Michael
                                                                Carducci,         Active
       Phase I/II Study of SuberoylanilideJohns Hopkins University in Combination with the VEGF Inhibitor Bevacizu
6896                      NY045              Montefiore Medical Center
                                                                Nanus, David      Active
       A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Isotretinoin (13
6898                      NY045              Montefiore Medical Center LewisActive
                                                                Silverman,
       A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in
6914                      MD017              Johns Hopkins toStearns,
                                                                 Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA
       A Pilot Study Evaluating Surrogates of Response University Vered Closed to Accrual
6916                       of Vorinostat in Patients with Advanced Melanoma Closed to Accrual
       A Phase II Study PMHC                                    Balzer-Haas, Naomi
                                             Princess Margaret Hospital Phase 2 Consortium
6947                      OH007              Ohio (NSC 649890) Medical Center a 30 Minute Loading Dose
                                                                Blum, William      as
       A Dose Escalation Study of FlavopiridolState UniversityAdministeredClosed to Accrual & TreatmentFollowed b
6957                       of Fenretinide (4-HPR) + Rituximab in Patients with B-cell Lymphoma
       A Phase I-II Trial WA020                                 Gopal, Ajay       Center
                                             University of Washington Medical Active
6958                      HIVNCI             National Cancer Institute HIV-AIDS ctive
                                                                Yarchoan, Robert Malignancy Branch
                                                                                  A
       A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Indiv
6963                       of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma
       A Phase II Study CA043                City of Hope                         C
                                                                Kirschbaum, Mark losed to Accrual
6974                      NCISB              National Cancer Institute Surgery Branch to Accrual & Treatment
                                                                Rosenberg, Steven Closed
       A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1
6977                      NCIMB              National Cancer InstituteJames Active
                                                                Gulley, Medicine Branch
       Randomized Pilot Phase II Study of Docetaxel Alone or in Combination with PANVAC(TM)-V (Vaccinia) and P
6980                      TN008               Evaluation of Combined EGFR Blockade with Erlotinib and Cetuximab in P
                                                                Goff,
       A Phase I/II Clinical and BiologicalVanderbilt University Laura            Active
6981                      of BAY            Montefiore Medical CenterScott Closed Treatment Treatment
                                                              Tagawa,
       A Phase I/II Trial NY045 43-9006 Plus Gemcitabine and Capecitabine in theto Accrual &of Patients with Advan
6986                      of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma
       A Phase I/II Trial MN026                               Merchan, Jaime Active
                                            Mayo Clinic Rochester
6996                      CO085             University of Colorado at Denver Health Sciences Center
                                                              Study of Sorafenib
                                                                               Active
       Phase I/II Clinical, Pharmacological, and Biological Messersmith, Wells(BAY 43-9006) in Combination with Cet
7000                      of Flavopiridol Administered University Medical Center
       A Phase II Study OH007                                 Byrd, John       Closed Followed & Treatment
                                            Ohio State as a 30 Minute Loading Dose to Accrualby a 4-Hour Continuous
7002                      OH007             Ohio State University Medical Center
                                                               30-Minute Bolus Followed by a 4-Hour Infusion in Lympho
       A Phase I/II Study of Flavopiridol Administered as aJones, Jeffrey Active
7003                       Bortezomib (PS-341)of Hope
       Phase II Study ofCA043                                 with Advanced Closed to Accrual
                                            City for Patients Gandara, DavidBronchiolo-Alveolar Carcinoma (BAC) or A
7004   Gemcitabine andTX035                 M D Anderson for Metastatic
                                                              Arun, Banu       Closed to
                           R115777 Combination TherapyCancer Center Breast CancerAccrual & Treatment
7009                      NY016             Memorial Study Tse, Archie
                                                              of 17-N-Allylamino-17-Demethoxy & Treatment
                                                                               Closed
       An Open-Labeled Non-Randomized Phase ISloan Kettering Cancer Center to AccrualGeldanamycin (17AAG)
7024                      MN026             Mayo Clinic Rochester
                                                              Schelman, Williamlosed to Tumors
                                                                               C
       A Phase II Trial of Bevacizumab and Erlotinib in Patients with Advanced BiliaryAccrual
7028                      of BAY            University of Chicago
                                                              Kindler, Hedy    Closed to Accrual
       A Phase II Study IL057 43-9006 for Patients with Imatinib and Sunitinib Resistant Gastrointestinal Stromal Tu
7036                      OH076             Cincinnati Children's Hospital Medical Center
                                                              Wagner, Lars Closed to Accrual & Treatment
       A Pilot Study of Temozolomide and O6-Benzylguanine for Treatment of High-Grade Glioma, Using Autologous
7037                      OH029             Case Western Reserve UniversityActive
                                                              Savvides, Panayiotis
       Phase II Trial of BAY 43-9006 in Patients with Advanced Anaplastic Carcinoma of the Thyroid
7043                      OH007             Ohio State University Medical Tanios
                                                               in Combination with
                                                                               Active
       A Phase I Study of a Prolonged Infusion of TriapineBekaii-Saab, Center a Fixed Dose Rate of Gemcitabine in
7044                      OH007             Ohio State with Radiation TherapyActive
                                                              Bekaii-Saab, Tanios
                                                                                in
       A Phase I Study of Triapine® in Combination University Medical Center Locally Advanced Pancreas Cancer
7046                      MN026             Progressive Metastatic TimothyClosed to Accrual
                                                              Hobday,
       A Phase II Trial of Bay 43-9006 in Mayo Clinic Rochester Neuroendocrine Tumors
7048                      HIVNCI            National Cancer Institute HIV-AIDS ctive
                                                              Yarchoan, Robert Malignancy Branch
                                                                               A
       Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients with Kaposi's Sarcoma
7060                      NY016             Memorial Sloan Kettering Cancer Center to Accrual
                                                              Maki, in Non-GIST Sarcomas
       A Multicenter Phase II Study of Sorafenib (BAY 43-9006)Robert           Closed
7071                      of BAY            University of Chicago
                                                              Godwin, John Closed to
       A Phase II Study IL057 43-9006 in Relapsed Chronic Lymphocytic Leukemia Accrual
7077                      CA043             City of Versus Lara, Primo         Closed to Accrual
       Randomized Phase II Trial of Sequential Hope Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443
7080                      OH029              of O6Benzylguanine and Kevin Active
                                                              Cooper, Topical
       Phase I/II Multicenter Clinical TrialCase Western Reserve UniversityCarmustine in the Treatment of Refractory
7089                      PA110             University of and Moschos, Stergios
                                                              cDC-Based Intralymphatic Vaccines in Patients with Metas
       Phase I Evaluation of Alpha-Type-1 DC-Based Pittsburgh Cancer Institute Active
7099                      of AZD2171 in Breast Cancer Cancer Institute
       A Phase II Study MA036                                 Burstein, Harold
                                            Dana-Farber Stage IV (10006202)Closed to Accrual
7102                      of AZD2171 in Patients with RecurrentInstitute Primary Peritoneal Serous or Fallopian Tube
       A Phase 2 Study MA036                                  Matulonis, UrsulaClosed to Accrual & Treatment
                                            Dana-Farber Cancer Ovarian,
7103                       AZD2171 (NSC University in Patients withHedy
       Phase II Study ofIL057                                 Kindler, Malignant Mesothelioma
                                            #732208) of Chicago                Active
7105                      of AZD2171 in Recurrent Glioblastoma Hospital Cancer Center
       A Phase II Study MA034                                 Batchelor, Tracy Closed to Accrual & Treatment
                                            Massachusetts General
7111                      of AZD2171 in Patients with Advanced Renal Cell CarcinomaAccrual
       A Phase 2 Study IL057                                  Stadler, Walter Closed to
                                            University of Chicago
7128                      of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RC
       A Phase 2 Study PMHC                                   Sridhar, Srikala 2 Consortium
                                            Princess Margaret Hospital PhaseClosed to Accrual
7129                      of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
       A Phase 2 Study PMHC                                   Hirte, Holger     2 Consortium
                                            Princess Margaret Hospital PhaseClosed to Accrual
7133                      of AZD2171 in Adult PatientsRochester
       A Phase 2 Study MN026                                  Neurofibromatosis Type to and
                                                                               Closed 1 Accrual
                                            Mayo Clinic with Babovic-Vuksanovic, Dusica Extensive Plexiform and Pa
7135                      of AZD2171 in the TreatmentRochester with Acute Leukemia and Myelodysplastic Syndrom
       A Phase II Study MN026                                 Juckett,
                                            Mayo Clinic of Patients Mark       Active
7137                      of AZD2171 in Previously Margaret Hospital PhaseClosed to Accrual & Treatment Melano
       A Phase II Study PMHC                                  McWhirter, Elaine2 Consortium
                                            Princess Untreated Patients with Metastatic or Recurrent Malignant
7146                      TX098             Cancer Therapy and Research Center at The UT in& Treatment with CCI-
                                                              Beeram, Muralidhar
                                                                               Closed to Accrual Combination
       Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib)Health Science Center at
7147                      of AZD2171 in Hepatocellular CarcinomaHospital Cancer Center
       A Phase 2 Study MA034                                  Zhu, Andrew
                                            Massachusetts General              Active
7149                      of the            M of BAY 43-9006 (Sorafenib)
                                                              Kim, Center      Active
       Phase 1/2 Study TX035Combination D Anderson CancerKevin and CCI-779 (Temsirolimus) in Patients with
7156                      Tipifarnib        M D Anderson CancerSorafenib Closed to Accrual
                                                               and David
       Phase I Study of TX035 (IND# 58359, R115777)Hong,Center (IND# 69896, BAY 43-9006) in Patients with
7178                      PMHC              Princess Margaret Hospital PhaseClosed to Accrual & Treatment
                                                              Siu, Lillian      2 Consortium
       A Phase I Study of BAY 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib; TarcevaTM ) in Advance
7190                      of CCI-779 in Combination of Virginia
       A Phase 2 Study VA009                                  Slingluff, Craig Active
                                            University with Bevacizumab in Stage III or IV Melanoma
7200                      TX098              Pharmacodynamic Research Center at The UT Health Science Center at
                                                              Beeram, Muralidhar
                                                                               Closed to Accrual & Treatment
       A Phase II, Pharmacokinetic (PK),Cancer Therapy and(PD) and Biological Correlative Study of the Efficacy an
7204                      OH007             Ohio State University Medical Center
                                                              Shah, Manisha
       A Pilot Study of Flavopiridol in Patients with Advanced Solid Tumors Closed to Accrual & Treatment
7207                       PSA Based Vaccine and Cancer InstituteJames Closed to with Metastatic Androgen Indep
       Phase I Trial of aNCIMB                                Gulley, Medicine Branch
                                            National an Anti-CTLA-4 Antibody in Adults Accrual
7208                       Bevacizumab Plus Erlotinib in Patients with Advanced Hepatocellular& Treatment
       Phase II Study ofMN026                                 Philip,
                                            Mayo Clinic Rochester Philip       Closed to Accrual Cancer (HCC)
7211                      MN026             Mayo Clinic Delay Disease Progression into Accrual & Treatment
       A Phase II Trial of Bevacizumab to Prevent or RochesterShanafelt, Tait Closed Patients with Relapsed/Refractor
7225                      CA043             City Oral         Yen, Yun         Closed to Accrual & Treatment
       A Phase I and Pharmacokinetic Study of Hope3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP,
7229                      NY045              (Ixabepilone) and CenterEllen Active
                                                              Chuang,
       A Phase I/II Study of BMS 247550Montefiore MedicalPegylated Liposomal Doxorubicin (Doxil®) in Patients wit
7237                      34003             Chinese University of Hong Kong-Prince of Wales Hospital
                                                              Yeo, Winnie      Temporarily Closed to Pharmacokinetic a
       A Phase I/II Study of PXD101 in Patients with Unresectable Hepatocellular Carcinoma with Accrual
7251                      CA043             City of Hope      Luu, Thehang     in Advanced Solid Tumor Malignancies
       A Phase 1 Trial of PXD101 in Combination with 13-cis-Retinoic Acid Active
7258                       the Histone Deacetylase Inhibitor Cashen, Amanda
       Phase II Study ofMN026                                 PXD101 for the Treatment Accrual & Treatment
                                            Mayo Clinic Rochester              Closed to of Myelodysplastic Syndrome
7265                      of PXD101 in Patients with Relapsed or Kenneth ClosedMyelogenous Treatment or Patients
       A Phase 2 Study CA043                City of Hope      Foon, Refractory Acute to Accrual & Leukemia
7267                      of PXD101 in Platinum Resistant Epithelial OvarianClosed toand Micropapillary/Borderline (L
       A Phase 2 Study PMHC                                   Oza, Amit         Tumors Accrual & Treatment
                                            Princess Margaret Hospital Phase 2 Consortium
7281                      of PXD101 in Combination of Colorado
       A Phase 1 Study CO015                                  Eckhardt, (PS-341) in Patients with Advanced Solid Tumor
                                            University with Bortezomib Sue Closed to Accrual & Treatment
7285                      PXD101 in Combination with Azacitidine (5-Aza) for Advanced Hematologic Malignancies
       Phase I Study of IL057                                 Odenike, Olatoyosi
                                            University of Chicago              Active
7309                      MA034             Monotherapy in Recurrent or Metastatic Center Neck Squamous Cell Ca
                                                              Rocco, James Temporarily and
       Phase II Clinical Trial of AZD2171 Massachusetts General Hospital Cancer Head Closed to Accrual
7311                      of UCN-01 in Combination with Perifosine in Patients Cancer Center and Refractory Acute Le
       A Phase 1 Study MD015                                  Gojo, Ivana       Active
                                            University of Maryland Greenebaum with Relapsed
7313                      WI020             University of Wisconsin Hospital and Clinics
                                                              Callander, NatalieActive
       Phase II Trial of Bevacizumab Combined with Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapse
7314                       CC-5013 (Lenalidomide) and CCI-779MedicalCraig
       A Phase I Trial ofOH007                                Hofmeister, CenterClosed to Accrual
                                            Ohio State University in Patients with Relapsed or Refractory Multiple Myel
7317                      of 5-Azacitidine in Combination with Interferon-AlfaClosed to Accrual & or Metastatic Melano
       A Phase 1 Study CT018                Yale University Sznol, Mario        2B in Unresectable Treatment
7325   Dose-Dense andOH029                  Case Western Reserve UniversityClosed to Accrual & Treatment
                                                              Krishnamurthi, Smitha
                          Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in S
7341                      of Gemcitabine, Paclitaxel, and Cancer Center Pegfilgrastim for the Treatment of Patients
       A Phase II Study MDA                                   Pagliaro, Lance
                                            M D Anderson Doxorubicin, with Active
7347                       Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone,Accrual & Treatment
       Phase I/II Trial ofCA136                               Harzstark, Andrea losed to and Prednisone in Hormone R
                                                                                C
                                            University of California San Francisco Medical Center-Mount Zion
7351                      MN026             Mayo Clinic Rochester
                                                              McWilliams, (17-AAG) in Combination with Gemcitabine in
       A Phase II Trial of 17-N-Allylamino-17-DemethoxygeldanamycinRobert       Active
7353                      CA221             Veterans with Dexamethasone in Active Myeloma
                                                              Lichtenstein, AlanMultiple
       A Phase I Study of CCI-779 in Combination Administration Los Angeles Healthcare System
7354                      NCIMB             National Cancer Institute Ravi
                                                              Madan, MedicineActive
                                                                                 Branch
       A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC/TRICOM and Flutamide, vs. Fluta
7357                      PA110             University of Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and
                                                              Tarhini, Ahmad Active
       Safety and Immunogenicity of Vaccination with Pittsburgh Cancer Institute
7358                      of Sorafenib andNational Cancer Institute MedicineActive
       A Phase II Study NCIMB                                 Epithelial Ovarian,Branch
                                             Bevacizumab in Kohn, Elise           Fallopian, and Peritoneal Cancer
7368                      OH007             Ohio State University Medical Center
                                                              Andritsos, Leslie Closed to Accrual & Treatment
       A Phase I Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Fo
7378                      of AFP464 (Aminoflavone Prodrug) in Patients withActive
       A Phase 1 Study MI020                                  Heath,
                                            Wayne State University Elisabeth Advanced Solid Tumors
7380                      and Pharmacological Trial of Rochester Matthew Active Prodrug (AFP464) Administered 3
       A Phase 1 Study MN026                                  Goetz,
                                            Mayo Clinic Once Weekly Aminoflavone
7389                       AZD2171 (NSC Wayne State University with Pemetrexed in Relapsed Non-Small Cell Lung
       Phase 2 Study ofMI020                                  Gadgeel,
                                            732208) in Combination Shirish Active
7395                      of AZD2171 in Metastatic Cancer InstituteWilliam Prostate to Accrual
       A Phase II Study NCIMB                                 Dahut, Medicine Branch
                                            National Androgen Independent Closed Cancer
7416                      of BAY            National Cancer Institute MedicineActive (ErbituxTM) in EGFR Expressin
                                                              Kummar, with Cetuximab
       A Phase II Study NCIMB 43-9006 (Sorafenib) in Combination Shivaani        Branch
7427                      of Halichondrin B Analog (E7389) Koczywas, MariannaCisplatin in Advanced Solid Tumors
       A Phase 1 Study CA043                City of Hope                        Active
                                                               in Combination with
7431                      NY016             Memorial Sloan Kettering Cancer Center
                                                                Analog Martee Recurrent Epithelial Ovarian, Fallopian T
       A Multi-Center Phase 2 Study of the Halichondrin BHensley,E7389 inClosed to Accrual
7435                      CA043             City of B Analog Quinn,#David
       A Phase I/II Study of E7389 Halichondrin Hope                            Active
                                                              (NSC 707389; IND # 64395) in Metastatic Urothelial Trac
7437                      of the            City Analog       Gitlitz, Barbara Closed to Accrual
       A Phase 2 Study CA043Halichondrin B of Hope E7389 in Patients with Advanced Non-Small Cell Lung Cancer
7440                      PA015             Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Canc
                                                              Argiris,
       A Phase II Trial of Cetuximab and University of Pittsburgh Athanassios   Active
7444                      11030              Analog E7389 in Network-Princess Margaret Hospital
                                                               Combination      Active
       A Phase I Study of Halichondrin B University HealthGoel, Rakesh with Gemcitabine in Patients with Refractory
7448                      of the            University HealthMoore, Malcolm Closed to for Patients with Locally Advan
                                                               Network-Princess Margaret Hospital
       A Phase II Study 11030 Halichondrin B Analog E7389 as Second Line TherapyAccrual & Treatment
7451                      MI020             Wayne State University Prednisone Compared to Docetaxel and Prednison
                                                              Heath,
       A Randomized, Phase II Trial of AZD2171, Docetaxel, andElisabeth Active
7458                      NCIPOB            National Cancer Institute PediatricActive
                                                              Mackall, Crystal Oncology Branch
       A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refr
7498                      11030             University HealthMoore, Malcolm Closed to Accrual & Treatment
                                                               Network-Princess Margaret Hospital
       Phase II Trial of VEGF Trap in Patients with Previously Treated Metastatic Colorectal Cancer
7502                      of VEGF-Trap in University HealthOza, Amit
       A Phase II Study 11030                                  Network-Princess Margaret Hospital
                                                                                Closed to Accrual
                                            Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas
7508                      of Single         Memorial Sloan Kettering Cancer Center
                                                              Pfister, David    Active
       A Phase II Study NY016 Agent Intravenous (IV) VEGF Trap in Patients with Poor Prognostic Recurrent and/
7518                      of VEGF           City of Hope      Kirschbaum, Mark
       A Phase II Study CA043 Trap (NSC 724770) in Patients with MDS Active
7521                      of VEGF           Montefiore Medical Center
                                                              Niesvizky-Iszaevich, Ruben
                                                                                Active
       A Phase 2 Study NY045 Trap (NSC 724770) in Relapsed and Progressive Multiple Myeloma (MedDRA1002
7522                      Evaluating the Efficacy of VEGF Trap in Patients with Recurrent Inoperable Stage III or Stag
       A Phase 2 Study CA043                City of Hope      Tarhini, Ahmad Closed to Accrual
7529                      NJ066             Cancer Institute Endothelial Growth Factor
                                                              Tan, Antoinette
       Pilot Study of GW786034 (Pazopanib), a Vascular of New Jersey Active Receptor Tyrosine Kinase Inhibi
7534                      TX035             M D Anderson Cancer Center
                                                              Hong, David       Active
       Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizum
7537                      OH029             Case Western with SU11248
                                                              Rini, Brian
       A Phase I Study of Bevacizumab in Combination Reserve UniversityActive
7540                      CA043             City of Hope      Pinski, Jacek     Active
       Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors
7548                      MDA               M D Anderson Cancer Sargramostim
                                                                Plus Center     Closed to Treatment of Newly Diagnosed
       Single-Arm, Open-label, Phase II Trial of RituximabMcLaughlin, Peter for theAccrual
7552                      of AZD0530 in Patients with Metastatic or Locally Advanced Gastric Carcinoma
       A Phase 2 Study 11030                                   Network-Princess Closed to Accrual &
                                            University HealthAu, Heather-Jane Margaret Hospital Treatment
7555                      of AZD0530 in Patients with Advanced, Recurrent Non-Small Cell Lung Cancer Who Have P
       A Phase 2 Study 11030                                   Network-Princess Margaret Hospital
                                            University HealthLaurie, Scott      Active
7557                      of AZD0530 in Recurrent or Metastatic Soft Tissue Closed to Accrual
       A Phase 2 Study 11030                                   Network-Princess Margaret Hospital
                                                                                Sarcoma
                                            University Healthvon Mehren, Margaret
7565                       AZD0530 (NSC M D Anderson CancerCathy
       Phase II Study ofTX035                                 Eng, Center       Closed to Accrual & Colorectal
                                            735464) in Patients with Previously Treated Metastatic Treatment Cancer
7567                      of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced B
       A Phase II Study NY016                                 Hudis, Clifford Active
                                            Memorial Sloan Kettering Cancer Center
7584                      of AZD0530 for Patients with Recurrent Matthew Center to Accrual & TreatmentCell Carcin
       A Phase II Study NY016                                 Fury, or Cancer Closed
                                            Memorial Sloan Kettering Metastatic Head and Neck Squamous
7597                      of AZD0530 in Metastatic Melanoma
       A Phase 2 Study IL057                                  Gajewski, Thomas
                                            University of Chicago               Closed to Accrual & Treatment
7602                      MN026             Mayo Clinic Rochester
                                                              Messersmith, WellsTemporarily
       A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer Closed to Accrual
7605                      of an Oral Histone Deacetylase Inhibitor, B.
       A Phase II Study MD017                                 Smith, MS-275 (NSC 706995), in Combination with Sargra
                                            Johns Hopkins University            Active
7609                       Sorafenib (BAY 43-9006) inUniversity Medical Center
       Phase II Study ofOH007                                 Shah, Manisha Closed to Accrual
                                            Ohio State Patients with Metastatic Medullary Thyroid Carcinoma
7613                      ECOG              Eastern Cooperative Oncology Group
                                                               Adjuvant Chemotherapy
       Identifying Genomic Predictors of Recurrence after Sparano, JosephClosed to Accrual & Treatment
7623                      of GW786034 (Pazopanib) in Asian PatientsTeck Recurrent/Metastatic Nasopharyngeal Carc
       A Phase 2 Study 47005                                  Lim, Wan with Closed to Accrual & Treatment
                                            National Cancer Centre
7627                      of GW             Mayo Clinic Rochester Keith
                                                              Bible,
       A Phase II Study MN026 786034 (Pazopanib) in Advanced Thyroid Cancer     Active
7638                      of GW786034 (Pazopanib) HealthLeighl, Natasha Closed to MetastaticTreatment
       A Phase 2 Study 11030                                   Network-Princess Margaret Hospital
                                            University in Patients with Recurrent and/or Accrual & Invasive Breast Carc
7640                       of GW786034 (Pazopanib) HealthChi, Kim Bicalutamide in Hormone Refractory Prostate Can
       A Phase 2 Study 11030                                    without        Active
                                            University with or Network-Princess Margaret Hospital
7650                       of GW786034 (Pazopanib) in AdvancedCenter
       A Phase 2 Study TX035                                  Phan, Low-Grade or Intermediate-Grade Neuroendocrine
                                            M D Anderson Cancer AlexandriaClosed to Accrual
7659                      IL057             University of Chicago
                                                              Posadas, Stage Closed to Accrual
       A Randomized, Phase II Study of GW786034 (Pazopanib) in Edwin D0 Relapsed Androgen Sensitive Prostate
7661                        and Efficacy Study with the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients
       A Phase II SafetyMN026                                 Vaishampayan, Ulka
                                            Mayo Clinic Rochester              Temporarily Closed to Accrual
7674                      IL057             University of Chicago
                                                              Fleming, Gini    Closed to Accrual
       Phase II Trial of CCI-779 (Temsirolimus) in Patients with Locally Advanced or Metastatic Breast Cancer
7678                      NCIMB              153Sm-EDTMP Gulley, MedicineActive
                                                               (Quadramet)
       A Randomized Phase 2.5 Study ofNational Cancer InstituteJameswithBranch   or without a PSA/TRICOM Vaccine in M
7689                      CA043             City Hope         (NSC 722929, IND 67368) in Acute Leukemias
                                                                               C
       Phase I and Pharmacodynamic Study of GTI-2040 Kirschbaum, Mark losed to Accrual & Treatment
7702                      MN026             Mayo Clinic Rochester
                                                              Kumar,
       A Phase II Trial of Sunitinib (SU11248) in Multiple MyelomaShaji        Closed to Accrual & Treatment
7703                      of a CombinationMontefiore Medical Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevac
       Phase I/II Study NY045                                 Sparano,
                                             of Suberoylanilide Center JosephClosed to Accrual
7704                      MD017             Johns Hopkins University
                                                              Karp, Judith     Active
       Phase II Trial of Triapine (IND #68338, NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone)
7713                       of Sunitinib Malate in Recurrent orOza, Amit Endometrial Carcinoma
       A Phase 2 Study 11030                                    Metastatic     Active
                                            University Health Network-Princess Margaret Hospital
7718                       of Sunitinib Malate (Sutent®; SU11248) in PatientsClosed to Accrual or High-Risk Myelody
       A Phase II Study 11030                                  Network-Princess Margaret Hospital
                                            University HealthYee, Karen        with Intermediate-2
7731                      OH029             Case Standard Infusion Gemcitabine in Solid Tumors
                                                              Krishnamurthi, Smitha
       A Phase I Study of Sunitinib Malate and Western Reserve UniversityClosed to Accrual
7735                      IL057             University of Chicago
                                                              Cohen, Ezra      Closed Differentiated Thyroid Cancers an
       Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectableto Accrual
7745                      OH007             Ohio State University Medical Center
                                                              Cavaliere, Robert losed to Accrual & Treatment
                                                                               C
       A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas
7754                       of Imatinib Mesylate (STI571; NSC #716051; IND 61135) in Patients with Inoperable AJCC S
       A Phase II Study NY016                                 Carvajal, RichardActive
                                            Memorial Sloan Kettering Cancer Center
7756                       Trastuzumab (NSCD Anderson Her2/neu Positive Cancer of the Gallbladder or Biliary Tract
       A Phase II Study TX035                                 Kaseb, Ahmed Closed to Accrual
                                            M 688097) in Cancer Center
7757                      TX035             M D Anderson Cancer VEGF Trap (AVE0005, NSC# 724770) in Patients wit
                                                               Plus Center
       Phase I/II and Pharmacokinetic Study of Docetaxel Coleman, RobertActive
7758                       of Dasatinib in Advanced Melanoma
       A Phase 2 Study CT018                Yale University Kluger, Harriet Closed to Accrual & Treatment
7759                      MD114             Combination withRudin, Charles Cancer
                                                                5-Azacytidine Patients with Recurrent Advanced Non-S
       A Phase I/II Study of Entinostat in Sidney Kimmel Comprehensive in ActiveCenter at Johns Hopkins Hospital
7768                      IL057             University of Chicago
                                                              Maitland, Michael Normotensive Patients with Advanced M
       A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) inctive  A
7786                       of Dasatinib (NSC 732517) of Chicago
       A Phase II Study IL057                                 Kindler, Hedy    Closed to Accrual
                                            University in Previously-Treated Patients with Metastatic Colorectal Cancer
7792                      CA043             City of Hope      Lenz, Heinz-JosefActive
       A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
7798                       Dasatinib in NonM D Anderson Cancer Center
       Phase II Study ofTX035                                  Cancer
                                             Small Cell Lung Johnson, Faye Closed to Accrual & Treatment
7813                       of Dasatinib In Patients With Transplant And Non-Transplant Related Unresectable or Metas
       A Phase 2 Study OH007                                  Olencki, ThomasActive
                                            Ohio State University Medical Center
7828                       Dasatinib (BMS-354825) in Patients withUniversityActive
       Phase II Study ofOH029                                 Nock, Metastatic Adenocarcinoma of the Pancreas
                                            Case Western ReserveCharles
7831                       Sunitinib        Case Patients with Kaposi's Sarcoma in East
                                                              Remick, Scot
       Phase II Study ofOH029 (SU11248) inWestern Reserve UniversityApproved Africa
7832                      NCIMIP            National Cancer Institute Peter Active
                                                              Choyke, Imaging Imaging
       A Phase 0 Trial of "111 Indium CHX-A" DTPA TrastuzumabMolecularin CancerProgram
7834                      NCILMB            National Cancer Institute Lab of Molecular Biology
                                                              Kreitman, RobertActive
       A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
7844                      NCIMET            National Cancer Institute Mantle Cell Branch
                                                              Dunleavy, KieronActive
       A Phase I/II Study of Flavopiridol in Relapsed or Refractory Metabolism Lymphoma (MCL) and Diffuse Large B
7848                      MN026             Mayo Clinic Rochester
                                                              Galanis, EvanthiaTemporarily Closed to Accrual
       A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin®) in Patients
7853                      OH007             Ohio State University Medical Center
                                                              Cohn, David      Active
       A Phase 1/2 Study of Reovirus Serotype 3 - Dearing Strain (Reolysin®) (NSC 729968) in Patients with Ovarian
7856                      NCIPOB            National Cancer Institute PediatricActive
                                                              Widemann, BrigitteOncology Branch
       Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar®) in
7859                      NCIMB             National Cancer Institute MedicineActive and Lymphomas
                                                              Kummar, Solid Tumors
       A Phase I Study of Batracylin (NSC 320846) in Subjects with Shivaani     Branch
7860                      Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma
       Phase I Study of NCIDER                                Kong, Heidi      Active
                                            National Cancer Institute Dermatology Branch
7864                      NY016             Memorial Sloan Kettering Cancer Center to Accrual & Treatment
                                                              Slovin, Susan Closed
       Neoadjuvant Androgen Depletion in Combination with Vorinostat Followed by Radical Prostatectomy for Local
7868                      NY045             Montefiore Medical Center Dawn
                                                              Hershman,        Active
       A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-D
7869                       of Depsipeptide, M Histone Deacetylase Center inClosed to Accrual
       A Phase II Study TX035                                 Fayad, Luis
                                            a D Anderson Cancer Inhibitor, Relapsed or Refractory Mantle Cell or Di
7881                       of Pertuzumab inDana-Farber Cancer Institute in Cetuximab-Refractory Metastatic Colorecta
       A Phase I/II Trial MA036                               Fuchs, Charles Active
                                             Combination with Cetuximab
7888                        CCL21           University of Californiain Non-Small Cell Lung )
                                                              Lee, at          Active
       A Phase I Trial ofCA006 Gene Modified Dendritic Cells Jay Los Angeles (UCLA Cancer
7889                      a Pharmacologically Derived Hybrid Bolus-Infusion Closed to Accrual
       Phase I Study of MD017                                 Karp, Judith
                                            Johns Hopkins University           Schedule of Flavopiridol (NSC 649890, IN
7893                      Bortezomib        National Cancer Institute Cisplatin Oncology Branch& Treatment
                                                              Van Waes, Carter Closed to Accrual
       Phase I Study of NCIROB and Cetuximab without or withRadiation in Combination with Radiation Therapy f
7898                      WI020             University in Patients withGeorgeCell Cancer
                                                              Wilding, Renal Active
       Pharmacodynamic Study of Sunitinib Malate of Wisconsin Hospital and Clinics and Other Advanced Solid Ma
7902                       Decitabine in Acute MyeloidUniversity Medical Center
       Phase II Study ofOH007                                 Blum,
                                            Ohio State Leukemia William Closed to Accrual
7909                       of AZD6244 in Advanced or Metastatic and Research Institute
       A Phase II Study FL065                                 O'Neil, Bert     Closed to Accrual & Treatment
                                            Moffitt Cancer Center Hepatocellular Carcinoma
7916                      MI020             Wayne State University
                                                              LoRusso, PatriciaActive
       A Phase I Study of Intravenously Administered FAU (1-(2'-deoxy-2'-fluoro-B-D-arabinofuranosyl) Uracil, NSC#
7918                       AZD6244 in Iodine-131Cancer Center and ResearchCarcinoma and Papillary Thyroid Carcin
       Phase 2 Study ofFL065                                  Hayes, David     Closed to Accrual
                                            Moffitt Refractory Papillary Thyroid Institute
7925                       of AZD6244 in Relapsed orof Chicago AMLOlatoyosi
       A Phase 2 Study IL057                                  Odenike,
                                            University Refractory              Closed to Accrual
7932                       of AZD6244 in Biliary Cancers
       A Phase 2 Study OH007                                  Bekaii-Saab, Tanios
                                                                               Closed to Accrual & Treatment
                                            Ohio State University Medical Center
7937                      NY016             Memorial Sloan Kettering Cancer Center to Accrual & Treatment
                                                              Krug, bcl-2      Closed
       Phase I/II Study of Obatoclax Mesylate (GX15-070MS), aLee Antagonist, Plus Topotecan in Relapsed Smal
7943                      GX15-070 (NSC City of Hope Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin'
       Phase I Study of CA043               #729280) and Tuscano, JosephActive
7945                       of Obatoclax Mesylate (GX15-070MS)Institute
       A Phase 1 Study MA036                                  Brown, Jennifer Active
                                            Dana-Farber Cancer in Combination with Fludarabine-Based Chemoimmun
7952                        of Obatoclax Mesylate Clinic Rochesterin Combination with Bortezomib for the Treatment of R
       A Phase I/II Trial MN026              Mayo (GX15-070MS)  Stewart, Alexander  Active
7955                       TX035             M D Anderson Cancer Center
                                                                Loghin, Monica Closed to Accrual
       A Randomized Phase 2 Trial of Bevacizumab to Control Brain Radiation Damage
7958   A Phase 2 Study WA020                 University of Washington Medical Temporarily Closed to Accrual and [18F
                                                                 Imaging with [18F]-Fluoromisonidazole (FMISO)
                            of Positron Emission TomographyRajendran, Joseph        Center
7967   A Phase 1 Study PA110                 University with Carboplatin andInstitute in Advanced Solid Malignancies
                                                                Ramalingam, Paclitaxel
                            of ABT-888 in Combinationof Pittsburgh CancerSuresh     Active
7968   A Phase 1 Study MD017                 Johns Hopkins Topotecan
                                                                Karp, Judith        Active
                            of ABT-888 in Combination with University Plus Carboplatin for Relapsed and Refractory Ac
7977                       MI172             Barbara Ann Karmanos Cancer Plus Intravenous Irinotecan (CPT-11, NSC
                                                                LoRusso, Patricia
       A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664)Institute       Active
7981                       NCIMB             National Cancer Institute MedicineActive
                                                                Kummar, Shivaani     Branch
       A Phase I Study of ABT-888 in Combination with Topotecan Hydrochloride in Adults with Refractory Solid Tum
7998                       NJ066             Cancer Institute of New Jersey
                                                                Tan, Antoinette in Solid
       A Phase I Study of ABT-888 in Combination with CyclophosphamideActive Tumors or Non-Hodgkins Lymph
8008                       Decitabine (Dacogen) State University Medical Center
       Phase I Study of OH007                                   Blum, William       Acute to Accrual
                                             Ohio and Bortezomib (Velcade) inClosedMyeloid Leukemia
8014                        of AT101, to Abrogate BCL-2 Mediated ResistanceActive
       A Phase II Study NJ066                                   DiPaola, Robert to Androgen Ablation Therapy in Patients
                                             Cancer Institute of New Jersey
8016   A Phase 1 Study NJ066                  (Ascenta's AT-101) in Mark
                                                                Stein, Jersey Active
                            of R-(-)-gossypolCancer Institute of NewCombination with Paclitaxel and Carboplatin in Solid
8027                        of AT-101 in RecurrentClinic Rochester SmallMariaLung Cancer
       A Phase II Study MN026                                   Stage
                                             Mayo Extensive Baggstrom, CellClosed to Accrual & Treatment
8029                        Fluorine-18 3'-deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
       Phase II Study ofACRIN                                   Kostakoglu, Lale Active
                                             American College of Radiology Imaging Network
8030                       MA034              Combination with Daily Hospital Cancer Center
                                                                Batchelor, Tracy Active
       A Phase Ib/II Study of AZD2171 inMassachusetts General Temozolomide and Radiation in Patients with Newl
8035                        of the Orally Administered Negative Enantiomer of Active
       A Phase II Study MN026                                   Menefee, Michael
                                             Mayo Clinic Rochester                  Gossypol (AT-101) in Patients with Advan
8045   A Phase 1 Study FL065                 Moffitt Cancer Center andScott Active
                                                                Antonia, Research Institute
                            of 1-Methyl-D-Tryptophan in Patients with Advanced Malignancies
8046                       OH007             Ohio State University Medical Center
                                                                Blum, Kristie       Active
       Phase 1 Trial of Flavopiridol in Combination with Lenalidomide in Patients with Relapsed or Refractory B-Cell
8052                        of [18F]         University of as a Marker of Hormone Sensitivity of Metastatic Breast Canc
                                                                Mankoff, David Center
       A Phase 2 Study WA020 Fluoroestradiol (FES)Washington Medical Active
8054                       NCIMB             National Cancer Institute MedicineActive
                                                                Kohn, Elise          Branch
       A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
8057                       PA015             University of Pittsburgh
                                                                Ramalingam, Suresh  Closed to Accrual
       Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying D
8060                       NY016             Memorial Study of Irinotecan and Active
                                                                Shah, Manish Alvocidib
       A Multicenter Random Assignment Phase II Sloan Kettering Cancer Center (Flavopiridol) Versus Irinotecan
8062   A Phase 1 Study WI020                 University in CombinationGeorge Active and
                                                                Wilding, with Cisplatin
                            of R-(-)-Gossypol (AT-101) of Wisconsin Hospital and Clinics Etoposide in Patients with Adva
8063                       CA043             City of Hope       Shibata, StephenActive
       A Phase 1 and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and
8064                       FL065             Moffitt Cancer Center and ResearchLarge
                                                                Grant, and Diffuse Institute
       Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Steven Active B-Cell Lymphomas
8069                       TN116             Vanderbilt-Ingram Cancer Center Active in Colorectal Cancer Patients with
                                                                Chan, the Combination
       A Preoperative Biological Trial of Cetuximab, Dasatinib or Emily
8070                       FL065             Moffitt Cancer Cetuximab and Sorafenib or Single Agent Cetuximab in Pat
                                                                Gilbert, Jill
       Phase II Randomized Trial of the Combination ofCenter and Research Institute Active
8071                       WI020             273063) and Cilengitide (EMD 121974) in Subjects with Accrual &Treatmen
                                                                Sondel, Paul        Temporarily
       A Pilot Trial of Hu14.18-IL2 (EMD University of Wisconsin Hospital and Clinics Closed toCompletely Resecta
8076                       11030             University HealthMoore, Malcolm Active
                                                                Network-Princess Margaret Hospital
       The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure
8077                       MD017             Johns Hopkins University
                                                                Karp, Judith        Active
       A Randomized Phase II Trial of Tipifarnib (R115777, Zarnestra, NSC #702818, IND #58,359) in Combination w
8079                         Concurrent Chemoradiation/Chemoreirradiation with Cetuximab (ERBITUX®), Sunitinib, and
       A Phase I Trial ofIL057                                  Villaflor, Victoria Active
                                             University of Chicago
8085                        Using            National Cancer Institute Surgery Active
                                                                Rosenberg, Steven
       A Phase II Study NCISBShort-Term Cultured Anti-Tumor AutologousBranch         Lymphocytes Following a Lymphocyte De
8087                        of Active        Duke University Medical Michael Closed to Accrual
                                                                Morse, Center
       A Phase II Study NC010 Immunotherapy with Panvac or Autologous, Cultured Dendritic Cells Infected with P
8109                       IMC-A12           742460) in Combination AungTemsirolimus CCI-779 (NSC# 683864) in Patie
       Phase I Study of TX035 (NSC# M D Anderson Cancer Center  Naing, with         Active
8124   A Phase 2 Study NY016                 Memorial in Hepatocellular Carcinoma
                                                                Abou-Alfa, Ghassan
                            of IMC-A12 (NSC 742460) Sloan Kettering Cancer Center   Temporarily Closed to Accrual
8129                        IMC-A12          Mayo Clinic Rochester
                                                                Ma, Cynthia         Active
       Phase I/II Trial ofMN026 in Combination with Temsirolimus in Patients with Metastatic Breast Cancer
8131                       IL057             and A12 in Advanced Rashmi Sarcoma
                                                                Chugh,
       A Phase 1/2 Study of Doxorubicin University of Chicago Soft Tissue Active
8148                       CO085             University Anti-IGF-1R Monoclonal Antibody IMC-A12 in
                                                                Camidge, David Active
       A Phase I/Randomized Phase II Study of theof Colorado at Denver Health Sciences Center Combination with
8155                         Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sor
       A Phase I Trial ofCA189                                  O'Donnell, Robert
                                             University of California At Davis Active
8169                        of Suberoylanilide Hydroxamic Acid andSteven
       A Phase II Study MN026                                   Attia,              Active
                                             Mayo Clinic Rochester Bortezomib in Advanced Soft Tissue Sarcomas
8174                       NCIMB             National Cancer Institute MedicineClosed to Accrual
                                                                Giaccone, Giuseppe   Branch
       A Multicenter Phase II Study of Belinostat (PXD101) in Previously Chemotherapy Treated Thymoma and Thym
8183                        Patients         National Cancer Institute a Non-Myeloablative Lymphocyte Depleting Regim
                                                                Kammula, Udai Active
       Phase II Study inNCISB with Metastatic Melanoma Using Surgery Branch
8187                       NCIMB             National Cancer Institute Ravi
                                                                Madan, Medicine of a Vaccine ( GI-6207) Consisting of Wh
       An Open Label Phase I Study to Evaluate the Safety and TolerabilityActive     Branch
8190                       Trial of          Moffitt Cancer Center and Research Institute
                                                                Weber, Jeffrey Active
       A Dose Ranging FL065 Adenovirus CCL-21 Transduced MART-1/gp100 Peptide-Pulsed Dendritic Cells Matu
8196                        of Imatinib Mesylate in Children and Adults with Sclerotic Skin Changes of Chronic Graft-Ver
       A Phase II Study MD004                                   Cowen, Edward Active
                                             National Institutes of Health
8199                        Phase            University a Recombinant Gary Active
       Multi-Institutional IL057 II Study of IMC-A12,of Chicago Hammer, Human IgG1/Gamma Monoclonal Antibody Direc
8201                       MA148             Massachusetts General Hospital Active
                                                                Sorensen, Alma
       Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using
8209   A Phase 2 Study CA141                 Stanford UniversityColevas, Alexander  Active
                            of Sequential and Concurrent Chemoradiation for Patients with Advanced Nasopharyngeal C
8210                       NCILMB            National Study Institute Lab of Molecular Biology
                                                                Hassan, Raffit Active
       A Phase 1, Single Center, Dose-EscalationCancerof SS1(dsFv)PE38 Administered Concurrently with Pemetre
8213   A Phase 1 Study MA034                 WBRT in Patients with Hospital Cancer
                                                                Eichler, April      Active
                            of AZD2171 and Massachusetts GeneralBrain MetastasesCenter
8217                       NCIMB             National Cancer Institute Medicine Branch
                                                                Dahut, and Prednisone
       A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel,William Active (ART-P) for Treatment of Metasta
8218                       MN026             Mayo Clinic Rochester Amy
                                                                Weise,              Closed to Accrual
       Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients
8224                        Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) with Esc
       Inhibition of DNA NV039                                  Samlowski, Wolfram
                                             Nevada Cancer Institute                Active
8226                         NCILMB            National Cancer Institute Lab Adult T-Cell Leukemia
                                                                  Kreitman, RobertActive
           Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide forof Molecular Biology
8231                         MN026             Mayo Clinic and Erlichman, Charles
           Phase I Trial of the Combination of GDC-0449Rochester                    Active
                                                                  Erlotinib +/- Gemcitabine
8233                         MN026             Mayo Clinic Rochester
                                                                  in Patients with Endometrial, Ovarian, Hepatocellular Carc
           A Phase II Trial of Temsirolimus and Bevacizumab Erlichman, Charles      Active
8236                         IN007             Indiana University MedicalPatrick Closed to Accrual
                                                                  Loehrer, Center
           Phase II Trial of AZD0530 for Patients with Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic
8237                         MD017             Johns Hopkins University
                                                                  Karp, Judith      Active
           Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890
8238                         NCIMB             National Cancer Institute MedicineActive
                                                                  Bates, Susan       Branch
           A Phase I Study of Belinostat in Combination with Cisplatin and Etoposide in Adults with Small Cell Lung Carc
8242                         NCIETI            National Cancer Institute Daniel Active
                                                                  Fowler, Experimental Transplantation & Immunology Bran
           Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinom
8252                         NY016             Memorial 748727] in Patients with V600E
                                                                  Chapman, Paul Active
           Phase II Trial of Hyd-Sulfate AZD6244 [NSCSloan Kettering Cancer Center BRAF Mutated Melanomas
8258                         NY016             Memorial Sloan Kettering Cancer Center
                                                                  Feldman, Plus Oxaliplatin
           A Non-Randomized Phase 2 Study of Alvocidib (Flavopiridol) DarrenActive with or without 5-FU and Leucov
8271                         IL057             University Recurrent Stuart
                                                                  Wong,              c-KIT
           Phase II Trial of Dasatinib (BMS 354825) for of Chicago or MetastaticActive Expressing Adenoid Cystic Carcino
8275                         NCIMB             National Cancer Institute MedicineActive
                                                                  Kummar, Cyclophosphamide in Adults with Refractory Sol
           A Phase I Study of ABT-888 in Combination with MetronomicShivaani         Branch
8276                         NCIMB             National Cancer Fojo, Antonio theBranch
                                                                   Zactima) Plus
           A Targeted Phase I/II Trial of ZD6474 (Vandetanib;Institute MedicineActive Proteasome Inhibitor, Bortezomib (Velc
8277                          of Bevacizumab National Cancerwith Ixabepilone inActive
           A Phase II Study NCIMB                                 Fojo, Antonio      Branch
                                               in Combination Institute Medicine Subjects with Advanced Renal Cell Carc
8281                         MA034             Massachusetts General Cancers with BRAF Mutations Identified by Prospec
                                                                  Lawrence, Donald ctive
                                                                                    A
           Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Hospital Cancer Center
8282                          of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 -Mutated Can
           A Phase 1 Study PA015                                  Puhalla,
                                               University of Pittsburgh Shannon     Active
8283                         NCIMB              of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane
                                                                  Bates, Susan
           A Phase I, Dose-Escalation Study National Cancer Institute MedicineActive Branch
8288                         MN026             Mayo Clinic Rochester Shaji
                                                                  Kumar,
           Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma           Active
8296                         MA036              in Patients with Malignant Melanoma
                                                                  Hodi, Frank
           A Phase 1/2 Study of SCH727965Dana-Farber Cancer Institute               Active
8297                         WA008             Fred Hutchinson Walter, Research Center Ozogamicin (Mylotarg®) and Az
                                                                  Cancer with Gemtuzumab
           A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination Roland Active
8300                         NCIMB             National Cancer Institute MedicineActive
                                                                  Kummar, Shivaani   Branch
           A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Adva
8327                          of Triapine® (NSC #663249) andKunos, UniversityActive with Pelvic Radiation for Treatme
           A Phase 2 Study OH029                                   Cisplatin in Combination
                                               Case Western Reserve Charles
8333                         NCIMIP            National PET/CTKurdziel, Karen Active
                                                                    in Lymphoma
           A Pilot Study of 18F Fluorothymidine (FLT) Cancer Institute Molecular Imaging Program
8340                         MD017             Johns Use of University Standard Computed Tomography to Assess the T
                                                                  Wahl, to
           Phase II Single-Arm Trial Comparing the HopkinsFLT PETRichard Active
8347                         NCIMB             National Cancer Institute MedicineActive
                                                                  Giaccone, Giuseppe  Thymic
           Multicenter Phase II Study of IMC-A12 in Patients with Thymoma andBranch Carcinoma Who Have Been Pre
8351                          Phase            National Cancer Institute MedicineActive
                                                                  Doroshow, JamesBranch
           A Multi-Histology NCIMB II Study of 5-Fluoro-2-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)
8376                         NY011             New York University Langone of FOLFOX Plus
                                                                  Cohen, Deirdre Active
           A Randomized, Double Blind Placebo Controlled Phase 2 Study Medical Center or Minus GDC-0449 in Patie
8418                         IL057             University of Chicago
                                                                  Kindler, Hedy     Active
           A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449
8463                          Cediranib (AZD2171) in Patients Institute MedicineActive
           Phase II Study ofNCIMB                                 Kummar, Shivaani   Branch
                                               National Cancer with Alveolar Soft Part Sarcoma
AALL0232                     COG               Children's Oncology (ALL)
                                                                  Larsen, Eric
           High Risk B-Precursor Acute Lymphoblastic Leukemia Group                 Active
AALL02P2                     COG               Children's Oncology Group Lymphoblastic Leukemia (ALL) (Initial CR1 >/=
                                                                   from Acute
           Treatment of Late Isolated Extramedullary RelapseBarredo, Julio Active
AALL0331                     COG               Children's Oncology GroupKelly
                                                                  Maloney,
           Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Active
AALL03B1                     COG               Children's Oncology Group
           Classification of Acute Lymphoblastic Leukemia Loh, Mignon               Active
AALL03B2                     COG               Children's Oncology Group
                                                                  Relling, Mary
           Study of Pharmacogenetic Risk Factors for Avasular Necrosis CCG Active   1882
AALL0433                     COG               Children's OncologyChildhood
                                                                  of Group          Active
           Intensive Treatment for Intermediate-Risk Relapse Lew, Glen B-Precursor Acute Lymphoblastic Leukemia
AALL0434                     COG               Children's Oncology Group
                                                                  Winter, IND#      Active
           Intensified Methotrexate, Nelarabine (Compound 506U78; Stuart52611) and Augmented BFM Therapy for Ch
AALL04B1                     COG               Children's OncologyMatherly,
           Molecular Correlates of Methotrexate in Childhood ALLGroupLarry Active
AALL04B2                     COG               and Relapse Risk in Standard Risk ALL
                                                                  Aplenc, Richard Active
           Single Nucleotide Polymorphisms Children's Oncology Group
AALL05B1                     COG               Children's Oncology Group
                                                                  Hunger, StephenActive
           A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia R
AALL0622                     COG               Children's (Dasatinib: IND#
                                                                  Slayton, William Active
           Intensified Tyrosine Kinase Inhibitor TherapyOncology Group 73969, NSC# 732517) in Philadelphia Chromos
AALL0631                      of Risk DirectedChildren's Oncology with Joanne Active
           A Phase III StudyCOG                                   Hilden, Acute Lymphoblastic Leukemia (ALL): Randomizat
                                                Therapy for Infants Group
AALL06B1                     COG                Applicable Research to Generate Effective Treatments (TARGET) Initiative
                                                                  Hunger, StephenActive
           Childhood Cancer TherapeuticallyChildren's Oncology Group
AALL06N1                     COG               Children's Oncology for ALL
                                                                  Winick, Naomi Active
           A Study of Neurocognitive Function in Children TreatedGroup
AALL07P1                     COG               Children's Velcade®, IND
                                                                  Horton, Terzah Active
           A Phase II Pilot Trial of Bortezomib (PS-341, Oncology Group#58,443) in Combination with Intensive Re-Induc
AALL07P2                     COG               Children's Oncology Group
                                                                  Salzer, Wanda Closed to Accrual
           Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase® ; Crisantaspase; IND 290) Following Allergy t
AALL07P4                     COG               Children's Oncology Group Anne Active
                                                                  Angiolillo,
           A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594) or Intravenous Oncas
AALL08P1                     COG               Children's Oncology Group
                                                                  Dreyer, Zoann Temporarily Closed to Accrual
           Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study
AAML0431                       Down            Children's Oncology Myeloid
                                                                  Taub, Jeffrey     Active
           The Treatment ofCOG Syndrome Children with AcuteGroup Leukemia (AML) and Myelodysplastic Syndrom
AAML0523                     COG               Children's Oncology GroupBassem
                                                                   73,789)          Active
           A Phase I/II Study of CLOLAR® (Clofarabine, IND#Razzouk,in Combination with Cytarabine in Pediatric Patien
AAML0531                     COG               Children's Oncology Group
                                                                  Gamis, (Mylotarg®) Combined with Conventional Chemoth
           A Phase III Randomized Trial of Gemtuzumab Ozogamicin Alan               Active
AAML05P1                     COG               Children's Oncology Unrelated Donor Hematopoietic Stem Cell Transplanta
                                                                  Davies, Stella Active
           Killer Immunoglobulin-like Receptor (KIR) IncompatibleGroup
AAML0631                     COG               Diagnosed Childhood Acute
                                                                  Gregory, John Active
           Risk Adapted Treatment of Newly Children's Oncology Group Promyelocytic Leukemia (APL) Using Arsenic T
AAML06P1                     COG               Children's 76,431) in Combination with ChemotherapyTreatmentPatients wi
                                                                  Brown, Patrick Closed to Accrual & in Young
           A Pilot Study of Lestaurtinib (CEP-701, IND#Oncology Group
AAML07P1                       COG               Children's Oncology GroupJeffrey Active
                                                                   Moscow,
            A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemother
AAML08B1                       COG               Children's Disorder Group
                                                                   Sorrell, April   Active
            Biology Study of Transient Myeloproliferative Oncology (TMD) in Children with Down Syndrome (DS)
ABTR04B1                       COG               Children's Oncology Group
                                                                   from Pediatric Cancers for Biological and Pre-Clinical Ther
            Establishing Continuous Cell Lines and Xenografts Reynolds, Charles     Active
ABTR06C1                       COG               in Children       Berg, Stacey
            Pharmacokinetics of Daunomycin Children's Oncology Group                Closed to Accrual & Treatment
ACCRN07                        COG               Official COG Registry, The Childhood Cancer Research Network (CCRN)
                                                                   Reaman,          A
            Protocol for the Enrollment on the Children's Oncology GroupGregory ctive
ACNS0122                       to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery to Eliminate Al
            A Phase II Study COG                                   Goldman,
                                                 Children's Oncology Group Stewart  Closed to Accrual
ACNS0221                       of Conformal Radiotherapy Oncology GroupLow-Grade Gliomas
            A Phase II Study COG                                   Cherlow,
                                                 Children's In Patients with Joel Active
ACNS0223                       COG               Children's Oncology Group
                                                                   Chintagumpala, Murali <= 10 Years
                                                                                    Closed
            A Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children to Accrual with Progressive/Sym
ACNS0232                       COG               Children's Oncology Group
                                                                    Response-Based Radiotherapy for Newly Diagnosed Prim
            Radiotherapy Alone vs. Chemotherapy Followed byAllen, Jeffrey           Closed to Accrual
ACNS02B3                       COG               Children's Oncology Group Scott Active
                                                                   Pomeroy,
            A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
ACNS0331                       COG                Volume Boost Irradiation and Reduced
                                                                   Michalski,
            A Study Evaluating Limited TargetChildren's Oncology Group Jeff ActiveDose Craniospinal Radiotherapy (1
ACNS0332                       COG               Children's Oncology Group
                                                                    with Radiation Active
            Efficacy of Carboplatin Administered ConcomitantlyOlson, James and Isotretinoin as a Pro-Apoptotic Agent in
ACNS0333                       COG               Children's Oncology Group
                                                                   Reddy, Alyssa Temporarily System Accrual
            Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central NervousClosed towith Surgery, Intens
ACNS0334                       COG               Children's Oncology Group ClaireTemporarily Closed to Accrual
                                                                   Mazewski,
            A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medu
ACNS0621                       121974) (IND# 59073) in Recurrent or ProgressiveActive
            Cilengitide (EMD COG                                   MacDonald,        and
                                                 Children's Oncology Group Tobey Refractory Childhood High-Grade Gl
                               ACOSOG            American College of Surgeons Oncology to Accrual to
                                                                   Brain Radiation Closed in Addition
ACOSOG-Z0300A Phase III Randomized Trial of the Role of Whole Asher, Anthony TherapyTrials Group Radiosurgery in the
            A                  of Interferon-Based Adjuvant Chemoradiation in OncologywithAccrual
ACOSOG-Z05031 Phase II Study ACOSOG                                Picozzi, Vincent Closed to Resected
                                                 American College of Surgeons Patients Trials Group Pancreatic Adenoca
                               ACOSOG            American to 18 Weeks of Neoadjuvant Exemestane (25
                                                                   Ellis, Matthew James
                                                                                    Active
ACOSOG-Z1031A Randomized Phase III Trial Comparing 16College of Surgeons Oncology Trials Group mg daily), Letrozol
                               ACOSOG            American College of Surgeons Oncology Followed by
                                                                   Buzdar, Aman      FEC-75
ACOSOG-Z1041A Randomized Phase III Trial Comparing a Neoadjuvant Regimen ofActive Trials Group Paclitaxel Plus Tras
                               Evaluating        American College of Surgeons Oncology Trials Group
                                                                   Boughey, Surgery and
ACOSOG-Z1071A Phase II Study ACOSOG the Role of Sentinel Lymph NodeJudy Active Axillary Lymph Node Dissection Fo
                               ACOSOG            American College of Surgeons the Treatment Group
                                                                   Simmons, RacheActive
ACOSOG-Z1072A Phase II Trial Exploring the Success of Cryoablation Therapy inOncology Trialsof Invasive Breast Carcinoma
                               ACOSOG            American College of Surgeons Active
ACOSOG-Z3081Molecular Mechanisms of OSCC Tumor Invasion Ziober, Barry Oncology Trials Group
                                 Analysis        American College of Surgeons Oncology Trials Group
                                                                   Harpole, David Closed to Accrual
ACOSOG-Z4031Use of ProteomicACOSOGof Serum Samples for Detection of Non-Small Cell Lung Cancer
                               ACOSOG            American College of Surgeons Oncology Trials Plus Brachytherapy in High
                                                                   Fernando, Hiran Closed to Accrual
ACOSOG-Z4032A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Group
                               ACOSOG            American College of Surgeons Oncology Trials Group
                                                                   Dupuy, Damian Active
ACOSOG-Z4033A Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage IA Non-Small Cell Lung Cancer
                               of Neoadjuvant Therapy with Cisplatin, Docetaxel, PanitumumabGroupRadiation Therapy Fol
ACOSOG-Z4051A Phase II Study ACOSOG                                Reed, Carolyn Active
                                                 American College of Surgeons Oncology Trials Plus
                               of Preoperative Gemcitabine and Pisters, Peter Pancreatectomy Group
ACOSOG-Z5041A Phase II Study ACOSOG                                Erlotinib Plus   Active
                                                 American College of Surgeons Oncology Trials and Postoperative Gemcitab
                               ACOSOG            American College Local Excision for uT2uN0 Rectal Cancer
                                                                   Garcia-Aguilar, Julio
                                                                                    Closed to Accrual
ACOSOG-Z6041A Phase II Trial of Neoadjuvant Chemoradiation and of Surgeons Oncology Trials Group
                               ACOSOG            American College of Surgeons Oncology Trials Group
                                                                   Fleshman, James ctive
                                                                                    A
ACOSOG-Z6051A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resecti
                                                 American of Adjuvant STI571 Oncology Trials Group Treatment
ACOSOG-Z9001A Phase III Randomized Double-Blind StudyCollege of Surgeons(Gleevec™) Versus Placebo in Patients Follo
                               ACOSOG                                               C
                                                                   DeMatteo, Ronald losed to Accrual &
                               ACOSOG            American College of Surgeons Oncology
                                                                   Engel, (GIST)
ACOSOG-Z9081Genetic Risk Factors for Gastrointestinal Stromal Tumors LawrenceActive Trials Group
ACRIN-6654                     ACRIN             American College of Radiology Closed to Accrual
                                                                   Cancer
            Contemporary Screening for the Detection of Lung Aberle, DeniseImaging Network
ACRIN-6660                      in the            of Pediatric Malignancies
                                                                   Siegel, Marilyn Active
            Whole-Body MRIACRINEvaluationAmerican College of Radiology Imaging Network
ACRIN-6661                     ACRIN             American College of Radiology Imaging Network
                                                                   Dupuy, Damian Closed to Accrual & Treatment
            A Phase I/II Study of Percutaneous Radiofrequency Ablation of Bone Metastases Using CT Guidance
ACRIN-6662                     Calculation of Volumes of Enhancing Radiology Imaging Plus Edema from Routine MR Imag
            Semi-Automated ACRIN                                   Ertl-Wagner, Birgit
                                                                                    Active
                                                 American College of Tumor and Tumor Network
ACRIN-6664                     ACRIN                               Johnson, Charles Closed to Accrual & Treatment
            National CT Colonography Trial American College of Radiology Imaging Network
ACRIN-6666                     ACRIN             American College of Radiology Closed to Accrual
                                                                   Berg, Wendie
            ACRIN 6666: Screening Breast Ultrasound in High-Risk Women Imaging Network
ACRIN-6668                     ACRIN             American College of Radiology Imaging Locally Advanced Non-Small Cell Lu
                                                                   Machtay, MitchellC for Network
            Positron Emission Tomography Pre- and Post-Treatment Assessmentlosed to Accrual
ACRIN-6673                     ACRIN             American College of Radiology Imaging Network
                                                                   Dodd, Gerald     Closed to Accrual & Treatment
            Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhoti
ACRIN-6678  FDG-PET/CT as ACRIN                  American College of Radiology Imaging Network
                                                                   Weber, Wolfgang  Active
                               a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non
ACRIN-6682                     ACRIN             American College of Radiology Imaging Network
            Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer                   Active
                                                                   Dehdashti, Farrokh
ADVL0221                       of Trabectedin ( ET-743, Yondelis®) in Children with Recurrent Rhabdomyosarcoma, Ewing
            A Phase II Study COG                                   Baruchel,
                                                 Children's Oncology Group SylvainClosed to Accrual & Treatment
ADVL0413                       COGC              COG Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 72
                                                                   Widemann,
            A Phase I Study of the RAF Kinase and Phase 1 Consortium Brigitte       Active
ADVL0419                       of Valproic Acid in Children withConsortium
            A Phase 1 Study COGC                                   Su, Jack         Closed to Tumors Including CNS
                                                 COG Phase 1 Recurrent/Progressive Solid Accrual & Treatment Tumors
ADVL04P2                        and              Children's Oncology Group
                                                                   Raetz, Elizabeth Active
            A Feasibility PilotCOGPhase 2 Study of Chemoimmunotherapy with Epratuzumab (IND #12034) for Children w
ADVL0515                       COGC              COG Phase 1 Consortium for Closed to Accrual Diagnosed and Recurr
                                                                   Carboplatin
            A Phase I Study of Vinblastine in Combination with Jakacki, ReginaChildren with Newly& Treatment
ADVL0525                       of Pemetrexed in Children with Recurrent Malignancies to Accrual & Treatment
            A Phase II Study COG                                   Warwick,
                                                 Children's Oncology GroupAnne Closed
ADVL0612                       COGC              COG an Oral Consortium
                                                                   DuBois, Steven Active
            A Phase I Study of Sunitinib (SU11248),Phase 1 Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Ref
ADVL06B1                       COG               Children's Oncology Group
                                                                   Skolnik, Jeffrey Active
            A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children w
ADVL0714                       COGC              COG Phase 1 Consortium
                                                                   Park, Julie      Temporarily Closed to Accrual &Treatmen
            A Phase I Study of VEGF Trap (NSC # 724770, IND# 100137) in Children with Refractory Solid Tumors
ADVL0812                       COGC              COG Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with
                                                                   Mosse, Yael
            A Phase I/II Study of MLN8237, an Oral Phase 1 Consortium               Active
ADVL0813                       COGC              COG Phase 1 Consortium
                                                                   Fouladi, Maryam Active
            A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination
ADVL0815                     COGC               COG Phase 1 forBender, Julia
                                                                   Children        Active
           A Phase I Study of Pazopanib as a Single Agent Consortium with Refractory Solid Tumors
ADVL0816                     COGC               COG Phase 1 Consortium
                                                                  Aplenc, Richard Temporarily Closed to Accrual
           A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with
ADVL0821                      of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND #100947, NSC #742460) in Child
           A Phase II Study COG                                   Weigel, Brenda Active
                                                Children's Oncology Group
ADVL0911                     COGC               of Seneca ValleyBurke,(NTX-010), A Replication-Competent Picornavirus, i
           A Phase 1 Dose Escalation Study COG Phase 1 Consortium  Virus Michael Active
ADVL0912                     COGC               COG Oral Small Molecule
                                                                  Mosse, Yael      Active
           A Phase 1/2 Study of PF-02341066, an Phase 1 Consortium Inhibitor of Anaplastic Lymphoma Kinase (ALK) a
ADVL0916                     COGC                Bortezomib in Children with
                                                                  Muscal, Jodi     Active
           A Phase I Study of Vorinostat andCOG Phase 1 Consortium Refractory or Recurrent Solid Tumors, Includin
AEPI05N1                     COG                Children's Oncology Group Retinoblastoma
                                                                  Bunin, and
           Carcinogen Metabolism, DNA Repair, Parental ExposuresGreta              Active
AEWS0331                     Tumor              Children's National Group Ewing A
                                                                  Hawkins,         Tumour
           European Ewing COG Working Initiative of OncologyGroupsDouglas ctive Studies 1999 (EURO-E.W.I.N.G.
AEWS07B1   A COG Study for COG                  Children's Oncology Group Stephen
                                                                  Lessnick,
                              Collecting and Banking Ewing Sarcoma Specimens       Active
AEWS07P1                     COG                Children's Oncology Group
                                                                  Mascarenhas, Leo Topotecan and Cyclophosphamide to Sta
           A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Closed to Accrual & Treatment
AEWS08B1                      of p53            Children's Oncology Group Stephen
                                                                  Lessnick,
           Prognostic ValueCOG and/or p16 Alterations in Ewing Sarcoma Active
AGCT0132                      of Reduced Therapy in theOncology Group
           A Phase III StudyCOG                                   Frazier, A.      Active
                                                Children's Treatment of Children with Low and Intermediate Risk Extracran
AGCT0521                     COG                Children's Oncology Group
                                                                  Rodriguez-Galindo, Carlos
                                                                                   Active
           Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors with Paclitaxel, Ifosfamide and Ca
AHEP0731                     COG                Children's Oncology Group Howard
           Treatment of Children with All Stages of HepatoblastomaKatzenstein,     Active
AHOD0031                     COG                Children's Oncology Group DebraClosed to Accrual
                                                                  Friedman,
           A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for C
AHOD03P1                     COG                Children's Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
                                                                  Appel, Burton Active
           Treatment of Children with Newly-DiagnosedOncology Group
AHOD0431                      for the           Children's Oncology Group
                                                                   Adolescents     Closed Diagnosed
           A Phase III StudyCOG Treatment of Children andKeller, Frank with Newlyto Accrual Low Risk Hodgkin Dis
AHOD04B1                      (HD)
           Hodgkin DiseaseCOG Banking Study                       Higman, MeghanActive
                                                Children's Oncology Group
AHOD0521                      of Bortezomib (Velcade, PS-341, INDGroup in Combination with Ifosfamide/Vinorelbine in
           A Phase II Study COG                                   Horton, Terzah Closed to Accrual & Treatment
                                                Children's Oncology #58443)
ALTE03N1                     COG                Children's        Bhatia, Smita
           Key Adverse Events After Childhood Cancer Oncology Group                Active
ALTE05N1                     COG
           Umbrella Long-Term Follow-Up Protocol                  Bhatia, Smita
                                                Children's Oncology Group          Active
ALTE07C1                     COG                Children's Oncology Outcomes in Children with Cancer
                                                                  Segovia, LeanneActive
           Neuropsychological, Social, Emotional, and Behavioral Group
AMC-045                      AMC                AIDS-AssociatedSparano, in HIV-Associated Anal Carcinoma
                                                                   Malignancies Clinical
           Phase II Trial of Combined Modality Therapy Plus CetuximabJosephActiveTrials Consortium
AMC-046                       1%                AIDS-AssociatedStier, ElizabethClinical Trials Consortium
                                                                   Malignancies Perianal Accrual & Intraepithelial Lesion
           Phase IIA Trial ofAMCTopical Cidofovir for Treatment of High-Grade Closed toSquamous Treatment
AMC-047                      AMC                AIDS-AssociatedLevine, Alexandra
                                                                   Malignancies Clinical Trials Consortium
                                                                                   and Prednisone (DR-COP) In Patients wit
           A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, Closed to Accrual
AMC-048                      AMC                AIDS-AssociatedNoy, Ariela
                                                                   Malignancies Clinical Trials Consortium
                                                                                   Closed to Accrual
           Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Pene
AMC-050                      AMC                AIDS-AssociatedDittmer, Dirk Clinical Trials with Liposomal Anthracycline
                                                                   Malignancies Active
           Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients TreatedConsortium
AMC-051                      AMC                AIDS-AssociatedKrown, Susan Clinical Trials Consortium
                                                                   Malignancies Closed
           A Pilot Study of Rapamycin in Patients with HIV-Related Kaposi's Sarcoma to Accrual & Treatment
AMC-052                      AMC                AIDS-AssociatedWilkin, TimothyClinical Trials Consortium
                                                                   Malignancies Closed to Accrual
           A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavir
AMC-053                      AMC                AIDS-AssociatedReid, Erin
                                                                   Malignancies Clinical Trials Combined
                                                                                   Active
           Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of VelcadeConsortium with (R)ICE in Su
AMC-054                      AMC                AIDS-Associated and Immunogenicity of the Merck Quadrivalent Human Pa
                                                                   Malignancies Active
           A Single-Arm, Open-Label Pilot Study of the SafetyPalefsky, Joel Clinical Trials Consortium
AMC-058                      AMC                AIDS-AssociatedBerry, J.
                                                                   Malignancies Clinical Trials Consortium
                                                                                   Active
           A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamo
AMC-059                       of PTC299 in Patients with HIV-Related Kaposi'sClinical Trials Consortium
           A Phase 1/2 TrialAMC                                    Malignancies Active
                                                AIDS-AssociatedKrown, Susan Sarcoma
AMC-060                      AMC                AIDS-Associated Have Sex with Men (MSM)
                                                                   Malignancies Active
           HPV Infection in Indian HIV-Seropositive Men Who Palefsky, Joel Clinical Trials Consortium
AMC-061                      AMC                of Sunitinib in Patients with Cancer Who Also Have HIV and are on HAART
                                                                   Malignancies Active
           A Phase 1/Pharmacokinetic StudyAIDS-AssociatedDeeken, John Clinical Trials Consortium
AMC-064                      AMC                AIDS-AssociatedWagner-Johnston,from Patients with Aggressive B-Cell Lym
                                                                    DNA in Plasma Nina
                                                                                   Active
           Evaluation of Serum Free Light Chains and Clonal IgMalignancies Clinical Trials Consortium
ANBL0032                     COG                Children's Oncology Group
                                                                  Yu, Alice        Active
           Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following My
ANBL00P3                     COG                Children's Gammaglobulin Therapy for Patients with Neuroblastoma Assoc
                                                                  De Group
           A Phase III Randomized Trial of Intravenous Oncology Alarcon, PedroctiveA
ANBL0531                     COG                Children's Oncology Group
                                                                  Twist, Clare
           Response and Biology-Based Therapy for Intermediate-Risk Neuroblastoma  Active
ANBL0532                     COG                Children's Oncology Group
                                                                  Park, Julie      Active
           Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neurobla
ANBL0621                      of ABT-751, an Orally Bioavailable Tubulin Binding Closed in Children with Relapsed or Refra
           A Phase II Study COG                                   Fox, Elizabeth Agent, to Accrual
                                                Children's Oncology Group
ANBL06B1                     Neuroblastoma Tumorigenesis Maris, John
           Genetic Basis of COG                 Children's Oncology Group          Active
ANBL07B1                     COG                Children's Samples Group
                                                                  Hogarty, MichaelActive
           Analysis of Circulating MYCN DNA in Serum Oncology Obtained from Patients with Neuroblastoma
ANHL0131                     COG                Children's Oncology Group Large Cell
                                                                  Kraveka,         Closed to Accrual
           A Phase III Trial of Treatment of Advanced-Stage Anaplastic Jacqueline Lymphoma (ALCL) with Standard APO
ANHL01P1                     COG                Children's Addition Group
                                                                  Cairo, Mitchell Closed to Accrual & Treatment
           A Pilot Study to Determine the Toxicity of theOncologyof Rituximab to the Induction and Consolidation Phases
ANHL0221                      of the            Children's Oncology Group
                                                                  Gross, Thomas Closed Rituximab (CPR) in Children, Ado
           A Phase II Study COG Combination of Cyclophosphamide, Prednisone andto Accrual & Treatment
ANHL04B1                     COG                Children's Oncology Group Amanda
           Rare and Cutaneous Non-Hodgkin Lymphoma Registry       Termuhlen,       Active
AOST0221                      of Aerosolized GM-CSF (NSC # 613795,Carola 11042) in Patients with First Pulmonary Recu
           A Phase II Study COG                                   Arndt, IND#
                                                Children's Oncology Group          Closed to Accrual & Treatment
AOST0331                     COG                Children's Oncology Group
                                                                   Osteosarcoma Active
           A Randomized Trial of the European and AmericanMarina, Neyssa Study Group to Optimize Treatment Strate
AOST06B1                     COG                Children's Oncology Group
                                                                  Gorlick, Richard Active
           A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
AOST06P1                     COG                Children's Oncology Group
                                                                  Goldsby, Robert Active
           Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment o
AOST08B1                     COG                Children's for Osteosarcoma
                                                                  Savage, Sharon Active
           Retrospective Study of Genetic Risk Factors Oncology Group
ARAR0331                         COG               Children's Oncology Group
                                                                    Rodriguez-Galindo, Carlos
                                                                                       Active
              Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chem
ARAR0332                         COG               Children's Oncology Lymph
                                                                    Rodriguez-Galindo, Carlos and Multiagent Chemotherapy
              Treatment of Adrenocortical Tumors with Surgery plus Group Node Active   Dissection
AREN0321                         COG               Children's Oncology Group
                                                                    Dome, Jeffrey
              Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Active
AREN03B1                          Wilms            Children's Oncology GroupElizabeth
              Categorization ofCOG Tumors by Genetic Expression     Perlman,           Active
AREN03B2                         COG               Children's Oncology Group
                                                                     Study
              Renal Tumors Classification, Biology, and Banking Grundy, Paul           Active
AREN04B1                         COG               Children's Oncology Group Gail Active
                                                                    Tomlinson,
              The Incidence, Inheritance, and Prognostic Significance of Polymorphisms in the RASSF1A Gene in Children
AREN0532                         COG               Children's Oncology Group Wilms
                                                                    Fernandez,
              Treatment for Very Low and Standard Risk Favorable HistologyConrad Tumor Active
AREN0533                         COG               Children's Oncology Group
                                                                    Dix, David
              Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms TumorsActive
AREN0534                         COG               Children's Oncology Group
                                                                    Ehrlich, Peter     Active
              Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
ARET0231                         COG               Children's Oncology Group
                                                                    Jubran, Rima       Active
              A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma
ARET0321                         COG               Children's Oncology Group
                                                                    Dunkel, Ira        Active
              A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma
ARET0332                         COG               Children's Oncology Histopathologic High-Risk Features and the Role of Ad
                                                                    Chintagumpala, Murali to Accrual
              A Study of Unilateral Retinoblastoma With and WithoutGroup               Closed
ARST0331                         COG               Children's of Cyclophosphamide With or Without Radiation Therapy for Pati
                                                                    Walterhouse, David
              Vincristine, Dactinomycin, and Lower Doses Oncology Group                Active
ARST0332                         COG               Children's Oncology Group
                                                                    Spunt, Sheri       Active
              Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Ye
ARST0531                         COG               Children's Oncology Group
                                                                     Cyclophosphamide (VAC) versus VAC Alternating with Vin
              Randomzed Study of Vincristine, Dactinomycin andHawkins, Douglas ctive   A
ASCT0431                         COG               Children's Oncology Group Michael
                                                                    Pulsipher,         Active
              A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cel
ASCT0521                         COG               Children's Oncology Group for Active
                                                                    (Etanercept)
              Soluble Tumor Necrosis Factor Receptor: Enbrel® Yanik, Gregory the Treatment of Acute Non-Infectious Pul
ASCT0631                         COG               Children's Oncology Group
                                                                     Bone Marrow vs. Conventional Bone Marrow as
              A Phase III Randomized Trial of G-CSF Stimulated Grupp, Stephan Temporarily Closed to Accrual a Stem C
BCDM 8235                        IBCSG             International Breast Cancer Study Group
                                                                    Cole, Interaction Effects
              Overview Analysis Using STEPP Methodology to Assess Bernard Active Between Randomized Treatment
                                 BMTCTN            Blood and Marrow Transplant Clinical Trials Network
                                                                    Laport, Ginna Active
BMT-CTN 0701 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed
                                 SWOG              Southwest Oncology Group
                                                                    Maloney, David Closed to Accrual
BMTCTN-0102 A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Th
                                 SWOG              Southwest Oncology Group
                                                                    Vose, Julie        Active
BMTCTN-0401 Phase III Rituxan/BEAM vs Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) f
C80405                           CALGB             Cancer and or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuxima
                                                                    Venook, Alan
              A Phase III Trial of Irinotecan/5-FU/LeucovorinLeukemia Group B Active
                                 CALGB             Cancer for Leukemia Group B Closed to Accrual & Treatment
                                                                    Farag, Sherif
CALGB-100101 A Phase II Trial of Intravenous Pentostatinand the Treatment of Patients with Refractory Chronic Graft-Versus
                                  of Allogeneic Transplant andOlderDevine, Steven Active
CALGB-100103 A Phase II Study CALGB                                  Patients with
                                                   Cancer for Leukemia Group BAML in First Morphologic Complete Remissio
                                 CALGB             Cancer and Leukemia Group B Closed to Accrual
                                                                    McCarthy, Philip
CALGB-100104 A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND # 70
CALGB-10101 A Phase II Study CALGB                  Rituximab Induction Followed by Closed to Accrual & Treatment
                                                                    Lin, Thomas
                                  of Fludarabine + Cancer and Leukemia Group B Alemtuzumab (Campath-1H, NSC #71596
                                 CALGB             Cancer and Leukemia Group B Closed to Accrual & Treatment
                                                                    Stock, Wendy
CALGB-10102 A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC # 715969, IND # 10864) During Inten
                                  of an Oral        Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC
                                                                    Gupta, Pankaj
CALGB-10105 A Phase II Study CALGB VEGFCancer and Leukemia Group B Closed to Accrual
CALGB-10301 Phase II Study ofCALGB                 Cancer and Leukemia Group B Closed to Accrual Therapy for
                                                                    Orlowski, Robert
                                  Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial & Treatment Adult Patie
                                 CALGB             Cancer and Leukemia Group Adults with
                                                                    Stock, Wendy
CALGB-10403 An Intergroup Phase II Clinical Trial for Adolescents and Young B Active Untreated Acute Lymphoblastic Le
                                 CALGB             Cancer and Leukemia John Fludarabine
                                                                    Byrd, Four
CALGB-10404 A Genetic Risk-Stratified, Randomized Phase II Study of Group B Active / Antibody Combinations for Patien
                                 CALGB             Cancer and Leukemia John Untreated to Accrual
                                                                    Patients with
CALGB-10501 A Phase III Intergroup CLL Study of Asymptomatic Byrd, Group B ClosedChronic Lymphocytic Leukemia Ra
                                 CALGB             Cancer and Leukemia Group B Closed to Accrual
                                                                    (IND Eyal
CALGB-10502 Dose Escalation and Phase II Study of Bortezomib Attar,#58443, NSC # 681239) Added to Standard Daunoru
CALGB-10503 Phase II Study ofCALGB                 Cancer and Leukemia Group B Active
                                                                    Blum, William
                                  Maintenance Therapy with Decitabine (NSC# 127716, IND #50733) Following Standard Indu
                                 CALGB             Cancer and Leukemia (Daunorubicin/Cytarabine) and Consolidation (High-
                                                                    Stone, Richard
CALGB-10603 A Phase III Randomized, Double-Blind Study of InductionGroup B Active
                                 CALGB             Cancer and Leukemia Group B
                                                                     Sublobar Resection for
CALGB-140503 A Phase III Randomized Trial of Lobectomy VersusAltorki, Nasser Active Small (</= 2 cm) Peripheral Non-S
                                 CALGB             Cancer and Leukemia Group B Closed to
                                                                    Bueno, Raphael
CALGB-150303 Gene Ratios for Prognosis in Lung Cancer Using Tissues from CALGB 9761 Accrual & Treatment
                                 CALGB             Cancer in Patients WithPasi
                                                                    Janne, Stage NSCLC treated on CALGB-30106
CALGB-150508 Evaluation of EGFR and K-RAS Mutationsand Leukemia Group B III Closed to Accrual & Treatment
                                 CALGB             Cancer and andKratzke, Robert Closed to Accrual & Treatment
                                                                     Disease in B
CALGB-150509 Additional Circulating Markers of AngiogenesisLeukemia GroupMesothelioma Patients Treated on CALGB-301
                                 CALGB             Cancer on Leukemia Group
                                                                    Janne, Patients Closed to IB NSCLC in CALGB
CALGB-150601 The Impact of KRAS and EGFR Mutationsand Outcome of Pasi B with Stage Accrual & Treatment 9633
                                 Study the         Cancer and Leukemia in Resected Lung
                                                                    Salgia, Ravi
CALGB-150607 A Pilot Project to CALGB Expression of c-MET and p53Group B Active Adenocarcinoma Specimens
              Correlative Science Studies in Colon Cancer, A Companion Study toActive 9581 and 89803
CALGB-150705-ICSC                CALGB                              Bertagnolli, B
                                                   Cancer and Leukemia GroupMonica      CALGB
                                 CALGB             Cancer and Leukemia Group B Closed to Accrual & Treatment
                                                                    Janne, Pasi
CALGB-150713 Genomic Characterization of Adenocarcinomas of the Lung from Never or Former Light Smokers
                                 CALGB             Cancer and LeukemiaMing B Active
                                                                    You, Group
CALGB-150803 A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC from the CALGB
                                 CALGB             Cancer and Leukemia GroupMonica
                                                                    Bertagnolli, B Active
CALGB-150806 Correlative Science Studies in Untreated Metastatic Adenocarcinoma of the Colon or Rectum
                                 CALGB             Cancer and Leukemia Group Saikrishna
                                                                    Yendamuri, B Active
CALGB-150901 MicroRNA Profiling Using an Updated Microarray to Prognosticate Early Lung Cancer
                                 CALGB             Cancer and Leukemia GroupClaraActive
                                                                    Bloomfield, B
CALGB-20202 Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
                                 CALGB             Cancer and Leukemia Group B Active
CALGB-20203 Molecular Markers of Chronic Lymphocytic Leukemia       Byrd, John
                                 CALGB             Cancer and Leukemia Group B Active
                                                                    Farag, Sherif
CALGB-20206 A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts
                                 CALGB             Cancer and Leukemia Maria
                                                                     in Acute Myeloid Leukemia: A CALGB Leukemia Tissue B
CALGB-20501 Multidrug Resistance Protein Gene PolymorphismsBaer, Group B Active
                                 CALGB             Cancer and Leukemia Group B Normal
                                                                    Marcucci, with
CALGB-20502 Molecular Genetic Studies of Acute Myeloid Leukemia (AML) Guido ActiveCytogenetics
                               CALGB            Cancer and Leukemia Group B Active
                                                                  Rowley, Janet
CALGB-20801 Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray
                               of PTK787/ZK222584 (NSC#LeukemiaIND# 66370) in Patients with Unresectable Malignant
CALGB-30107 A Phase II Study CALGB                                Jahan, Thierry
                                                Cancer and 719335, Group B Closed to Accrual & Treatment
                               CALGB            Cancer Combination Carboplatin, Etoposide, and Chest Radiotherapy in Lim
                                                                  Kelley, Michael
CALGB-30206 Induction Cisplatin/Irinotecan Followed by and Leukemia Group B Closed to Accrual & Treatment
                               CALGB            Cancer and 704865, IND# 7921) Closed to Accrual & Treatment
                                                                  Ready, Neal
CALGB-30306 Cisplatin, Irinotecan and Bevacizumab (NSC# Leukemia Group B for Untreated Extensive Stage Small Cell L
                               of BAY           Cancer and Leukemia Group B Closed Mesothelioma
                                                                  Janne, Pasi
CALGB-30307 A Phase II Study CALGB 43-9006 (NSC #724772) in Patients with Malignantto Accrual & Treatment
                               CALGB            Cancer (Erlotinib) (NSC Pasi
                                                                  Janne, #718781; IND# 63,383) with
CALGB-30406 A Phase II Randomized Study of OSI-774 and Leukemia Group B Closed to Accrual or without Carboplatin
                               CALGB            Cancer and Leukemia Group B Closed to Accrual or without Cetuximab in
                                                                  Govindan, Ramaswamy
CALGB-30407 A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin with & Treatment
                               CALGB            Cancer and Leukemia Sunitinib Active
                                                                  Ready, Neal
CALGB-30504 Combination Chemotherapy with or without Maintenance Group B Malate (IND 74019; NSC 736511) for Untre
                               CALGB            Cancer and Leukemia Group B Active
                                                                  Harpole, David
CALGB-30506 A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the
                               of Dasatinib (NSC # 732517) Leukemia Group B Closed to Accrual
CALGB-30601 A Phase II Study CALGB                                Dudek, Arkadiusz
                                                Cancer and in Patients with Previously Treated Malignant Mesothelioma
                               of Induction Chemotherapy Followed byGroupRogerio
CALGB-30605 A Phase II Study CALGB                                Lilenbaum, B Active
                                                Cancer and Leukemia Thoracic Radiotherapy and Erlotinib in Poor-Risk St
                               CALGB            Cancer and Leukemia Trial of
                                                                  Socinski, Mark Active
CALGB-30607 Randomized, Phase III, Double-Blind Placebo-ControlledGroup BSunitinib (NSC# 736511, IND # 74019) as M
                               CALGB            Radiotherapy Regimens Jeffrey
                                                                  Bogart, in Patients with
CALGB-30610 Phase III Comparison of Thoracic Cancer and Leukemia Group B Active Limited Small Cell Lung Cancer Als
                               CALGB            Cancer and Leukemia Group B
                                                                  Socinski, Mark or Sunitinib (NSC # 736511, IND # 74019
CALGB-30704 A Randomized Phase II Study to Assess the Efficacy of PemetrexedActive
                               CALGB            Cancer and Leukemia Group COX-2 Inhibition in COX-2 Expressing Advan
                                                                  Edelman, Martin
CALGB-30801 A Randomized Phase III Double Blind Trial Evaluating Selective B Active
                               CALGB             Inhibition of EGFBurstein, Harold Active
                                                                    and Group B
CALGB-40302 Endocrine Therapy with or withoutCancer and Leukemia HER2 Growth Factor Receptors: A Randomized, Dou
                               CALGB            Cancer and Leukemia Group Weekly Nanoparticle Albumin Bound NAB-Pa
                                                                  Rugo, Hope
CALGB-40502 A Randomized Phase III Trial of Weekly Paclitaxel Compared toB Active
                               CALGB             Anti-VEGF Leukemia Randomized, Phase III Trial of Endocrine Therapy A
                                                                  Dickler, Maura
CALGB-40503 Endocrine Therapy with or withoutCancer and Therapy: AGroup B Active
                               CALGB            Cancer and LeukemiaTrastuzumab, Lapatinib, or Both as Neoadjuvant Trea
                                                                   with Group
CALGB-40601 Randomized Phase III Trial of Paclitaxel CombinedCarey, Lisa B Active
                               CALGB            Cancer of the Addition of Carboplatin +/-
                                                                  Sikov, William
CALGB-40603 Randomized Phase II 2 x 2 Factorial Trial and Leukemia Group B Active Bevacizumab to Neoadjuvant Wee
                               CALGB            Cancer and Leukemia with Newly Closed to Accrual CNS Lymphoma
                                                                  Rubenstein, B Diagnosed Primary
CALGB-50202 Intensive Chemotherapy and Immunotherapy in Patients Group James
                               CALGB            Cancer and Leukemia Group B Closed to Accrual & Treatment
                                                                  Straus, (AVG)
CALGB-50203 Phase II Trial of Doxorubicin, Vinblastine and Gemcitabine David Chemotherapy for Non-Bulky Stage I and II
                               CALGB            Cancer and Leukemia Group B with Molecular Profiling in Untreated De N
                                                                  Wilson, Wyndham
CALGB-50303 Phase III Randomized Study of R-CHOP v. Dose-Adjusted Epoch-R Active
                               CALGB            Cancer vs. Leukemia Group B Active
                                                                  Leonard, John
CALGB-50401 A Randomized Phase II Trial of Rituximaband Lenalidomide (Revlimid(TM), CC-5013) (IND# 73034) vs. Ritixu
                               CALGB            Cancer and Leukemia GroupMyron losed to Accrual & Treatment
                                                                  Czuczman, B C
CALGB-50402 A Phase II Trial of Extended Induction Galiximab (Anti-CD80 Monoclonal Antibody) (BB-IND #12373) Plus Ritu
                               CALGB            Cancer and Leukemia Group B Active
                                                                  Kaplan, Lawrence
CALGB-50403 A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Che
                               CALGB            Cancer and + Lenalidomide B Active
                                                                  Morrison, Vicki
CALGB-50501 A Phase II Trial of Bortezomib (NSC #681239)Leukemia Group(Revlimid (TM) , CC-5013) (NSC #703813) for
                               of Galiximab (Anti-CD80) for Leukemia Group B Closed to Accrual
CALGB-50602 A Phase II Study CALGB                                Smith, Sonali
                                                Cancer and Patients with Relapsed/Refractory Hodgkin Lymphoma
                               CALGB            Cancer and Leukemia Group Monoclonal Antibody)
                                                                  Grant, Barbara
CALGB-50701 A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22B Closed to Accrual (CALGB IND #101241)
                               CALGB            Cancer and Leukemia Group B
                                                                  Lewis, Lionel     ABCC2
CALGB-60805 A Study of the Docetaxel Pharmacodynamics and Polymorphisms inActive and SLCO1B3 in Caucasian and
                               CALGB            Cancer and Cost Analysis in B Active
                                                                  Bunnell, Craig
CALGB-70301 Quality of Life, Employment and Informal CareLeukemia Group Women Receiving Adjuvant Chemotherapy fo
                               CALGB            Cancer and or Oxaliplatin/5-FU/Leucovorin with and without Cetuximab (C2
                                                                  Venook, Alan
CALGB-80203 A Phase III Trial of Irinotecan/5-FU/LeucovorinLeukemia Group B Closed to Accrual & Treatment
                               CALGB            Cancer and Leukemia Group B Active
                                                                  Ilson, David
CALGB-80302 A Phase II Trial of Preoperative Irinotecan, Cisplatin and Radiation in Esophageal Cancer
                               CALGB            Cancer and Leukemia Group B Closed to Accrual & Treatment
                                                                  Kindler, Hedy
CALGB-80303 A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC# 704865 IND #7921) Versus Gemcitab
                               CALGB            Cancer and Leukemia Group B Closed to Cancer After Progression on O
                                                                  Ocean, Allyson
CALGB-80402 Phase II Trial of LE-SN38 (IND #74,054) in Patients with Metastatic Colorectal Accrual & Treatment
                               CALGB            Cancer and Leukemia Group B Closed to Accrual
                                                                  Enzinger, Peter
CALGB-80403 Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cance
                               CALGB            Cancer and Leukemia Group
                                                                  O'Neil, 101263) Closed to with Metastatic Colorectal Canc
CALGB-80502 A Phase II Trial of Irinotecan and AZD2171 (CALGB IND# Bert B in Patients Accrual
                               of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients Treatment
CALGB-80603 A Phase II Study CALGB                                O'Reilly, Eileen
                                                Cancer and Leukemia Group B Closed to Accrual & with Previously Treat
                               CALGB            Cancer Plus Doxorubicin Versus Active
                                                                  Abou-Alfa, Ghassan
CALGB-80802 Phase III Randomized Study of Sorafenib and Leukemia Group B Sorafenib in Patients with Advanced Hepa
                               CALGB            Cancer and Leukemia Group Bof Active
                                                                  Smith, Study
CALGB-90202 A Randomized Double-Blind, Placebo-Controlled Phase IIIMatthew Early Versus Standard Zoledronic Acid to
                               CALGB            Cancer and Leukemia Group B
                                                                  Eastham, JamesActive
CALGB-90203 A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostate
                               CALGB            Cancer Alfa-2B or Interferon Alfa-2B Plus Bevacizumab in Patients with Ad
                                                                  Rini, Group
CALGB-90206 A Randomized Phase III Trial of Interferonand LeukemiaBrian B Closed to Accrual
                               CALGB            Cancer and Leukemia William
                                                                  Phase III Trial Closed to Accrual and Prednisone with an
CALGB-90401 A Randomized Double-Blinded Placebo Controlled Kelly, Group B Comparing Doctaxel & Treatment
                               CALGB            Cancer and Comparing Gemcitabine,
                                                                  Rosenberg, B Active
CALGB-90601 A Randomized Double-Blinded Phase III StudyLeukemia Group Jonathan Cisplatin, and Bevacizumab to Gemc
             ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for James
CALGB-9741A-ICSC               CALGB                              Ellis, Group B Active
                                                Cancer and Leukemia Matthew Response to Adjuvant Dose-Dense Therapy
E1103                          ECOG              Combination with the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Za
                                                                  Gradishar, William
             A Phase II Trial of Capecitabine inEastern Cooperative Oncology Group Closed to Accrual & Treatment
E1104                          ECOG             Eastern Cooperative Oncology Group
                                                                  Swaby, Ramona Closed to with Trastuzumab (Herceptin) i
             A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination Accrual & Treatment
E1105                          ECOG             Eastern Cooperative Oncology Trial of to Accrual
                                                                  Mayer, Ingrid    Closed
             E1105: A Randomized Phase III Double-Blind Placebo-ControlledGroup First-Line Chemotherapy and Trastu
E1201T1                        ECOG             (SNP) in Platinum-/Radiation Pathway
                                                                  Yoon, Harry      Active
             Single Nucleotide Polymorphisms Eastern Cooperative Oncology Group Genes to Predict Outcome in Patient
E1208                          ECOG             Eastern Cooperative Oncology Group
                                                                  Kauh, John       Active
             A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable H
E1302                          ECOG             Eastern Cooperative Oncology Group
                                                                  Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitini
                                                                                   Closed to Accrual & Treatment
             Phase III Randomized, Placebo Controlled, Trial of Argiris, Athanassios
E1304                                                               PS-341 (Velcade™)
                                                Eastern Inhibitor,Gilbert, Jill
             Phase II Two Arm Trial of the Proteasome Cooperative Oncology Group in Combination with Irinotecan or PS
                               ECOG                                                Closed to Accrual & Treatment
E1305                        ECOG             Eastern Cooperative Oncology Group
                                                                Argiris, Athanassios
                                                                                  Active
          A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Me
E1402                        of Reduced Intensity Allogeneic Bone Oncology Group
          A Phase II Study ECOG                                 Foss, Francine Closed to Accrual
                                              Eastern Cooperative Marrow Transplantation for the Treatment of Relapsed
E1404                        of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma
          A Phase II Study ECOG                                 Horning, Sandra Closed to Accrual & Treatment
                                              Eastern Cooperative Oncology Group
E1405                        of VcR-CVAD with Rituximab Maintenance for Untreated Mantle Cell Lymphoma
          A Phase II Study ECOG                                 Kahl, Brad
                                              Eastern Cooperative Oncology Group  Closed to Accrual
E1496T1                      ECOG             Eastern Cooperative Oncology Group
          Identification of Biomarkers in Follicular LymphomaGascoyne, Randall    Active
E1504                         C225            Eastern Cooperative Oncology Suresh
                                                                Ramalingam, with Advanced Bronchioalveolar Carcinoma
          Phase II Study ofECOG (Cetuximab) for the Treatment of PatientsGroup    Closed to Accrual
E1505                        ECOG             Eastern Cooperative Oncologywithout
                                                                Wakelee, or Group Active
          A Phase III Randomized Trial of Adjuvant Chemotherapy withHeather Bevacizumab for Patients with Comp
E1508                        ECOG             Eastern and Etoposide in Combination
                                                                Belani, Chandra Temporarily Closed to Accrual
          A Randomized Phase II Study of Cisplatin Cooperative Oncology Group with Either Hedgehog Inhibitor GDC-
E1602                        ECOG             Eastern Cooperative Oncology Group
                                                                Slingluff, Craig Closed to Accrual
          A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and H
E1603                        ECOG             Eastern Cooperative Oncology Group
                                                                Lawson, David Melanoma
          Phase II Trial of Depsipeptide (NSC 630176) in Advanced MalignantClosed to Accrual & Treatment
E1902                        of Reduced Intensity Allogeneic Stem Oncology Groupfor the Treatment of Myelodysplastic S
          A Phase II Study ECOG                                 Luger, Selina
                                              Eastern Cooperative Cell Transplant Temporarily Closed to Accrual
E1904                        of MOAD (Methotrexate, CooperativeL-asparaginase and Dexamethasone) with Subcutaneo
          A Phase II Study ECOG                                 Wiernik, Peter Active
                                              Eastern Vincristine, Oncology Group
E1905                        ECOG             Eastern with or withoutSteven
                                                                Gore, the Histone Deacetylase Inhibitor Entinostat for the
          A Randomized Phase II Trial of AzacitidineCooperative Oncology Group    Active
E1906                        ECOG             Eastern Cooperative Oncology Group
                                                                Litzow, Mark      Active
          A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinos
E1A05                        ECOG             Eastern Cooperative Oncology Group
                                                                Fonseca, Rafael Closed to Accrual
          Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) - Lenalidomide (Revlimid®)
E1A06                        ECOG             Eastern Cooperative Oncology Group
                                                                Stewart, AlexanderActive
          An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MP
E1B03     Pemetrexed PlusECOG                 Eastern Cooperative Oncology Group
                                                                Hanna, Nasser Closed to Accrual
                              Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomi
E1F03                        of Temozolomide and Radiation Therapy in Patients with Brain Metastasis from Non-Small C
          A Phase II Study ECOG                                 Robins, H.
                                              Eastern Cooperative Oncology Group  Closed to Accrual
E1F05                         Rituximab GivenEastern CooperativeStandard Chemotherapy in Primary Central Nervous Sy
          Phase II Study ofECOG                                 Swinnen, Lode Temporarily Closed to Accrual
                                                in Conjunction with Oncology Group
E1Y03                        ECOG             Eastern Cooperative Oncology Group
                                                                 Studies
          Master Protocol for Pharmacogenetic and GenomicO'Dwyer, Peter Closed to Accrual
E1Z03                        ECOG             Eastern Cooperative Oncology Group
                                                                Wagner, Lynne Closed to Accrual
          Quality of Life Companion Study for JMA27 (NCIC-MA.27): A Randomized Phase III Trial of Exemestane Vers
E2103                        ECOG             Eastern Cooperative Oncology Group
                                                                Moulder, Stacy Closed to Accrual
          A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone (BMS-247550) and Carboplatin in Patients with HER
E2104                        ECOG             Eastern Cooperative Oncology Group
                                                                Miller, Kathy     Closed to Accrual
          Phase II Feasibility Trial Incorporating Bevacizumab into Dose Dense Doxorubicin and Cyclophosphamide Fo
E2202                        ECOG             Eastern A Multicenter Feasibility Study to Accrual
                                                                Luketich, James Closed
          Minimally Invasive Esophagectomy (MIE): Cooperative Oncology Group
E2204                        ECOG              II Study of Bevacizumab (NSC 704865) to Accrual
                                                                Berlin, Jordan Closed
          An Intergroup Randomized PhaseEastern Cooperative Oncology Group or Cetuximab (NSC 714692) in Com
E2205                        to Measure Response Rate and Toxicity of Neo-Adjuvant Chemoradiotherapy with Oxaliplati
          A Phase II Study ECOG                                 Gibson, Michael Closed to Accrual & Treatment
                                              Eastern Cooperative Oncology Group
E2303                        ECOG             (C225) Cooperative Oncology Group
                                                                Wanebo, Harold Closed to Accrual
          Phase II Evaluation of Cetuximab EasternCombined with Induction Paclitaxel and Carboplatin Followed by C22
E2402                        of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
          A Phase II Study ECOG                                 Advani, Ranjana Closed to Accrual
                                              Eastern Cooperative Oncology Group
E2404                        ECOG             Eastern Cooperative Patients Group
                                                                Ganjoo, Kristen Peripheral T-Cell
          Bevacizumab and CHOP (A-CHOP) in Combination for OncologywithClosed to Accrual or Natural Killer Cell Ne
E2501                        ECOG             Eastern Cooperative Oncology Group
                                                                Schiller, Joan    Closed to Lung Cancer Who Have Failed
          A Double Blind Phase II Study of BAY 43-9006 in Patients with Non-Small Cell Accrual
E2603                        ECOG             Eastern Cooperative Oncology Group
                                                                Flaherty, Keith Closed to Accrual
          A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Vers
E2607                        ECOG             Eastern Cooperative Oncology Advanced or Stage IV Mucosal, Acral and S
                                                                Lawrence, Donald ctive
          A Phase II Trial of Dasatinib in Patients with Unresectable LocallyGroupA
E2804                        ECOG             Eastern Cooperative Oncology Group
                                                                Flaherty, Keith Active
          The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Ther
E2805                        ECOG             Eastern Cooperative OncologyCarcinoma
                                                                Balzer-Haas, Group
          ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Naomi     Active
E2902                        ECOG             Eastern Transferase Inhibitor Group
                                                                Luger, Selina     Closed Acute Myeloid Leukemia (AML) P
          A Phase III Randomized Study of FarnesylCooperative OncologyR115777 into Accrual
E2903                        ECOG             Eastern Cooperative Oncology Group
                                                                Kempin, SanfordActive
          Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previousl
E2905                        ECOG             Eastern Frequency Oncology Group
                                                                List, Alan        Active
          Randomized Phase III Trial Comparing theCooperativeof Major Erythroid Response (MER) to Treatment with L
E2A02                         PS-341          Eastern High-Risk, Newly Diagnosed
                                                                Dispenzieri, Angela
                                                                                  Closed to Accrual
          Phase II Study ofECOG for Patients with Cooperative Oncology Group Multiple Myeloma
E3200T2                       Forms            in Colorectal Cancer - Possible Value
                                                                Bates, David      Active
          Alternative SpliceECOG of VEGF Eastern Cooperative Oncology Group in Anti-VEGF Therapy
E3201                        ECOG             Eastern Postoperative Irinotecan, Closed to Accrual & Treatmentvs. Oxalipla
                                                                Benson, Al
          Intergroup Randomized Phase III Study of Cooperative Oncology Group     5-Fluorouracil and Leucovorin
E3204                         Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followe
          Phase II Study ofECOG                                 Landry, Jerome Closed to Accrual
                                              Eastern Cooperative Oncology Group
E3205                        ECOG             Eastern 5-Fluorouracil and Radiation
                                                                Garg, Madhur Active
          Phase II Trial of Cetuximab Plus Cisplatin, Cooperative Oncology Group in Immunocompetent Patients with An
E3303                         C225              Cetuximab) in Combination with Cisplatinto Accrual
                                                                Langer, Corey Closed and Definitive Radiation in Unres
          Phase II Study ofECOG (Erbitux orEastern Cooperative Oncology Group
E3402                                                           Witzig, Thomas Closed Patients with Previously Untreate
          A Phase II Trial of R-CHOP Followed by Zevalin™ Radioimmunotherapy for to Accrual
                             ECOG             Eastern Cooperative Oncology Group
E3404                        ECOG             Eastern Cooperative Oncology Group
                                                                Swinnen, Lode Closed to Accrual
          Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scan
E3503                        ECOG             Eastern Cooperative Oncology Group
                                                                Brahmer, Julie Closed to Accrual & Treatment
          A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to O
E3503T1                      ECOG             Eastern Cooperative Oncology Group
                                                                Kolesar, Jill     Active
          Development of a Model to Predict Progression Free Survival After Treatment with Erlotinib in E3503
E3803                         a Weekly Schedule of BMS-247550 for PatientsGroup
          Phase II Study ofECOG                                 Liu, Glenn        Closed to Accrual & Treatment
                                              Eastern Cooperative Oncology with Hormone Refractory Prostate Cancer
E3805                        ECOG             Eastern Cooperative Oncology Group
                                                                Sweeney, Christopher
                                                                                  Active
          CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in
E3903                        ECOG             Eastern Diagnostic Oncology Patients
                                                                Paietta, ElisabethActive
          Ancillary Laboratory Protocol for CollectingCooperativeMaterial onGroup Considered for ECOG Treatment T
E3A05                        ECOG             Eastern Diagnostic Oncology Group Considered for Studies of Plasma
                                                                Callander, on Patients
          Ancillary Laboratory Protocol for CollectingCooperativeMaterialNatalie  Active
E4203                         Treatment Selection Based UponMeropol, Neal GroupSynthase Expression in Previously Un
          Phase II Study ofECOG                                  Tumor Thymidylate
                                              Eastern Cooperative Oncology Active
E4206                          ECOG              Eastern Cooperative Oncology inClosed towith Low-Grade Neuroendocrine
                                                                   Holen, Kyle
             A Phase II Clinical and Biologic Study of AMG 706 and OctreotideGroup   Patients Accrual
E4402                          ECOG              Eastern Cooperative Oncology Group
                                                                   Kahl, Brad       Closed to Accrual
             Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumo
E4503                            Evaluate the Tumor Biochemical Effects StevenEGFR Tyrosine Kinase Treatment
             Phase II Study toECOG                                 Keller, of the
                                                 Eastern Cooperative Oncology Group Closed to Accrual & Inhibitor OSI-774 (Er
E4508                          ECOG              Eastern Carboplatin Oncology Group Combination with Cetuximab, IMC-A1
                                                                   Hanna, Paclitaxel in
             Three-Arm Randomized Phase II Study of Cooperative and Nasser Active
E4805                          ECOG              Eastern Cooperative Oncology Group
                                                                   Pili, Roberto    Doses
             A Randomized Phase II Study to Determine the Effect of 2 Different Active of AVE0005 (VEGF Trap) in Patien
E4903                           of Lenalidomide (CC-5013) in Combination with Group
             A Phase II Study ECOG                                 Tefferi, Ayalew Closed to Accrual & Treatment
                                                 Eastern Cooperative Oncology Prednisone for the Treatment of Myelofibros
E4A03                          ECOG              Eastern Plus Dexamethasone Versus to Accrual
                                                                   Rajkumar, S.     Closed
             A Randomized Phase III Study of CC-5013Cooperative Oncology Group CC-5013 Plus Low Dose Dexametha
E4A08                          ECOG              Eastern Cooperative Oncology Group
                                                                   Dispenzieri, Angela
                                                                                    Approved
             A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and D
E5103                          ECOG              Eastern Cooperative Oncology Group
                                                                   Miller, Kathy    Active
             A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizuma
E5202                          ECOG              Eastern 5-FU, LeucovorinAl
                                                                   Benson, and Oxaliplatin Versus 5-FU, Leucovorin, Oxalipl
             A Randomized Phase III Study ComparingCooperative Oncology Group       Active
E5203                           to Evaluate Overall Response Rate of Oncology Group
             A Phase II Study ECOG                                 Sun, Weijing     Closed to Accrual & Treatment
                                                 Eastern Cooperative BAY 43-9006 (Sorafenib) Combined with Docetaxel an
E5204                          ECOG              Eastern Postoperative Oxaliplatin,Closed to Accrual Leucovorin vs Oxalipla
                                                                   Benson, Al
             Intergroup Randomized Phase III Study of Cooperative Oncology Group     5-Fluorouracil and
E5803                          ECOG              Eastern Cooperative Oncology Group
                                                                   Liu, Glenn       Closed to Accrual
             Phase II Trial of GW572016 in Patients with Recurrent Prostate Cancer as Evident by a Rising PSA
E5805                          ECOG              Eastern Cooperative Oncology Group
                                                                   Stein, Mark      Closed to Accrual
             A Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Ca
E6202                          ECOG              Eastern Cooperative Oncology Carcinoma Accrual & Treatment
                                                                   Berlin, Jordan Closed to
             A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Group
E8802                          ECOG              Eastern Cooperative OncologyNaomi
                                                                   Balzer-Haas, Group
                                                                                    Closed to Accrual
             Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features
E9802                           of PROSTVAC-V (Vaccinia)/TRICOM Oncology Group
             A Phase II Study ECOG                                 DiPaola, Robert Closed to Accrual
                                                 Eastern Cooperative and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF
GOG-0076DD                       Phase            Cetuximab Oncology #714692) Closed to Accrual & Treatment
                                                                   Farley, John
             A Limited AccessGOG II Trial of Gynecologic(C225,NSCGroup              in Combination with Cisplatin (NSC #1198
GOG-0076GG                       Phase            Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination with Cispla
                                                                   Miller, David
             A Limited AccessGOG II Trial of Gynecologic Oncology Group             Temporarily Closed to Accrual
GOG-0086P                      GOG               Gynecologic Oncology Group Carol
                                                                   Aghajanian,      Active
             A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), P
GOG-0087M                      GOG               Gynecologic Oncology Group
                                                                   Monk, Bradley Temporarily Closed to of Advanced, Pers
             A Phase II Evaluation of Trabectedin (Yondelis®, R279741, IND# 75,111) in the Treatment Accrual
GOG-0126R                      GOG               Gynecologic Oncology Group
                                                                   Coleman, RobertClosed to Accrual
             A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, F
GOG-0126T                      GOG               Gynecologic Oncology Don
                                                                   IND #729990) Active
             A Phase II Evaluation of Belinostat (NSC #726630, Dizon,Group and Carboplatin (NSC #241240) in the Trea
GOG-0127V                      GOG               Gynecologic Oncology Group
                                                                   Alberts, David Active
             A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Non Squamous Ce
GOG-0129Q                      GOG               Gynecologic Oncology Group
                                                                   Tait, David      Closed to of Recurrent or Persistent Endo
             A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment Accrual & Treatment
GOG-0130E                      GOG               Gynecologic Oncology Group
                                                                   Miller, Brigitte Closed to Accrual & Treatment
             A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC #628503) in the Treatment of Rec
GOG-0146Q                      GOG               Gynecologic Oncology Group
                                                                   Herzog, Thomas Closed the Treatment of Recurrent Platin
             A Phase II Evaluation of Topotecan (NSC #609699) Administered Weekly into Accrual
GOG-0170F                      GOG               Gynecologic Oncology Group
                                                                   Matei, ® NCI-Supplied to Accrual & Treatment
             A Phase II Evaluation of Bay 43-9006 (Sorafenib, NexavarDaniela ClosedAgent, NSC #724772 IND # 69,896
GOG-0170G                      GOG                (GW572016) (NCI-Supplied Agent, NSC #727989, IND #70,252) in the Trea
                                                                   Garcia, Agustin Closed to Accrual & Treatment
             A Phase II Evaluation of Lapatinib Gynecologic Oncology Group
GOG-0170I                      GOG               Gynecologic Oncology Group
                                                                   Behbakht, Kian Closed #683864, & Treatment
             A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC to Accrual IND #61010) in the Trea
GOG-0170J                      GOG               Gynecologic Oncology Group
                                                                   Usha, Lydia      Closed Persistent
             A Phase II Evaluation of Enzastaurin (Lilly IND #60,933) in the Treatment of to Accrual or Recurrent Epithelial
GOG-0170K                      GOG               Gynecologic Oncology Recurrent or Persistent Epithelial Ovarian, Fallopian
                                                                   Rocereto, Thomas
             A Phase II Evaluation of Mifepristone in the Treatment of Group        Closed to Accrual & Treatment
GOG-0170L                      GOG                 (IND # 79,697) in the Group
                                                                   Schilder, RussellClosed to Accrual & Treatment
             A Phase II Evaluation of AMG 706Gynecologic OncologyTreatment of Persistent or Recurrent Epithelial Ovaria
GOG-0170M                      GOG                (Sprycel®, NSC Schilder, RussellClosed to of Persistent or Recurrent Epith
                                                                   #732517) in
             A Phase II Evaluation of DasatinibGynecologic Oncology Group the Treatment Accrual
GOG-0170N                      GOG               Gynecologic Oncology Michael Temporarily Closed to of Persistent or Re
                                                                   Gold, Group
             A Phase II Evaluation of a Urokinase-Derived Peptide (A6) (IND #64,298) in the Treatment Accrual
GOG-0186F                      GOG               Gynecologic Oncology Trabectedin (Yondelis®, R279741, IND #101018) wit
                                                                    Plus Bradley Closed to Accrual
             A Phase II Evaluation of Docetaxel (NSC #628503)Monk,Group
GOG-0188     Phase II Study ofGOG                Gynecologic Oncology Group
                                                                   Covens, Allan Closed to
                                 Faslodex ® in Recurrent/Metastatic Endometrial Carcinoma Accrual
GOG-0205                       GOG               Gynecologic Oncology Group
                                                                   Moore, Chemotherapy for the Treatment of Locally-Advan
             A Phase II Trial of Radiation Therapy and Weekly CisplatinDavid        Closed to Accrual
GOG-0206                       GOG               Gynecologic Oncology Group with Closed to Accrual &Carcinoma
                                                                   Levenback,
             Lymphatic Mapping and Sentinel Node Identification in Patients Charles Stage1B1 Cervical Treatment
GOG-0210                       GOG               Gynecologic Oncology Group
             A Molecular Staging Study of Endometrial Carcinoma    Creasman, WilliamActive
GOG-0211                       GOG               Gynecologic Oncology Term
                                                                   Short Richard Closed to Accrual & Treatment
             A Phase II Pilot Investigation of the Relationship of Zaino,GroupDepo-Provera (Medroxyprogesterone Acetate)
GOG-0212                       GOG               Gynecologic Oncology Group
                                                                   Markman, Maurie  Active
             A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent P
GOG-0213                       GOG               Gynecologic Oncology Groupand Paclitaxel Alone or in Combination with Be
                                                                   Carboplatin
             A Phase III Randomized Controlled Clinical Trial of Coleman, RobertActive
GOG-0218                       GOG               Gynecologic Oncology Group
                                                                   Placebo Versus Closed to Accrual
             A Phase III Trial of Carboplatin and Paclitaxel Plus Burger, Robert Carboplatin and Paclitaxel Plus Concurren
GOG-0219                       GOG               Gynecologic Oncology GroupPaul Closed to Accrual Tirapazamine
                                                                   DiSilvestro,
             A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and & Treatment (IND# 46
GOG-0220                       GOG               Gynecologic Oncology Group
                                                                   Kohn, Elise      Closed to Accrual
             Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures) for Epithelial Ovarian Cancer Diagnosis
GOG-0221                        Glycan           Gynecologic Oncology Group
                                                                   Gold, Advanced Active
             Glycoprotein andGOG Profiling in Patients with Locally Michael Cervical Cancer (STAGE IB2, IIA > 4 CM,
GOG-0222                       GOG               Gynecologic Oncology with Recurrent Cervical Cancer Treatment
                                                                   McMeekin, D. Closed to Accrual &
             Prospective Evaluation of Pelvic Exenteration in Patients Group
GOG-0227E                      GOG               Gynecologic Oncology Group
                                                                   Santin, Alessandro the to Accrual & Persistent
                                                                                     in
             A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692)Closed Treatment of Treatment or Recurre
GOG-0229D                      GOG                (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Pers
                                                                   Leslie, Kimberly Closed to Accrual & Treatment
             A Phase II Evaluation of Lapatinib Gynecologic Oncology Group
GOG-0229E                      GOG               Gynecologic Oncology Group Carol
                                                                   Aghajanian,      Closed IND #7921) Treatment
             A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC #704865, to Accrual & in the Treatment of R
GOG-0229F                      GOG               Gynecologic Oncology Group
                                                                   Coleman, RobertClosed to Accrual
             A Phase II Evaluation of VEGF-Trap (Aflibercept, NSC #724770, IND #BB100137, NCI-Supplied Agent) in the
GOG-0229G                       GOG               Gynecologic Oncology Group
                                                                     Alvarez, Edwin Closed to Accrual
              A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #704865, IND #7921) and Te
GOG-0229H                       GOG                (NSC #748727, Coleman, RobertTemporarily of Recurrent or Persistent E
                                                                     IND #77782)
              A Phase II Evaluation of AZD6244Gynecologic Oncology Group in the TreatmentClosed to Accrual
GOG-0229I                       GOG               Gynecologic IND#105029), an Temporarily Closed to Accrual
                                                                     Powell, Matthew
              A Phase II Evaluation of Brivanib (BMS582664,Oncology Group Oral, Multitargeted Growth Factor Tyrosine K
GOG-0230C                                                            Huh, STI571 Closed to Accrual & Treatment
              A Phase II Evaluation of Gleevec™ (NCI-Supplied Agent:Group [Imatinib Mesylate], IND #61135, NSC# 716
                                GOG               Gynecologic OncologyWarner
GOG-0232B                       GOG                (Taxol ®, NSC #673089) and
                                                                     Powell, Matthew Closed to Accrual & Treatment
              A Phase II Evaluation of PaclitaxelGynecologic Oncology Group Carboplatin (Paraplatin ®, NSC #241240) in
GOG-0232C                       GOG                (Taxol®, NSC #673089), Carboplatin (Paraplatin®, NSCAccrual
                                                                     Aghajanian,
              A Phase II Evaluation of PaclitaxelGynecologic Oncology Group Carol      Temporarily Closed to #241240), and BS
GOG-0233                        GOG               Gynecologic Oncology Group
                                                                      to Primary Chemoradiation Therapy to Detect Retroperiton
              Utility of Preoperative FDG-PET/CT Scanning PriorAtri, Mostafa           Active
GOG-0235                        GOG               of YKL-40 in Patients with FIGO Stage III
                                                                     Bell-McGuinn, Active
              A Prospective, Longitudinal Study Gynecologic Oncology Group Katherine or IV Invasive Epithelial Ovarian, P
GOG-0238                        GOG               Gynecologic without Concurrent Weekly Cisplatin in Patients with Pelvic-On
                                                                     Cardenes, Higinia
              A Randomized Trial of Pelvic Irradiation with or Oncology Group          Active
GOG-0239                        GOG                #741078, IND #77782) in Women with Recurrent Low-Grade Serous Carci
                                                                     Farley, John
              A Phase II Trial of AZD6244 (NSCGynecologic Oncology Group               Closed to Accrual
GOG-0240                        GOG               Gynecologic Oncology Group
                                                                     Tewari, KrishnansuActive
              A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #
GOG-0242                         to Determine theGynecologic OncologyCurettage as Initial Management for Persistent Low R
              A Phase II Study GOG                                   Osborne, Raymond
                                                   Response to Second Group            Active
GOG-0248                        GOG               Gynecologic Oncology Group
                                                                     Fleming, Agent, NSC #683864, IND #61010) or the Comb
              A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Gini           Active
GOG-0249                        GOG               Gynecologic Oncology Group
                                                                     McMeekin, D. Active
              A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carbo
GOG-0251                        GOG               Gynecologic Oncology Group
                                                                     Brown, Jubilee Temporarily Closed to 7921) for
              A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC 704865, IND Accrual Recurren
GOG-0252                        GOG               Gynecologic Oncology Group
                                                                     Walker, Joan      Active
              A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube, and Pri
GOG-0258                        GOG               Gynecologic Oncology Group
                                                                     Matei, Daniela Active
              A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and
GOG-0261                        GOG               Gynecologic Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherap
                                                                     Powell, Matthew Active
              A Randomized Phase III Trial of Paclitaxel PlusOncology Group
GOG-8005                        GOG               Gynecologic Oncology Advanced Active
                                                                     Coukos, George Epithelial Ovarian Cancer
              Validation of Tumor-Infiltrating T-Cells as a Biomarker forGroup
GOG-9913                        GOG               Gynecologic Oncology Group
                                                                     Rose, Peter       Active
              A Phase I Study of Pelvic Radiation Therapy with Concomitant Weekly Cisplatin and Topotecan Chemotherap
GOG-9916                          Intravenous Paclitaxel, Intraperitoneal Carboplatin Active
              A Phase I Trial ofGOG                                  Walker, Joan
                                                  Gynecologic Oncology Group           and Intraperitoneal Paclitaxel or Intraveno
GOG-9917                        GOG               Gynecologic Oncology Group
                                                                     Morgan, Mark Active
              A Dose-Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carbop
GOG-9918                          Tailored Radiation Therapy with Concomitant Cetuximab (C225, NSC #714692) and Cisplat
              A Phase I Trial ofGOG                                  Moore, Kathleen Active
                                                  Gynecologic Oncology Group
GOG-9919                          Dose            Gynecologic Oncology Group
                                                                     Tiersten, Amy Closed to Accrual
              A Phase I Trial ofGOG Dense (Biweekly) Carboplatin Combined with Paclitaxel and Pegfilgrastim (Neulasta ®
GOG-9920                        GOG                Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Can
                                                                     McMeekin, D. Active
              A Phase I Study of IV DoxorubicinGynecologic Oncology Group
GOG-9921                        GOG               Gynecologic Oncology Group
                                                                     Dizon, Day        Active
              A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel onDon 1 Followed by IP Paclitaxel on Day 8 Every 21
IBCSG-24-02                     IBCSG             International Function Suppression and to Role of
                                                                     Fleming, Gini     Group
              A Phase III Trial Evaluating the Role of OvarianBreast Cancer Study Closedthe Accrual Exemestane as Adjuva
IBCSG-25-02                     IBCSG             International Breast Cancer Study Active
                                                                     Walley, Barbara Group
              A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenop
MA.17ICSC                       MA034             Massachusetts GeneralPaul
                                                                     Goss, Hospital Cancer Center
                                                                                       Active
              Quantitive Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC MA.
N0147                           NCCTG             North Central Cancer Treatment Closed
                                                                      Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without
              A Randomized Phase III Trial of Oxaliplatin (OXAL)Alberts, Steven Group to Accrual
N014A                            of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) for Pat
              A Phase II Study NCCTG                                 Alberts, Steven Closed
                                                  North Central Cancer Treatment Group to Accrual & Treatment
N027D                           NCCTG             North Central in Combination with Closed
                                                                     Sarkaria, Jann Radiation Therapy
              A Phase I Study of CCI-779 and Temozolomide Cancer Treatment Group to Accrual in Glioblastoma Multifo
N0321                           NCCTG             North Central Cancer Treatment Group Concurrent Thoracic Radiation Th
                                                                     Adjei, Carboplatin, and
              Phase I/II Study of PS-341 in Combination with Paclitaxel,Alex           Active
N0332                           NCCTG             North Central Cancer Treatment Group to Accrual & Treatment
                                                                     Perez, Edith      Closed
              Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
N0337                             Capecitabine in Combination withTan, Treatment Group to Accrual & Treatment
              Phase II Study ofNCCTG                                  Vinorelbine and Closed
                                                  North Central Cancer Winston         Trastuzumab for the First-or Second-Line
N0338                           NCCTG             North Central Cancer Treatment Group as Induction Therapy for
                                                                     Roy, Vivek         Weeks
              Phase II Trial of Docetaxel and Carboplatin Administered Every TwoClosed to Accrual & Treatment Stage II
N0346                           NCCTG             North Central Cancer Treatment Group to Accrual & Treatment
                                                                     Sinicrope, Frank Closed
              A Phase II Trial of Celecoxib (Celebrex ®) and Capecitabine (Xeloda ®) Combined with Pelvic Irradiation as N
N034A                           NCCTG             North Central Cancer George
                                                                     Kim, in Patients with Metastatic Pancreatic Adenocarcinom
                                                                                       Closed
              Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin Treatment Group to Accrual & Treatment
N038H                             II Study        North Combination with RituximabClosed
                                                                     Ansell, Stephen in Patients with Relapsed or Refractory M
              N038H: A PhaseNCCTG of CCI-779 in Central Cancer Treatment Group to Accrual & Treatment
N0422                           NCCTG             North Central Cancer Treatment Group Patients with Locally Advanced N
                                                                     Jatoi, Aminah Closed
              Cetuximab (C225) and Radiation in Elderly and/or Poor Performance Statusto Accrual & Treatment
N0432                           NCCTG             North Central Cancer Treatment First-Line Accrual & Treatment
                                                                     Perez, Edith      Closed
              Phase II Trial of Docetaxel with Capecitabine and Bevacizumab as Group toChemotherapy for Patients with
                                NCCTG              Changes, Plasma Hormone Changes, to Accrual
                                                                     Ingle, James      Closed
N0434 (MA.27D)The Association of Breast DensityNorth Central Cancer Treatment Groupand Breast Cancer Recurrence: A C
N0437                                             North Central Cancer Treatment Group to Accrual Patients with
              Phase II Trial of CT-2103 (Xyotax™) with Capecitabine as First-Line Chemotherapy for& Treatment Metastat
                                NCCTG                                Northfelt, DonaldClosed
N044E                           NCCTG             North Central Cancer Treatment Group to Accrual & Treatment
                                                                     Jatoi, Aminah Closed
              A Phase II Trial of Preoperative Radiation and Chemotherapy (Pemetrexed and Carboplatin) for Locally Advan
N0477                           NCCTG             North Central Cancer
                                                                     Sarkaria, Jann Active
              Optimizing EGFR Inhibitor-Based Therapies for GBM Treatment Group
N0489                            of Epratuzumab,North Central Cancer Treatment Group Previously Untreated Diffuse Large
              A Phase II Study NCCTG                                 Micallef, Ivana Closed
                                                   Rituximab (ER)-CHOP for Patients with to Accrual & Treatment
N048F                           NCCTG             North Central Cancer Treatment Lymphocytic Leukemia Patients
                                                                     Kay, Neil         Closed
              A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Group to Accrual & Treatment
N0528                           NCCTG             North Central Cancer Treatment or Without AZD2171 as First-Line
                                                                     Adjei, Alex       Closed
              A Randomized Phase II Study of Gemcitabine and Carboplatin withGroup to Accrual & Treatment Therapy
N0531                           Weekly            North Central Cancer Vivek
                                                                      bound)-Paclitaxel (nab-Paclitaxel) & Treatment
                                                                                       Closed
              Phase II Trial of NCCTG nab (nanoparticle albuminRoy, Treatment Group to Accrual (Abraxane®) in Combin
N0537                           NCCTG             North Central Cancer Treatment Group to Accrual & Treatment
                                                                     Hobday, TimothyClosed
              Phase II Trial of VEGF Trap in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline a
N0539                           NCCTG             North Central Cancer Treatment Group to Accrual
                                                                     Tan, Winston      Closed
              Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated w
N0543                           NCCTG             North Central Cancer Treatment Group
                                                                      of Irinotecan, Oxaliplatin, and Capecitabine as First-Line T
              A Phase II Trial of Pharmacogenetic-Based DosingMcWilliams, Robert       Active
N054C                              Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer
              Phase II Study ofNCCTG                                  Grothey, Axel Temporarily Closed to Accrual
                                                    North Central Cancer Treatment Group
N0572                             of Sorafenib and North Central Cancer Treatment Group
              A Phase I/II Trial NCCTG                                Jaeckle, Kurt     Active
                                                     CCI-779 in Patients with Recurrent Glioblastoma
N0574                             NCCTG             Role Central Brain Treatment Group
                                                                      Brown, Paul       Active
              Phase III Randomized Trial of the Northof WholeCancerRadiation Therapy in Addition to Radiosurgery in Patien
N0577                             NCCTG             North Central Cancer Treatment Group
                                                                      Jaeckle, Kurt     Active
              Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomita
N057K                             NCCTG             North Central Cancer Treatment Active (TMZ) Followed by Adjuvant Tem
                                                                      Sarkaria, Temozolomide
              Phase I/II Evaluation of Everolimus (RAD001), Radiation andJann Group
N0621                              the c-SRC Inhibitor AZD0530 After Four Cycles of Closed to Accrual
              Phase II Study ofNCCTG                                  Molina, Julian
                                                    North Central Cancer Treatment GroupCytoreductive Chemotherapy for Patients
N0623                              GW786034 in PatientsCentral Cancer Treatment Group to Accrual & Treatment
              Phase II Study ofNCCTG                                  Molina, Julian Closed
                                                    North with Malignant Pleural Mesothelioma
N0626                             NCCTG             North Central Sorafenib Versus Group to Accrual
                                                                      Adjei, Alex       Closed
              Phase II Randomized Study of Pemetrexed with Cancer Treatment Pemetrexed Alone as Second-Line Therap
N063D                              Lapatinib         Trastuzumab Treatment Optimisation
                                                                      Perez, Edith      Active
              ALTTO: AdjuvantNCCTG and/orNorth Central Cancer Treatment GroupStudy: A Randomised, Multi-Centre,
N064A                              Panitumumab, Chemotherapy,Cancer Treatment Group
              Phase II Study ofNCCTG                                  Kim, George
                                                    North Central and External BeamActiveRadiation in Patients with Locally Advanc
N064B                             NCCTG             North Central Cancer Treatment Group
                                                                      Kim, George       Active
              Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patie
N0675                             of Temozolomide and EverolimusMarkovic, Svetomir for Metastatic Melanoma
              A Phase II Study NCCTG                                   (RAD001) Therapy Closed
                                                    North Central Cancer Treatment Group to Accrual
N0682                             NCCTG             North Central Cancer Treatment Group in Previously Untreated Follicular
                                                                      Ansell, Stephen Closed
              A Phase II Clinical Trial of Denileukin Diftitox in Combination with Rituximab to Accrual
N0683                             of Sunitinib Malate for Treatment of Patients Tait Relapsed/Refractory Chronic Lymphocytic
              A Phase II Study NCCTG                                  Shanafelt, with Closed
                                                    North Central Cancer Treatment Group to Accrual & Treatment
N0723                             NCCTG             North Central Cancer Treatment Group to Accrual
                                                                      Adjei, Alex       Closed
              A Phase III Biomarker Validation Study of Second-Line Therapy in Patients with Advanced Non-Small Cell Lun
N0724                             NCCTG             North Central Cancer Treatment Active
                                                                      Schild, Non-Small Cell
              A Randomized Phase II Study of Oligometastatic Stage IV Steven Group Lung Cancer (NSCLC) Treated with
N0733                             NCCTG             North Central Cancer Treatment Group
                                                                      Haluska, Paul Active
              Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Posit
N0735                             NCCTG             North Central Cancer Treatment Group and Bevacizumab in Patients with
                                                                      Northfelt, DonaldClosed
              Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabineto Accrual
N0745                             NCCTG             North Central Cancer Treatment Active
                                                                      Alberts, as First-Line
              Phase I/II Randomized Trial of Sorafenib and BevacizumabSteven GroupTherapy in Patients with Locally Adva
N0747                             NCCTG             North Plus Capecitabine Versus Capecitabine Alone (with the Potential for
                                                                      Jatoi, Aminah Active
              A Randomized Phase II Trial of SunitinibCentral Cancer Treatment Group
N0775                             NCCTG             North Central Cancer Treatment Group
                                                                      Markovic, Svetomir ABI-007/Carboplatin (CBDCA) and Ava
                                                                                        or
              A Randomized Phase II Trial of Temozolomide (TMZ) and Avastin® Closed to Accrual
N0776                             NCCTG             North Central Cancer in Recurrent Glioblastoma Multiforme
                                                                      Galanis, Evanthia
              Phase II Trial of Avastin® in Combination with SorafenibTreatment Group   Temporarily Closed to Accrual
N0779                              Vorinostat (SAHA) in Combination with Bortezomib (PS-341)Accrual
              Phase II Study ofNCCTG                                  Galanis, Evanthia Closed
                                                    North Central Cancer Treatment Group to in Patients with Recurrent Glio
N078D                             Rituximab, Cladribine, Central Cancer Treatment Group in Newly Diagnosed Mantle Cell Ly
              Phase I/II Trial ofNCCTG                                Inwards, David Temporarily Closed to Accrual
                                                    North and Temsirolimus (RCT) Therapy
N0821                             NCCTG             North Central CancerGrace
                                                                      Dy, Treatment Group
                                                                                        Active
              A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nons
N083E                             NCCTG             North Central Cancer Treatment Group to Accrual and Lapatinib in Early B
                                                                       in Combination with Trastuzumab
              Phase II Safety Study of Docetaxel and CarboplatinPerez, Edith            Closed
N0871                             of Carboplatin (CBDCA), Paclitaxel (TAXOL), andGroup
              A Phase II Study NCCTG                                  Goetz, Matthew Active
                                                    North Central Cancer Treatment Everolimus (RAD001) in Previously Untrea
N0874                             NCCTG             North Central Cancer Treatment Group
                                                                      Galanis, Evanthia Active
              Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Thera
N0877                             NCCTG             North Central Cancer Treatment Group
                                                                      Laack, Nadia      Temporarily Standard Chemo-Radiother
              Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined withClosed to Accrual
                                  ABTC              Adult Brain Tumor and Patrick
                                                                      Wen, CCI-779 Closed to Accrual
NABTC-04-02 NABTC04-02: Phase I/II Study of OSI-774 (Erlotinib) Consortium (Temsirolimus) in Patients with Recurrent M
                                  ABTC              Adult Brain Tumor Consortium
                                                                      Wen, Patrick      Active
NABTC-04-03 A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide i
                                  ABTC               (Sorafenib) in Combination with Closed (Erlotinib), R115777 (Tipifarnib) o
                                                                      Gilbert, Mark
NABTC-05-02 Phase I/II Studies of BAY 43-9006Adult Brain Tumor Consortium OSI-774 to Accrual & Treatment
                                  ABTC               Trap in Patients de Groot, John Closed to Accrual
                                                                       with Recurrent
NABTC-06-01 Phase II Single Arm Trial of VEGFAdult Brain Tumor Consortium Temozolomide-Resistant Malignant Glioma
                                  ABTC               Trap) with Tumor Consortium
                                                                      Wen, Patrick
NABTC-07-01 Phase I Trial of Aflibercept (VEGFAdult Brain Radiation Therapy andActive    Concomitant and Adjuvant Temozolomid
NABTT-0304                        ABTC              Adult Brain with Radiation Therapy with Concurrent and Adjuvant Temozolo
                                                                      Fine, Howard
              A Phase II Trial of Talampanel in Conjunction Tumor Consortium            Closed to Accrual
NABTT-0306                        ABTC              Adult Brain EMDNabors, Louis Closedwith Concomitant and Adjuvant Te
                                                                       121974 in Conjunction to Accrual
              A Safety Run-in/Randomized Phase II Trial of Tumor Consortium
NABTT-0401                         BAY              Adult Brain Tumor Consortium
                                                                      Nabors, Louis Closed to Accrual
              A Phase I Trial ofABTC43-9006 for Patients with Recurrent or Progressive Malignant Glioma
NABTT-0504                        ABTC              Adult Brain Tumor Consortium
                                                                      Batchelor, Treatment of
              A Feasibility Assessment and a Phase I/II Trial of MLN518 for Tracy Active Patients with Recurrent Glioblasto
NABTT-0603                        of Hydroxychloroquine Brain Tumor Consortium
              A Phase I/II Trial ABTC                                 Rosenfeld, Myrna  Active
                                                    Adult in Conjunction with Radiation Therapy and Concurrent and Adjuvant T
NABTT-0702    A Phase 2 Study ABTC                   (Ascenta's AT-101) in Recurrent Closed to Accrual
                                                                      Fiveash, John
                                  of R-(-)-gossypolAdult Brain Tumor Consortium Glioblastoma Multiforme
NABTT-0703                        ABTC              Adult Brain Tumor Consortium
                                                                      Blakeley, Jaishri Active
              Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Dia
NABTT-0801                        of Temozolomide and ABT-888 inKleinberg,with Newly Diagnosed Glioblastoma Multiforme
              A Phase I/II Trial ABTC                                  Subjects Lawrence
                                                    Adult Brain Tumor Consortium        Active
              Analyses of c-Myc (MYC) and Topoisomerase II Cancer(TOP2A) Copy Number Aberrations; MYC, Insulin-like
NCCTG N9831-ICSC                  NCCTG                               Perez, Edith
                                                    North Central Alpha Treatment Group Active
NCIC-183                          of Sunitinib (SU11248; NSC 736511; INDScott in Patients with Advanced Malignant Pleura
              A Phase II Study NCIC                                   Laurie, of Canada Clinical Trials Group
                                                    National Cancer Institute 74019) Temporarily Closed to Accrual
NCIC-BR.19                        NCIC              National Cancer Institute of Canada Clinical Accrual & Treatment
                                                                      Goss, Glennwood   Closed to Trials Group
              A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor R
NCIC-MA.27                        NCIC              National Cancer Institute of Canada Clinical Trials Group
                                                                      Goss, Paul        Postmenopausal
              A Randomized Phase III Trial of Exemestane Versus Anastrozole in Closed to AccrualWomen with Receptor P
              A Randomized Phase III Trial of Exemestane versus Anastrozole in PostmenopausalGroup with Receptor P
NCIC-MA.27 (NON-COMPANION)        NCIC                                Goss, Paul        Closed to Trials
                                                    National Cancer Institute of Canada Clinical AccrualWomen
                                  NCIC              National Cancer Institute of Canada Clinical Accrual
                                                                      Goss, Paul        on Bone Trials Group
NCIC-MA.27B The Influence of Five Years of Adjuvant Anastrozole or Exemestane Closed toMineral Density in Postmenopau
NCIC-MY.10                        NCIC              National Cancer Stewart, Alexander
                                                                      Prednisone as Maintenance Therapy
                                                                                        Closed to Trials Group
              A Randomized Phase III Study of Thalidomide and Institute of Canada Clinical Accrual Following Autologous
NCIC-PR.11    A Phase III StudyNCIC                 National Cancer Institute of Canada Clinical Patients Diagnosed with Favou
                                                                      Klotz, Laurence Active
                                   of Active Surveillance Therapy Against Radical Treatment in Trials Group
NSABP-B-36                        Adjuvant          National Surgical Cycles of Breast and Bowel Project and Cyclophosphamide
                                                                       Adjuvant 5-Fluorouracil, Epirubicin
              A Clinical Trial of NSABP Therapy Comparing Six Elledge, Richard Closed to Accrual & Treatment
NSABP-B-37                        NSABP             National SurgicalWapnir, Irene
                                                                       Adjuvant Breast and Bowel Loco-regional Relapse of Brea
                                                                                        Resected Project
              A Randomized Clinical Trial of Adjuvant Chemotherapy for RadicallyClosed to Accrual
NSABP-B-38                        NSABP            National SurgicalSwain, Sandra Closed to Accrual Node-Positive
                                                                      Adjuvant Breast and Women with
              A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens inBowel Project& Treatment Breast C
NSABP-B-39                        NSABP            National SurgicalVicini, Frank
                                                                      Adjuvant Irradiation (WBI) versus Partial Breast Irradiatio
              A Randomized Phase III Study of Conventional Whole BreastBreast Active   and Bowel Project
NSABP-B-40                        NSABP            National SurgicalBear, Patients Active
                                                                      Adjuvant Breast and Bowel and Operable Breast Cancer
              A Randomized Phase III Trial of Neoadjuvant Therapy in Harry with Palpable Project
NSABP-B-42                        Determine the Efficacy of SurgicalMamounas, Eleftherios to Accrual
              A Clinical Trial to NSABP                               Adjuvant Breast Closed
                                                                                       and Bowel Project
                                                   National Five Years of Letrozole Compared to Placebo in Patients Complet
NSABP-B-43                        NSABP            National SurgicalCobleigh, Breast and Bowel Project
                                                                      Adjuvant MelodyActive
              A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation T
NSABP-BP-59                       NSABP            National SurgicalKrag, David
              Bone Marrow Analysis in Early-Stage Breast Cancer                        and Bowel Project
                                                                      Adjuvant Breast Active
NSABP-C-08                        NSABP            National SurgicalAllegra, Carmen and Bowel Project& Treatment
                                                                      Adjuvant Breast Leucovorin, and
              A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU),Closed to AccrualOxaliplatin (mFOLFOX6
NSABP-C-10                        NSABP            National SurgicalMcCahill, Breast Closed to Accrual
                                                                      Adjuvant (mFOLFOX6) Chemotherapy Plus Bevacizumab
                                                                                       and
              A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin Laurence Bowel Project
NSABP-R-04                        NSABP            National SurgicalBeart, Robert
                                                                      Adjuvant Breast Active
                                                                                       and Bowel Project
              A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with P
PACCT-1                           ECOG             Eastern Cooperative Oncology Group
                                                                     Sparano, JosephActive
              Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for T
PBTC-014                           R115777 and XRT in Pediatric Patients with NewlyClosed to Accrual & Treatment Intrinsic D
              Phase I/II Trial ofPBTC                                Haas-Kogan, Daphne
                                                   Pediatric Brain Tumor Consortium Diagnosed Non-Disseminated
PBTC-015                          PBTC             Pediatric Brain Tumor in Katherine losed to Accrual & Treatment
                                                                     Warren, Pediatric
              A Phase II Trial of O6-Benzylguanine and TemozolomideConsortiumCPatients with Recurrent or Progressive H
PBTC-016                          PBTC             Pediatric Brain (GW572016) in Pediatric Patients with Recurrent
                                                                     Fouladi, Maryam
              Molecular Biology and Phase II Study of LapatinibTumor ConsortiumClosed to Accrual & Treatment or Refract
PBTC-018                           CC-5013 (Lenalidomide) in Pediatric Patients with Closed to Accrual & Treatment CNS Tum
              A Phase I Trial ofPBTC                                 Warren, Katherine
                                                   Pediatric Brain Tumor Consortium Recurrent or Refractory Primary
PBTC-019                          PBTC             Pediatric Study of Intraventricular Topotecan for Children with Neoplastic M
                                                                     Blaney, Susan
              A Phase I Pharmacokinetic Optimal Dosing Brain Tumor ConsortiumActive
PBTC-020                          PBTC             Pediatric Brain Tumor ConsortiumActive
                                                                       Recurrent or
              A Phase I Clinical Trial of AZD2171 in Children withKieran, Mark Progressive Central Nervous System (CNS)
PBTC-021                           Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Childre
              A Phase I Trial ofPBTC                                 Blaney, Susan
                                                   Pediatric Brain Tumor ConsortiumClosed to Accrual
PBTC-022      Phase II Study ofPBTCBevacizumab Plus Irinotecan (Camptosar™ ) in Children with Recurrent, Progressive, or Re
                                                                     Gururangan, Sridharan
                                                   Pediatric Brain Tumor ConsortiumActive
PBTC-023                          PBTC             Pediatric Brain Tumor ConsortiumClosed to Accrual & Treatment
                                                                      (LY317615) in
              Phase I and Pharmacokinetic Study of Enzastaurin Blaney, Susan Children and Adolescents with Refractory P
PBTC-024                          PBTC             Pediatric Brain with Recurrent or Refractory CNS Malignancies
                                                                     Fouladi, Maryam
              A Phase I Study of MK-0752 in Pediatric Patients Tumor ConsortiumActive
PBTC-025                          PBTC             Pediatric Brain Tumor with Recurrent or
                                                                     Gajjar, Amar
              A Phase I Pharmacokinetic and Safety Study in Children ConsortiumActive Refractory Medulloblastoma to Iden
PBTC-025B                         PBTC              the Efficacy andGajjar, Amar
                                                                      Safety of GDC-0449 in
              A Phase II Clinical Trial EvaluatingPediatric Brain Tumor ConsortiumActive Adults with Recurrent or Refractory
PBTC-026                          PBTC             Pediatric Isotretinoin ConsortiumTemporarily Closed to Accrual
                                                                     Geyer, Jeffrey
              A Feasibility Study of SAHA Combined with Brain Tumorand Chemotherapy in Infants with Embryonal Tumors
PBTC-027                          PBTC             Pediatric Brain Tumor ConsortiumActive
                                                                     Su, Jack
              A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Childre
PBTC-N08                          PBTC             Pediatric Brain Tumor Consortium Newly Diagnosed Central Nervous Syste
                                                                     Rood, Brian
              Evaluation of Cerebral Spinal Fluid (CSF) Proteome in Children withClosed to Accrual & Treatment
RTOG 0229                         RTOG             Radiation Therapy Oncology Group
                                                                     Suntharalingam, Closed to Accrual & Treatment
                                                                                       Mohan
              A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followe
RTOG 0514                         a Head           Radiation Therapy Oncology Group
                                                                     Weber, Randal Active
              Establishment of RTOG and Neck Cancer Tissue/Specimen Repository
RTOG-0234                         RTOG             Radiation Therapy Oncology Group
                                                                     Harari, Paul      Closed to C225 (Cetuximab) for
              A Phase II Randomized Trial of Surgery Followed by Chemoradiotherapy Plus Accrual & Treatment Advance
RTOG-0247                         RTOG             Radiation Therapy Modality Group
                                                                     Meropol, Neal Closed to Accrual
              Randomized Phase II Trial of Neoadjuvant CombinedOncology Therapy for Locally Advanced Rectal Cancer
RTOG-0319                         to Evaluate Three Dimensional Conformal Radiation TherapyAccrual & Treatment to the Reg
              A Phase I/II Trial RTOG                                Vicini, Frank
                                                   Radiation Therapy Oncology Group    Closed to (3D-CRT) Confined
RTOG-0320                         RTOG             Radiation Therapy Oncology Group
                                                                      and Stereotactic Radiosurgery Alone
              A Phase III Trial Comparing Whole Brain Radiation Sperduto, Paul Closed to Accrual Versus with Temozo
RTOG-0321                         RTOG             Radiation Therapy Oncology External
                                                                     Hsu, I-Chow       Closed to Radiotherapy for Adenocarcino
              Phase II Trial of Combined High Dose Rate Brachytherapy and Group BeamAccrual & Treatment
RTOG-0324                         of Cetuximab (C225) in Combination with Chemoradiation to Patients& Treatment
              A Phase II Study RTOG                                  Blumenschein, George in Accrual with Stage IIIA/B Non-S
                                                   Radiation Therapy Oncology Group    Closed
RTOG-0330                         RTOG             Radiation Therapy Oncology Thalidomide (IND 48832; NSC 66847)
                                                                     Eisenberg, Group  C
              A Pilot Phase II Study of Pre-Operative Radiation Therapy and Burton losed to Accrual & Treatment for Low
RTOG-0415                         RTOG             Radiation Therapy Oncology Group
              A Phase III Randomized Study of Hypofractionated Lee, W.                 Closed to Accrual
                                                                      3D-CRT/IMRT Versus Conventionally Fractionated 3D-CR
RTOG-0417                         of Bevacizumab Radiation Therapy Oncology Group
              A Phase II Study RTOG                                  Schefter, Tracey Closed to and Cisplatin Chemotherapy in
                                                   in Combination with Definitive Radiotherapy Accrual & Treatment
RTOG-0418                         of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-Op
              A Phase II Study RTOG                                  Jhingran, Anuja Closed to Accrual & Treatment
                                                   Radiation Therapy Oncology Group
RTOG-0420                         of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide Plus Irinote
              A Phase II Study RTOG                                  Lieberman, Group
                                                   Radiation Therapy Oncology Frank    Closed to Accrual & Treatment
RTOG-0424                         of a Temozolomide-Based Therapy Oncology Group
              A Phase II Study RTOG                                  Fisher, Barbara Closed to Accrual
                                                   Radiation Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas
RTOG-0436                         RTOG             Radiation Therapy Oncology Group
                                                                     Suntharalingam, Active
                                                                                       Mohan
              A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with E
RTOG-0438                          Highly          Radiation Therapy Oncology Group
                                                                     Katz, Alan        Closed to Accrual
              A Phase I Trial ofRTOG Conformal Radiation Therapy for Patients with Liver Metastases
RTOG-0513                         of Temozolomide, Motexafin Gadolinium, andDavidClosed to Accrual & Treatment
              A Phase I/II Trial RTOG                                Brachman, 60 Gy
                                                   Radiation Therapy Oncology Group Fractionated Radiation for Newly Diagn
RTOG-0515                         RTOG             Radiation Therapy Oncology Group
                                                                     Bradley, Jeffrey Closed to Accrual
              A Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-S
RTOG-0521                         RTOG             Radiation Therapy Oncology Group vs AS and 3DCRT/IMRT Followed by C
                                                                       and 3DCRT/IMRT
              A Phase III Protocol of Androgen Suppression (AS)Sandler, HowardClosed to Accrual
RTOG-0522                         RTOG             Radiation AcceleratedKie-Kian and
                                                                     Ang, Radiation Closed to Accrual & Treatment
              A Randomized Phase III Trial of Concurrent Therapy Oncology Group Cisplatin Versus Concurrent Accelerat
RTOG-0524                         of a CombinationRadiation TherapyTrastuzumab with Daily Irradiation or Paclitaxel Alone with
              A Phase I/II Trial RTOG                                Michaelson, M. Active
                                                    of Paclitaxel and Oncology Group
RTOG-0525                         RTOG             Radiation Therapy Oncology Group
                                                                     Gilbert, Mark     Closed to Accrual
              Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patien
RTOG-0526                         RTOG             Radiation Therapy Oncology Group
                                                                     Crook, Juanita Active
              A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate
RTOG-0529                         RTOG             Radiation in Combination Lisa 5-Fluorouracil and Mitomycin-C for Reductio
                                                                     Kachnic, with Closed to Accrual & Treatment
              A Phase II Evaluation of Dose-Painted IMRTTherapy Oncology Group
RTOG-0534                         RTOG             Radiation Therapy with Pelvic Lymph
                                                                     Pollack, Alan     Active
              A Phase III Trial of Short Term Androgen DeprivationOncology Group Node or Prostate Bed Only Radiother
RTOG-0539                         RTOG             Radiation Therapy Oncology Radiotherapy for Intermediate- and High-Risk
                                                                     Rogers, C.
              Phase II Trial of Observation for Low-Risk Meningiomas and of Group      Active
RTOG-0611                         RTOG              Patients Therapy Radiation Therapy
                                                                     Camphausen, Kevin Closed Glioblastoma Multiforme:
              Urinary VEGF and MMP Levels in RadiationReceivingOncology Group for to Accrual & Treatment Prospec
RTOG-0612                        RTOG               Outcome in Patients with Intermediate-Risk Prostate Cancer Using DNA M
                                                                    Chakravarti, Arnab
              Investigating Markers of RadiationRadiation Therapy Oncology Group      Active
RTOG-0615                        of Concurrent Chemoradiotherapy Using Three-Dimensional Accrual & Treatment
              A Phase II Study RTOG                                 Lee, Nancy
                                                   Radiation Therapy Oncology Group   Closed to Conformal Radiotherapy (3D-C
RTOG-0617                        RTOG              Radiation Therapy Oncology Group High-Dose (74 Gy) Conformal Radioth
                                                                    Bradley, Gy) Versus
              A Randomized Phase III Comparison of Standard-Dose (60 Jeffrey Active
RTOG-0618                        RTOG              Radiation Therapy Oncology in the
                                                                    Timmerman, Robert Active
              A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT)Group Treatment of Patients with Operable Sta
RTOG-0619                        RTOG              Radiation Therapy Oncology Group
                                                                    Raben, Chemoradiotherapy and Vandetanib for High-Risk
              A Randomized Phase II Trial of Chemoradiotherapy VersusDavid Closed to Accrual
RTOG-0621                        RTOG              Radiation Therapy Oncology Group
                                                                    Hurwitz, Mark Active
              Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Can
RTOG-0622                        RTOG              Radiation Therapy Oncology Group
                                                                    Valicenti, RichardActive
              A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-R
RTOG-0623                        RTOG              Radiation Therapy Oncology Group
                                                                     Growth Factor Support for Accrual &with Limited Stage Sm
              A Phase II Trial of Combined Modality Therapy withLilenbaum, Rogerio    Closed to Patients Treatment
RTOG-0625                        RTOG              Radiation Therapy Oncology Bevacizumab with Temozolomide in Recurren
                                                                    Gilbert, Mark
              A Randomized Phase II Trial of Bevacizumab with Irinotecan orGroup      Closed to Accrual
RTOG-0627                        RTOG              Radiation Therapy Oncology Group
                                                                    Lassman, Andrew   Active
              Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme
RTOG-0630                        RTOG              Radiation Therapy Oncology Primary
                                                                    Wang, Dian        Active
              A Phase II Trial of Image Guided Preoperative Radiotherapy forGroup Soft Tissue Sarcomas of the Extremi
RTOG-0712                        RTOG              Radiation Therapy Oncology Bladder
                                                                    Coen, John        Active
              A Phase II Randomized Study for Patients with Muscle-InvasiveGroup Cancer Evaluating Transurethral Sur
RTOG-0724                        RTOG              Radiation Therapy Oncology Pelvic
                                                                    Jhingran, Anuja Active
              Phase III Randomized Study of Concurrent Chemotherapy and Group Radiation Therapy with or without Adjuv
RTOG-0813     Seamless PhaseRTOG                   Radiation Therapy Oncology Group
                                                                    Bezjak, Andrea Active
                                 I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-
RTOG-0815                        RTOG              Radiation Dose-EscalatedAlvaro Active with or without Short-Term Androg
                                                                    Martinez, Radiotherapy
              A Phase III Prospective Randomized Trial ofTherapy Oncology Group
RTOG-0822                        RTOG              Radiation Therapy Oncology Group losed Modulated
                                                                    Garofalo, Michael C
              A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity to Accrual Radiation Therapy (IM
RTOG-0825                        RTOG              Radiation Therapy Oncology Concurrent Chemoradiation and Adjuvant Tem
                                                                    Gilbert, Mark
              Phase III Double-Blind Placebo-Controlled Trial of ConventionalGroup    Active
RTOG-0915                        RTOG              Radiation Stereotactic Body Group
                                                                    Videtic, Gregory M.
                                                                                      Active
              A Randomized Phase II Study Comparing 2 Therapy OncologyRadiation Therapy (SBRT) Schedules for Medic
S0106                             of the           Southwest Oncology Group Stephen
                                                                    Petersdorf,       Closed to Accrual
              A Phase III StudySWOGAddition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus S
S0205                            SWOG              Southwest Oncology GemcitabineClosed to Accrual & Treatment
                                                                    Philip, Philip
              A Phase III Randomized Open-Label Study Comparing Group                  Plus Cetuximab (IMC-C225) Versus Gem
S0217                            SWOG              Southwest Oncology GroupPrakash
                                                                     Cisplatin        Closed and Docetaxel (NSC-628503) aft
              Adjuvant Chemo-Radiotherapy with Combination ofNeupane, (NSC-119875)to Accrual & Treatment
S0220                            SWOG              Southwest Oncology Group
                                                                    Kraut, Michael Closed to Accrual & Treatment
              A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Foll
S0221                            Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Eith
              Phase III Trial of SWOG                               Budd, George Active
                                                   Southwest Oncology Group
S0221A-ICSC                      SWOG              Southwest Oncology in ROS-related Genes on Toxicity and Breast Cancer
                                                                    Ambrosone,
              Impact of Antioxidant Supplements and PolymorphismsGroup Christine      Active
S0226                            SWOG              Southwest Oncology Group
                                                                    Mehta, Rita       Closed to as First
              Phase III Randomized Trial of Anastrozole Versus Anastrozole and FulvestrantAccrual Line Therapy for Post
S0232                            SWOG              Southwest Trial Comparing
                                                                    Zonder, Jeffrey Closed to (DEX) & Treatment
              Double-Blinded Placebo Controlled Phase III Oncology Group DexamethasoneAccrual to the Combination of D
S0301                            of Induction with Southwest Oncology Group Thomas
              A Phase II Study SWOG                                 Chauncey,         Closed to all by Continuous IV
                                                   Daunorubicin, Cytarabine, and CyclosporineAccrual & Treatment Infusion fo
S0304                            SWOG              Southwest Trial of Induction
                                                                    Thomas, CharlesClosed to Followed
              A Phase II Feasibility Translational Research Oncology Group Chemotherapy Accrual by Concomitant Chem
S0306                             Irinotecan in Patients with Advanced Transitional Cell Carcinoma of theTreatment
              Phase II Study ofSWOG                                 Beer, Tomasz Closed to Accrual & Urothelium
                                                   Southwest Oncology Group
S0307                            BisphosphonatesSouthwest Oncology Group
              Phase III Trial of SWOG                               Gralow, Primary Closed Cancer
                                                    as Adjuvant Therapy for Julie     Breast to Accrual
S0307A                           Quality           Southwest Oncology (A Companion
                                                                    Hershman,
              Long-Term BoneSWOG in Women with Breast CancerGroup Dawn Study to S0307)Closed to Accrual
S0309                            SWOG              Southwest Oncology Group
              Myeloma Specimen Repository Protocol, Ancillary Rimsza, Lisa            Active
S0310                            SWOG              Southwest Oncology Group
                                                                    Davies, Angela Closed to Accrual & Treatment
              Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients with Selected Stage IIIB and IV
S0312                            of IV Gemcitabine and Oral Oncology GroupPatients with Advanced Renal Cell Cancer
              A Phase II Study SWOG                                 Van Veldhuizen, Peter to Accrual & Treatment
                                                   Southwest Capecitabine in          Closed
S0313                            SWOG               Field Radiotherapy Group
                                                                    Miller, Thomas Closed to Accrual & Treatment
              Evaluation of CHOP Plus InvolvedSouthwest OncologyFollowed by Yttrium-90 Ibritumomab Tiuxetan for Stage
S0325                            SWOG              Southwest Imatinib, Group
                                                                    Druker, Brian     Closed to Accrual
              A Phase IIb Study of Molecular Responses toOncology at Standard or Increased Doses, or Dasatinib (BMS-35
S0329                             Biweekly         Southwest Oncology Group
                                                                    Kucuk, Omer       Closed to Accrual & Treatment
              Phase II Study ofSWOG Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients with Recurrent or
S0330                            SWOG              Study of OSI-774Albritton, Karen Closed Nerve Sheath Tumors,
                                                                     in Group
              U.S./Canada Sarcoma Intergroup Southwest OncologyMalignant Peripheral to Accrual & Treatment Phase II
S0331                            SWOG              Southwest Oncology Group in Neuroendocrine Carcinoma of the Skin (Mer
                                                                    Samlowski,
              A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) Wolfram    Closed to Accrual & Treatment
S0333                            of Double         Southwest Oncology Newly
                                                                    Forman, Stephen   Closed to Accrual
              A Phase II Study SWOG Induction Chemotherapy forGroup Diagnosed Non-L3 Adult Acute Lymphoblastic
S0334                            SWOG              Southwest Oncology Group
                                                                     Studies Diane Closed to Accrual
              Cytogenetic and Fluorescence In Situ HybridizationPersons,in Multiple Myeloma
S0337                            SWOG              Southwest Oncology Group
                                                                    Messing, EdwardActive
              A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients With
S0339                            SWOG              Southwest Oncology Group
                                                                    Davies, Angela Closed to First-Line
              A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the Accrual & Treatment of Advanc
S0340                            SWOG              Southwest Oncology Group
                                                                    Solitary Plasmacytoma to Accrual & Treatment
                                                                                      Closed
              A Prospective Observational Study of Patients with Jakubowiak, Andrzej Using a Modified Staging System S
S0341                            SWOG              Southwest Oncology Group
                                                                     with Advanced Closed to Cell Lung Treatment
              Phase II Trial of OSI-774 (NSC-718781) in PatientsHesketh, Paul Non-Small Accrual & Cancer and a Perform
S0342                            SWOG              Concurrent Chemotherapy
                                                                    Herbst, Roy       Closed to Accrual & Treatment
              Phase II Selection Design Trial of Southwest Oncology Group+ Cetuximab vs. Chemotherapy Followed by Cet
S0344                            SWOG              Southwest Oncology Group
                                                                    Randall, R.       Closed to Accrual & Treatment
              A Phase II Surgical Trial of Intralesional Resection of Low-Grade Intracompartmental Chondrosarcoma of Bon
S0345                            of Imatinib (NSC-716051) inOncology with Locally Advanced or Metastatic Dermatofibrosarco
              A Phase II Study SWOG                                 Schuetze,
                                                   Southwest Patients Group Scott Closed to Accrual & Treatment
S0350                            SWOG              Southwest Oncology Group Solumedrol (PEGS) in Peripheral T-Cell Non
                                                                    Mahadevan,
              Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine PlusDaruka  Active
S0353                             Intravesical Gemcitabine in Oncologywith Superficial Bladder Accrual Who Have Progressed
              Phase II Study ofSWOG                                 Skinner, Eila
                                                   Southwest Patients Group           Closed to Cancer
S0354                            of CNTO           Monoclonal Antibody Against
                                                                    Pinski, Jacek     Closed to Accrual
              A Phase II Study SWOG 328, A Southwest Oncology Group Interleukin-6 (IL-6), in Patients with Hormone
S0355                            SWOG              of Epothilone B AnalogueAngela Closed to Accrual & Treatment with Ad
                                                                    Davies, BMS-247550 (NSC-710428D) in Patients
              A Phase I Pharmacokinetic Study Southwest Oncology Group
S0356                      SWOG              Southwest Oncology Group Lawrence
                                                             Leichman,        Closed to Curable
        Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for PotentiallyAccrual Esophageal Cancer: A
S0400                      of Depsipeptide (NSC-630176) in Petrylak, with Advanced Transitional Cell Carcinoma of the
        A Phase II Study SWOG                                 Patients Daniel Closed to Accrual & Treatment
                                             Southwest Oncology Group
S0410                      SWOG              Southwest Oncology Group
                                                             Smith, Eileen    Closed to Accrual
        Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's D
S0412                      of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896)& Treatment
        A Phase II Study SWOG                                Ryan, Christopher
                                             Southwest Oncology Group         Closed to Accrual in Combination with In
S0413                       GW572016 (NSC-727989) as First LineSyma
        Phase II Study ofSWOG                                Iqbal, Therapy in Patients with Advanced or Metastatic Ga
                                             Southwest Oncology Group         Closed to Accrual & Treatment
S0414                      SWOG              Southwest Oncology Group
                                                             Thomas, CharlesClosed to Accrual & Treatment
        Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic)
S0415                      SWOG              Southwest Oncology Group
                                                             Gold, Philip     Closed to Accrual Phase II
        Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer - & Treatment
S0417                      of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone Treatment with Refra
        A Phase II Study SWOG                Southwest Oncology GroupGordan
                                                             Srkalovic,       Closed to Accrual & in Patients
S0420                      SWOG              Southwest Oncology Group Stephen
                                                              in Patients     Closed to Accrual & Treatment
        Phase II Evaluation of BAY 43-9006 (NSC-724772)Williamson, with Recurrent or Metastatic Head and Neck C
S0421                      SWOG              Southwest Oncology Group
                                                             Quinn, David     Active
        Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormo
S0423                      SWOG              Southwest Oncology Group
                                                             Chow, Warren Closed to Accrual & Treatment
        Phase II Trial of Pemetrexed for Advanced Chondrosarcomas
S0424                      SWOG              Southwest Oncology Group Christine
                                                             Ambrosone,       Active
        Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Wo
S0425                      SWOG              Southwest Oncology Group
                                                             Ahmad, Syed      Closed Patients with Surgically Resectab
        Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for to Accrual
S0429                      SWOG              Southwest Oncology Group
                                                             Chen, Yuhchyau Closed to Accrual
        A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Sma
S0430                      SWOG              Southwest Oncology Cyclophosphamide and Capecitabine) in Patients with
                                                             Schott, Anne
        Phase II Trial of Simple Oral Therapy (Continuous Oral Group          Closed to Accrual
S0431                       Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland& Treatment
        Phase II Study ofSWOG                                Kane, MadeleineClosed to Accrual Carcinoma
                                             Southwest Oncology Group
S0432                      of Two            Southwest Oncology Group
                                                             Erba, Harry      Closed Farnesyl & Treatment
        Phase II Studies SWOG Different Schedules and Two Different Doses of theto Accrual Transferase Inhibitor R1
S0433                      SWOG              Southwest Oncology Group Jonathan
                                                             Friedberg,       Closed to Accrual
        Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131Tositumomab) in Combination with Cyclophosphamide
S0434                      SWOG              Southwest Oncology Group
                                                             Hussein, Mohamad Closed to Accrual
        A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple My
S0435                      SWOG              Southwest Oncology Group Platinum-Treated Extensive Stage
                                                             Gitlitz, with
        A Phase II Trial of BAY 43-9006 (NSC-724772) in PatientsBarbara Closed to Accrual & TreatmentSmall Cell
S0438                      SWOG              Southwest (Sorafenib; NSC-724772) withto Accrual
                                                             Margolin, Kim Closed Either CCI-779 (Temsirolimus; N
        A Randomized Phase II Trial of BAY 43-9006Oncology Group
S0500                      SWOG              Southwest Oncology GroupJeffreyActive
                                                             Smerage,
        A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metas
S0501                      SWOG              Southwest Oncology for Relapsed Hodgkin's or Non-Hodgkin's Lymphoma
                                                             Smith, Scott
        Nonmyeloablative Allogeneic Stem Cell TransplantationGroup            Closed to Accrual
S0502                      SWOG              Southwest Oncology Group
                                                             Blanke, Charles Closed to Accrual
        A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metas
S0505                      SWOG              Southwest Oncology Group Tissue Sarcomas
                                                             von Mehren,      Closed
        Phase II Trial of BAY 43-9006 (NSC #724772) in Advanced Soft Margaret to Accrual & Treatment
S0508                      SWOG              Southwest Oncology Group
                                                             Clark, Joseph Closed with Metastatic Malignant Melano
        A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patientsto Accrual & Treatment
S0509                      of Novel          Southwest Oncology Group
                                                             Garland, Linda Closed to Accrual
        A Phase II Study SWOG Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesotheli
S0512                      SWOG              Southwest Oncology Group
                                                             Aparicio, Ana    Closed to Accrual
        Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination with Carboplatin and Paclitaxel in Pat
S0514                       BAY 43-9006 (NSC #724772) as El-Khoueiry, Anthony
        Phase II Study ofSWOG                                Single Agent     Closed to Accrual & Treatment
                                             Southwest Oncology Group in Unresectable or Metastatic Gallbladder Ca
S0515                      SWOG              Southwest Oncology Group
                                                             Stopeck, Alison Closed to Accrual & (CHOP) and Rituxim
        Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, PrednisoneTreatment
S0517                      SWOG              Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgk
                                                             Kirschbaum,      C
        A Phase II Trial of Suberoylanilide Southwest Oncology Group Mark losed to Accrual & Treatment
S0518                      SWOG              Southwest Oncology Group
                                                             Yao, Octreotide Active
        Phase III Prospective Randomized Comparison of DepotJames             Plus Interferon Alpha Versus Depot Octre
S0520                       PXD101           Southwest Oncology Group Steven
                                                             Bernstein,       Closed to Accrual
        Phase II Study ofSWOG (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas
S0521                      SWOG              Southwest Oncology Group
                                                             Coutre, Steven with Previously Untreated Low and Interm
        A Randomized Trial of Maintenance Versus Observation for PatientsActive
S0526                      SWOG              Southwest Oncology Group
                                                             Lau, Derick      Closed to Accrual
        Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
S0528                      SWOG              Southwest Lapatinib Group
                                                             Gadgeel, Shirish NSC-727989; IND-75,093) and Everolimu
        Phase I Study Evaluating the Combination of Oncology (GW572016;Closed to Accrual
S0530                      SWOG              Clofarabine in Patients with
                                                             Advani, Anjali Closed to Accrual
        A Phase II Trial of Cytarabine and Southwest Oncology Group Relapsed or Refractory Acute Lymphoblastic Le
S0533                      SWOG              Southwest Oncology GroupConsolidation Docetaxel and the Addition of Bev
                                                             Wozniak,         Closed to Accrual
        A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Antoinette
S0535                      of ATRA,          Southwest Oncology Group
                                                             Lancet, Jeffrey Active
        A Phase II Study SWOG Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreat
S0536                      SWOG              Southwest Oncology Cetuximab and Bevacizumab (NSC-704865) Followed
                                                             Kim, Edward
        A Phase II Trial of Combination Carboplatin, Paclitaxel, Group        Closed to Accrual
S0600                      Irinotecan-BasedSouthwest Oncology Cetuximab (NSC-714692) or Bevacizumab (NSC-7048
        Phase III Trial of SWOG                              Gold, Philip
                                              Chemotherapy Plus Group         Active
S0601                      of Combination Rituximab-CHOP Bernstein, Steven
        A Phase II Study SWOG                                 and Bortezomib (Velcade®) (R-CHOP-V) Induction Therap
                                             Southwest Oncology Group         Closed to Accrual
S0605                      of Lenalidomide (Revlimid®, NSC-703813) MikkaelActive Untreated Non-M3, Deletion 5q Ac
        A Phase II Study SWOG                                Sekeres, for
                                             Southwest Oncology Group Previously
S0618                      SWOG              Southwest Oncology with Metastatic or Recurrent Squamous Cell Carcinom
                                                             Arnold, Susanne Closed to Accrual & Treatment
        Phase II Evaluation of E7389 (NSC-707389) in PatientsGroup
S0622                      of Two            Southwest Oncology Group
                                                             Schott, Anne     Active
        Phase II Studies SWOG Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Met
S0629                      SWOG              Southwest Oncology GroupGordan
                                                             Srkalovic,       Active
        Observational Study of Asymptomatic Waldenström's Macroglobulinemia and Phase II Study of Tandem Auto
S0635                      SWOG              Southwest Oncology Group
                                                             West, Howard Active
        A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (rhuMAb VEGF; NS
S0636                      SWOG              Southwest Oncology Group
                                                             West, Howard Active
        A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (rhuMAb VEGF; NS
S0703                      SWOG              Southwest Plus Gemtuzumab
                                                             Nand, Sucha      Active
        A Phase II Trial of Azacitidine (NSC-102816) Oncology Group Ozogamicin as Induction and Post-Remission
S0709                      SWOG              Southwest Oncology Group
                                                             Lara, Primo      Active
        A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NS
S0711                      SWOG              Dasatinib Oncology Group
                                                             Sarantopoulos, John
                                                                              Active
        Phase I Pharmacokinetic Study of Southwest(BMS-354825) (NSC-732517; IND-73969) in Patients with Advan
S0713                      of Oxaliplatin, Capecitabine,Oncology Group Radiation in Pre-Operative Therapy of Rectal C
        A Phase II Study SWOG                                Leichman,
                                             Southwest Cetuximab and Cynthia  Active
S0720         Phase II ERCC1 SWOG                 Southwest Therapy Trial Ralph
                                                                 Zinner, in         Active
                                 and RRM1-Based Adjuvant Oncology GroupPatients with Stage I Non-Small Cell Lung Canc
S0722                            SWOG             Southwest Oncology Group
                                                                 Ou, Sai-Hong Active
              A Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
S0727                            SWOG             Southwest Oncology Group
                                                                 Philip, + ErlotinibActive
              A Phase I and Randomized Phase II Trial of Gemcitabine Philip         (NSC-718781) + IMC-A12 (NSC-742460)
S0777                            SWOG             Southwest Oncology Group G. Active
                                                                 Durie, Brian
              A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD)
S0801                            of Iodine-131-Labeled Tositumomab in Combination with Cyclophosphamide, Doxorubicin, V
              A Phase II Study SWOG                              Friedberg,
                                                  Southwest Oncology Group Jonathan Active
S0802                            SWOG             Southwest Oncology Group
                                                                 with and without Active
              A Randomized Phase II Trial of Weekly Topotecan Allen, Jeffrey        AVE0005 (Aflibercept; NSC-724770) in P
S0805                             Combination of Hyper-CVAD andRavandi-Kashani, Farhad with or without Allogeneic Stem C
              Phase II Study ofSWOG                              Dasatinib          Active
                                                  Southwest Oncology Group (NSC-732517)
S0806                            of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with N
              A Phase I/II Trial SWOG                            Persky, Daniel Approved
                                                  Southwest Oncology Group
S0809                            SWOG             Southwest Oncology Group Edgar
                                                                 Ben-Josef,         Active
              A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine a
S0816                            SWOG             Southwest Oncology Group
                                                                 Press, Oliver      Active
              A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-P
S0819                            SWOG             Southwest Oncology Group
                                                                 Herbst, Roy        Carboplatin/Paclitaxel/Bevacizumab with
              A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel orActive
S0826                            SWOG             Southwest Oncology Group
                                                                 Lao, Christopher Temporarily Closed to Accrual
              A Phase II Trial of SCH 727965 (NSC 747135) in Patients with Stage IV Melanoma
S0919                            of Idarubicin andSouthwest Oncology GroupPravastatin for Relapsed Acute Myelogenous Le
              A Phase II Study SWOG                              Advani, Anjali Active
                                                  Ara-C in Combination with
                                 SWOG             Southwest Oncology Group
                                                                 Albain, Kathy      Active
S8814A-ICSC Molecular Predictors of Outcome on CAF plus Tamoxifen versus Tamoxifen Alone in Postmenopausal Wome
              Examination of SWOG                 Southwest AML-Specific and
                                                                 Stirewalt, Derek Closed to Accrual & Treatment
S9031-S9126-S9333-S9500-A the Prognostic Significance ofOncology Group Age-Associated Genes in AML Patients
                                                                  Quantitative
S9313A-ICSC Prediction of Therapeutic Response using AQUA™Rimm, David Protein Expression analysis of ER, PgR, and
                                 SWOG             Southwest Oncology Group          Active
SWOG-8897-ICSC                   SWOG             Southwest Oncology Group Christine
                                                                 Ambrosone,
              Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897   Active
              Investigation of Thioredoxin-1 Family Protein Oncology Group Tomislav
SWOG-9304A-ICSC                  SWOG                            Dragovich,         Closed
                                                  Southwest Expression in Rectal Cancer to Accrual & Treatment
                                 SWOG             Southwest Oncology Group
                                                                 CaMKIIgamma Closed to Accrual
SWOG-9333A Determining the Clinicopathological Significance of Collins, Steven Activation in AML & Treatment
Current Status             Conversion      Conversion        CTCAE v4.0
Date             Exempt?   Group           Date at CTEP Start Date
10/13/2008       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
7/27/2007        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
2/8/2006         No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
6/27/2005        No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
10/13/2008       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
9/9/2008         No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
4/20/2004        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
7/25/2006        No                         Group, non-CTMS 2011
                                                             April 1, 2011
                           Non-CooperativeLast week of March monitored studies
8/8/2006         No                         Group, non-CTMS 2011
                                                             April 1, 2011
                           Non-CooperativeLast week of March monitored studies
10/3/2006        No                        Last week of non-CTMS1, 2011
                                                             January monitored studies
                           NCI Intramural/Clinical Center,December 2010
6/9/2008         No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
3/16/2004        No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
8/15/2008        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
10/12/2004       No                        Last week of non-CTMS1, 2011
                                                             January monitored studies
                           NCI Intramural/Clinical Center,December 2010
6/13/2006        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
3/13/2008        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
12/15/2006       No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
4/27/2004        No                        Last week of non-CTMS1, 2011
                                                             January monitored studies
                           NCI Intramural/Clinical Center,December 2010
2/5/2004         No                        Last week of non-CTMS1, 2011
                                                             January monitored studies
                           NCI Intramural/Clinical Center,December 2010
5/16/2007        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
4/28/2010        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
6/27/2006        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
8/13/2008        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
10/23/2008       No                         Group, non-CTMS monitored
                           Non-CooperativeLast week of December 2010 studies
                                                             January 1, 2011
10/13/2004       No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
7/18/2008        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
12/11/2006       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
11/16/2007       No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
12/22/2005       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
11/20/2008       No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
1/5/2009         No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
3/10/2009        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
3/14/2005        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
3/16/2010        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
5/17/2010        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
5/20/2008        No                         Group, non-CTMS 2011
                                                             April 1, 2011
                           Non-CooperativeLast week of March monitored studies
11/10/2008       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
9/4/2008         No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
5/28/2009        No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
3/1/2004         No                         Group, non-CTMS 2011
                                                             April 1, 2011
                           Non-CooperativeLast week of March monitored studies
7/19/2004        No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
10/31/2007       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
3/12/2009        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
6/5/2009         No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
5/18/2009        No                         Group, non-CTMS monitored
                                                              ############
                           Non-CooperativeLast week of September 2010 studies
11/27/2006       No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
6/13/2007        No        CDS Web Submitter week of December 2010 2011
                                           Last              January 1,
2/23/2005        No                         Group, non-CTMS monitored
                                                             July 1,
                           Non-CooperativeLast week of June 2011 2011 studies
5/27/2008        No                                           2010
                           CTMS monitoredLast week of JulyAugust 1, 2010
12/6/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/23/2008    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
6/10/2008    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/29/2008    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/9/2005     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
8/30/2004    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
2/23/2007    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
12/14/2007   No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
12/11/2008   No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
2/16/2009    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
9/29/2008    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
11/13/2007   No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
4/30/2010    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
11/5/2009    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
8/5/2005     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/13/2008   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
4/7/2005     No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
11/18/2008   No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
6/28/2007    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
11/1/2004    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
11/8/2004    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
10/24/2008   No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
5/5/2005     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
2/19/2008    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
10/3/2005    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
4/1/2007     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
2/5/2009     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
11/28/2006   No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
7/5/2005     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
3/6/2007     No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
7/28/2006    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
3/3/2008     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
5/8/2008     No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
1/21/2009    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
1/5/2010     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/19/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
3/3/2006     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/7/2009    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
11/17/2009   No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
5/16/2008    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
2/21/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
3/15/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
11/22/2006   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/29/2008   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
3/10/2009    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
10/31/2008   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/25/2005   No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
8/13/2008    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
1/10/2008    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
4/22/2008    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
9/10/2005    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
12/22/2008   No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
5/17/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/11/2005    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
6/20/2005    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/5/2010     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
12/9/2005    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
9/18/2009    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
1/6/2010     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
8/29/2007    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
2/9/2009     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
9/11/2009    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
6/30/2009    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
6/14/2005    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
6/7/2006     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
12/20/2006   No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
3/7/2007     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
5/10/2006    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
7/22/2008    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
10/13/2008   No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
5/7/2009     No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
1/14/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
11/13/2008   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
2/15/2007    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
3/30/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
12/9/2005    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
11/26/2006   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
8/13/2007    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
11/15/2007   No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
5/16/2008    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
7/31/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
5/7/2008     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
11/14/2008   No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
1/22/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/7/2009     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
4/24/2006    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
2/18/2010    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
10/8/2008    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
5/4/2007     No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
1/22/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
12/8/2009    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
7/1/2008     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
4/24/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
10/15/2008   No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
5/8/2009     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
1/1/2006     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/22/2010    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
6/12/2006    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
12/7/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
11/26/2007   No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
8/24/2009    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
4/20/2010    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
6/12/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
4/26/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
12/13/2005   No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
11/9/2006    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
6/26/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
3/22/2010    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
10/2/2009    No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
4/24/2007    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
3/26/2010    No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
3/20/2008    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
11/24/2008   No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
2/19/2007    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
4/13/2007    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
1/5/2007     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
3/19/2010    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
6/19/2006    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
7/18/2006    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
10/23/2006   No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
2/1/2010     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
7/11/2006    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
12/21/2006   No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
10/13/2009   No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
10/23/2006   No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
12/4/2009    No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
10/16/2006   No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
11/14/2006   No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
12/22/2008   No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
11/21/2007   No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
11/5/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
10/21/2008   No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
5/10/2010    No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
8/12/2008    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
9/6/2007     No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
1/5/2007     No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
4/30/2009    No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
1/29/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
5/25/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
6/1/2006     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
11/27/2006   No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
5/1/2009     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
5/4/2010     No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
2/8/2008     No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
3/11/2009    No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
4/8/2008     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
10/25/2007   No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
7/14/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
1/29/2010    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
2/5/2009     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
4/25/2007    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
9/10/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
9/17/2007    Yes   Exempt          N/A - Exempt      N/A - Exempt
4/5/2010     No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
2/22/2008    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
7/23/2009    No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
9/6/2007     No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
12/7/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
4/20/2010    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
4/8/2010     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
6/12/2008    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
2/14/2007    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
3/17/2010    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
9/4/2009     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
5/17/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
8/4/2006     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
4/30/2007    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
5/13/2009    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of December 2010 studies
                                                    January 1, 2011
3/25/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
11/16/2009   No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
7/1/2009     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
4/5/2007     No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
6/15/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
1/18/2007    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
3/3/2010     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
8/11/2006    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/4/2007     No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
2/9/2009     No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
4/23/2007    No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
4/20/2009    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
11/7/2007    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/1/2007     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
8/2/2007     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/22/2007   No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
4/24/2006    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
2/1/2007     No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
1/11/2010    No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
4/7/2008     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
9/25/2008    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
3/15/2007    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
7/24/2007    No                   Last week of non-CTMS1, 2011
                                                    January monitored studies
                  NCI Intramural/Clinical Center,December 2010
5/11/2010    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
4/10/2007    No                    Group, non-CTMS monitored
                  Non-CooperativeLast week of June July 1, 2011 studies
                                                    2011
5/8/2009     No                    Group, non-CTMS monitored
                                                     ############
                  Non-CooperativeLast week of September 2010 studies
10/17/2007   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
11/20/2007   No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
10/19/2009   No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
5/6/2010     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/22/2007    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
1/25/2010    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
3/10/2009    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
7/6/2009     No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
9/18/2009    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
6/11/2009    No                    Group, non-CTMS 2011
                                                    April 1, 2011
                  Non-CooperativeLast week of March monitored studies
12/3/2009    No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
5/25/2010    No                                      2010
                  CTMS monitoredLast week of JulyAugust 1, 2010
12/20/2007   No                    Group, non-CTMS monitored
                                                    July 1,
                  Non-CooperativeLast week of June 2011 2011 studies
1/2/2008     No   CDS Web Submitter week of December 2010 2011
                                  Last              January 1,
7/1/2008     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
12/7/2009    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
4/29/2010    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
9/17/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
11/28/2007   No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
12/5/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
8/22/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
8/18/2008    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
5/18/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
7/21/2009    No                     Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                     January 1, 2011
7/6/2009     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
10/28/2009   No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
12/1/2008    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
4/22/2008    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
3/5/2009     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
11/16/2007   No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
8/8/2008     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
9/2/2008     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
11/19/2008   No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
9/9/2009     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
9/9/2009     No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
9/11/2007    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
5/8/2008     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
7/9/2008     No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
12/3/2009    No                     Group, non-CTMS monitored
                                                     July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
7/20/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
5/25/2008    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
2/21/2008    Yes   Exempt          N/A - Exempt      N/A - Exempt
1/4/2008     No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
7/18/2008    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
8/6/2007     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
7/15/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
5/7/2008     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
3/25/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
10/31/2008   No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
6/30/2008    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
10/1/2008    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
8/6/2009     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
6/8/2009     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
1/5/2010     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
9/23/2008    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
3/30/2009    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
1/21/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
11/24/2008   No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
12/31/2008   No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
7/30/2008    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
1/23/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
5/9/2008     No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
8/27/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
7/29/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
11/16/2009   No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
4/22/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
11/25/2008   No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
3/31/2009    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
9/8/2009     No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
3/31/2010    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
11/5/2008    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
7/27/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
5/15/2008    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
3/6/2009     No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
6/2/2009     No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
3/16/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
12/10/2008   No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
3/3/2009     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
12/20/2008   No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
7/14/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
4/20/2009    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
8/19/2009    No                                       2010
                   CTMS monitoredLast week of JulyAugust 1, 2010
7/21/2009    No                     Group, non-CTMS monitored
                                                      ############
                   Non-CooperativeLast week of September 2010 studies
9/14/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
5/20/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
5/25/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
7/13/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
5/10/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
9/23/2009    No    CDS Web Submitter week of December 2010 2011
                                   Last              January 1,
8/17/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
9/8/2009     No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
9/14/2009    No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
9/3/2009     No                     Group, non-CTMS 2011
                                                     April 1, 2011
                   Non-CooperativeLast week of March monitored studies
8/30/2009    No                    Last week of non-CTMS1, 2011
                                                     January monitored studies
                   NCI Intramural/Clinical Center,December 2010
12/29/2003   No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
9/2/2008     No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
4/11/2005    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
12/29/2003   Yes   Exempt          N/A - Exempt      N/A - Exempt
5/12/2003    Yes   Exempt          N/A - Exempt      N/A - Exempt
3/26/2007    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
1/22/2007    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
11/10/2003   Yes   Exempt          N/A - Exempt      N/A - Exempt
5/13/2004    Yes   Exempt          N/A - Exempt      N/A - Exempt
9/25/2006    Yes   Exempt          N/A - Exempt      N/A - Exempt
7/14/2008    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
1/14/2008    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
7/24/2006    Yes   Exempt          N/A - Exempt      N/A - Exempt
1/29/2007    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
3/23/2009    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
4/12/2010    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
7/21/2008    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
4/1/2010     No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
3/26/2007    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
3/12/2007    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
8/14/2006    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
1/21/2008    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
3/9/2009     No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
3/19/2010    No                    20%+ (minimum TBD
                   Cooperative Group                 of 16-17 protocols per quarter)
4/21/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/23/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/5/2007     Yes   Exempt         N/A - Exempt    N/A - Exempt
4/9/2010     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/24/2007   Yes   Exempt         N/A - Exempt    N/A - Exempt
7/18/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
11/28/2005   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
8/3/2007     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
5/18/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/16/2004    Yes   Exempt         N/A - Exempt    N/A - Exempt
4/12/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/26/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/4/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
4/15/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
6/9/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/13/2004   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
1/30/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
1/9/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
7/2/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
7/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
9/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
3/5/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
4/17/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
1/22/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
9/20/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
1/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
12/15/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
11/23/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
8/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
9/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 2-3
12/29/2008   Yes   Exempt         N/A - Exempt    N/A - Exempt
2/27/2004    No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
10/15/2004   No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
8/8/2006     No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
5/2/2003     Yes   Exempt         N/A - Exempt    N/A - Exempt
1/17/2007    No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
2/3/2006     No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
5/15/2009    Yes   Exempt         N/A - Exempt    N/A - Exempt
2/9/2009     No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
3/30/2007    No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
7/29/2009    No                    Group, non-CTMS monitored
                                                   ############
                   Non-CooperativeLast week of September 2010 studies
4/9/2010     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
5/30/2006    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/8/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/28/2005    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
7/29/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
1/15/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/16/2006   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/11/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/26/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/22/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
4/6/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
6/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/31/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
1/26/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/30/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/21/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/30/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
6/2/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
7/28/2003    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/4/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
2/8/2010     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/9/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
11/3/2003    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
11/5/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/14/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/6/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
1/2/2006     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
4/3/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/23/2006   Yes   Exempt         N/A - Exempt    N/A - Exempt
10/30/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/22/2004    Yes   Exempt         N/A - Exempt    N/A - Exempt
5/19/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
9/15/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
9/12/2006    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
2/25/2010    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
7/17/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
5/11/2010    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
9/22/2008    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
9/16/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
11/21/2008   No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
10/24/2008   No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
8/26/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
5/14/2008    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
9/22/2008    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
7/30/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
8/10/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
8/13/2009    No                    Group, non-CTMS monitored
                                                  July 1,
                   Non-CooperativeLast week of June 2011 2011 studies
10/18/2001   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/15/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/8/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
11/5/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
11/13/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/11/2006   Yes   Exempt         N/A - Exempt    N/A - Exempt
6/27/2007    Yes   Exempt         N/A - Exempt    N/A - Exempt
7/2/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/28/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/28/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
5/30/2005    Yes   Exempt         N/A - Exempt    N/A - Exempt
12/5/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
11/14/2005   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/4/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
8/25/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
1/13/2009    Yes   Exempt         N/A - Exempt    N/A - Exempt
2/20/2006    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/18/2006    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
6/19/2006    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/3/2004     Yes   Exempt         N/A - Exempt    N/A - Exempt
2/27/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
6/24/2004    Yes   Exempt         N/A - Exempt    N/A - Exempt
10/30/2006   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/26/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
7/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
4/16/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/4/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
5/14/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
9/20/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
2/5/2007     No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/26/2006   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
3/19/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
4/17/2006    No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
10/10/2008   No                   20%+ (minimum TBD
                   Cooperative Group              of 16-17 protocols per quarter)
12/3/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
2/23/2009    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
3/30/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 19
2/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 19
9/15/2005    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
8/14/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/15/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
7/3/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
2/6/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
2/3/2010     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
12/15/2008   No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/7/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
11/15/2007   No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/15/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/14/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
2/26/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
11/15/2006   No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
4/1/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
6/15/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
3/21/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
3/21/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
3/21/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
4/8/2009     Yes   Exempt         N/A - Exempt    N/A - Exempt
9/15/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
7/15/2007    Yes   Exempt         N/A - Exempt    N/A - Exempt
4/8/2009     Yes   Exempt         N/A - Exempt    N/A - Exempt
7/15/2009    Yes   Exempt         N/A - Exempt    N/A - Exempt
9/15/2009    Yes   Exempt         N/A - Exempt    N/A - Exempt
7/15/2009    Yes   Exempt         N/A - Exempt    N/A - Exempt
10/15/2008   Yes   Exempt         N/A - Exempt    N/A - Exempt
10/15/2004   Yes   Exempt         N/A - Exempt    N/A - Exempt
1/15/2004    Yes   Exempt         N/A - Exempt    N/A - Exempt
10/15/2006   Yes   Exempt         N/A - Exempt    N/A - Exempt
5/15/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
5/15/2008    Yes   Exempt         N/A - Exempt  N/A - Exempt
3/21/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/29/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/15/2007    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/31/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
6/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
6/15/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/15/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/15/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
2/15/2010    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/15/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
10/13/2008   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/15/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
12/1/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
11/6/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/27/2007    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/2/2005     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/15/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/20/2007    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
6/30/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
11/15/2007   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/24/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
10/15/2008   Yes   Exempt         N/A - Exempt  N/A - Exempt
10/17/2005   Yes   Exempt         N/A - Exempt  N/A - Exempt
5/29/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
2/15/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
11/18/2009   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
2/25/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/1/2009     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/14/2010    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/28/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
2/15/2010    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/15/2004    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
12/15/2006   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/1/2005     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/11/2010    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/15/2008    Yes   Exempt         N/A - Exempt  N/A - Exempt
2/27/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
9/10/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/28/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
5/15/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
10/28/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/28/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/22/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/8/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/10/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
11/14/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/24/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/18/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
12/12/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
6/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
3/5/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
1/12/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/15/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
9/23/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
6/29/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/18/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/16/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
5/7/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
2/29/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
3/13/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
2/24/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/15/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/16/2005   Yes   Exempt         N/A - Exempt  N/A - Exempt
3/24/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
11/6/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
1/9/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
1/8/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
2/6/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
3/24/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/27/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
5/7/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/22/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
5/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
9/14/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/24/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/7/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/16/2004   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
1/29/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
3/7/2005     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/24/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
12/30/2005   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
5/26/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/18/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/20/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
11/25/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/5/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/24/2006   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/13/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
8/19/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/28/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/8/2004     Yes   Exempt         N/A - Exempt  N/A - Exempt
8/30/2006    Yes   Exempt         N/A - Exempt  N/A - Exempt
2/4/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
3/18/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
9/12/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/19/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
9/11/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/21/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
11/15/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
6/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
1/22/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
11/2/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/4/2005     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/2/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/29/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
7/5/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
8/5/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
10/29/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
4/19/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/11/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 14
12/25/2008   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/3/2009     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/14/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
11/3/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/26/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
12/7/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
11/6/2006    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/25/2010    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
10/29/2007   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
2/4/2008     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/26/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/6/2007     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
10/30/2009   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/7/2007     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/6/2008     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/1/2008     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/19/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
1/4/2010     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
6/15/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/17/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/21/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/21/2008    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/22/2003    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/2/2008     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/21/2005    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
12/6/2007    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
8/10/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
12/31/2009   No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/2/2007     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/2/2007     Yes   Exempt         N/A - Exempt  N/A - Exempt
7/27/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
9/29/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
5/5/2008     No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
4/30/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
7/13/2009    No                   20%+ (minimum TBD
                   Cooperative Group            of 11-12 protocols per quarter)
3/22/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
5/17/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
12/14/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
8/1/2005     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
7/4/2008     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
7/27/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
9/24/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
9/24/2007    Yes   Exempt         N/A - Exempt    N/A - Exempt
2/25/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
11/23/2009   No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
4/6/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
4/26/2010    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
9/29/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
3/23/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/4/2010     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
7/27/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
6/29/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
8/17/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
9/7/2004     Yes   Exempt         N/A - Exempt    N/A - Exempt
9/10/2007    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
5/25/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
5/10/2004    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/3/2005     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
7/19/2009    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
1/17/2008    No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
2/2/2009     No                   20%+ (minimum TBD
                   Cooperative Group              of 11-12 protocols per quarter)
4/30/2010    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
8/4/2003     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
6/29/2006    Yes   Exempt         N/A - Exempt    N/A - Exempt
11/25/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
10/26/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
2/5/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
9/17/2004    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
11/6/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
5/20/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
7/6/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
8/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
1/13/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
3/10/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
9/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
2/6/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
7/31/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
1/5/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
11/13/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
11/24/2006   Yes   Exempt         N/A - Exempt    N/A - Exempt
5/18/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
2/22/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
1/29/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
1/30/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
3/21/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
12/19/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
5/11/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 10
10/20/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
3/24/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
7/28/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
9/22/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/4/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
8/26/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
1/26/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/9/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
2/11/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
6/19/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
3/27/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
10/3/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/19/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
1/13/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
12/4/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
10/31/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
7/30/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
3/29/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/10/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
7/31/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
1/12/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/23/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
1/29/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
5/14/2010    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
12/12/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
11/13/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
9/25/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
7/10/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
4/8/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group             of 10
12/1/2008    No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
12/16/2005   No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
4/15/2010    No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
11/10/2008   No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
7/21/2008    No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
7/6/2006     No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
12/31/2007   No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
8/8/2007     No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
1/4/2007     No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
10/11/2007   No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
9/1/2008     No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
5/28/2008    No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
6/2/2009     No    CDS Web Submitter week of December 2010 2011
                                  Last           January 1,
1/22/2008    Yes   Exempt         N/A - Exempt   N/A - Exempt
6/15/2009    No                   Last           July 1,
                   Cooperative Group week of June 2011 2011
4/22/2005    No                   Last           July 1,
                   Cooperative Group week of June 2011 2011
7/31/2008    No                   Last           July 1,
                   Cooperative Group week of June 2011 2011
1/10/2006    No                   Last           July 1,
                   Cooperative Group week of June 2011 2011
5/30/2008    Yes   Exempt         N/A - Exempt   N/A - Exempt
1/30/2009    No                   Last           July 1,
                   Cooperative Group week of June 2011 2011
6/15/2007    No                   Last            ############
                   Cooperative Group week of September 2010
12/31/2008   No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group             of 2
1/29/2010    Yes   Exempt         N/A - Exempt   N/A - Exempt
1/31/2008    No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
3/21/2005    No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
11/20/2006   No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
1/6/2010     No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
11/10/2008   No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
1/29/2007    Yes   Exempt         N/A - Exempt    N/A - Exempt
10/29/2007   No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
6/16/2009    No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
7/23/2004    No                   20%+ (minimum TBDprotocols per quarter)
                   Cooperative Group              of 2
4/7/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 14
12/22/2008   No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
8/4/2009     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
4/3/2009     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
2/8/2010     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
8/4/2005     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
3/16/2006    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
3/24/2010    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
8/2/2006     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
5/3/2010     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
7/10/2008    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
1/5/2009     No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
6/18/2009    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
4/15/2010    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
7/10/2009    No                    Group, non-CTMS monitored
                   Non-CooperativeLast week of December 2010 studies
                                                  January 1, 2011
10/8/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
6/8/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
9/26/2005    Yes   Exempt         N/A - Exempt    N/A - Exempt
3/29/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
2/23/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
9/30/2004    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
8/11/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
9/19/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
12/31/2005   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
6/19/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
12/11/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
8/3/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
1/21/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
1/16/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
8/11/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
6/30/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
3/12/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
7/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
2/20/2008    Yes   Exempt         N/A - Exempt    N/A - Exempt
8/21/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
9/8/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
7/26/2005    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
6/13/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
5/11/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
7/7/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
2/13/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
6/19/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group              of 8-9
3/3/2008     Yes   Exempt         N/A - Exempt    N/A - Exempt
6/20/2006    Yes   Exempt         N/A - Exempt  N/A - Exempt
6/8/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
11/27/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
12/18/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
5/3/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
4/8/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
4/3/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
7/6/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
5/19/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
1/24/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
3/25/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
12/9/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
9/16/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
2/2/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
9/14/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
11/13/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
4/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
9/3/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 8-9
8/20/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/18/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/1/2003    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/2/2006     Yes   Exempt         N/A - Exempt  N/A - Exempt
7/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/11/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2010     Yes   Exempt         N/A - Exempt  N/A - Exempt
11/15/2003   Yes   Exempt         N/A - Exempt  N/A - Exempt
1/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/28/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/1/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/15/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
7/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/1/2005     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/15/2007    Yes   Exempt         N/A - Exempt  N/A - Exempt
11/15/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/15/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/1/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/15/2005    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/15/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/15/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/1/2006     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/6/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/21/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2005    Yes   Exempt         N/A - Exempt  N/A - Exempt
1/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
1/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/15/2009   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
1/10/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
1/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/31/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
1/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/1/2007     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/1/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/25/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/15/2007   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
6/15/2006    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/15/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/15/2007    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
10/15/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
11/15/2008   No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
3/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2008     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
4/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
5/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
9/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/14/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/1/2008    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/1/2009     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
7/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
2/9/2010     No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
8/15/2009    No                   20%+ (minimum TBD protocols per quarter)
                   Cooperative Group            of 19
12/8/2006    Yes   Exempt         N/A - Exempt  N/A - Exempt
9/22/2008    Yes   Exempt         N/A - Exempt  N/A - Exempt
7/17/2006    Yes   Exempt         N/A - Exempt  N/A - Exempt
12/15/2006   Yes   Exempt         N/A - Exempt  N/A - Exempt
2/23/2009    Yes   Exempt         N/A - Exempt  N/A - Exempt
8/20/2008    Yes   Exempt         N/A - Exempt  N/A - Exempt
                                                                 High Level Conversion Schedule
                                                                                                                                               Date of Data        CTCAE v4.0 Start
   Conversion Quarter                Conversion Group                      Affected Lead Organizations/Conversion Groups
                                                                                                                                          Conversion at CTEP            Date
                          CTMS monitored studies                    All CTMS monitored studies                                            Last week of July 2010    August 1, 2010
                          Cooperative Group studies                 Per the Cooperative Group's accepted schedule (~20+% of portfolio)
                                                                                                                                         Last week of September
                                                                                                                                                                    October 1, 2010
Conversion Quarter 1      Non-Cooperative Group, Non-CTMS           TX035, MDA, MN026, TN024, CO085, WA020, VA009,WI020,                          2010
(ending September 2010)   monitored studies                         ACRIN
                          NCI Intramural/Clinical Center, non-
                          CTMS monitored studies                                                 NONE                                              N/A                   N/A
                          CDS Web Submitters

                          Cooperative Group studies                 Per the Cooperative Group's accepted schedule (~20+% of portfolio)
                                                                    25036, 25094, NJ066, EORTC, PA086, MA038, OH076, IN083,
                          Non-Cooperative Group/Network, Non-
                                                                    CT018, 47006, 47005, PMHC, 11030, MA148, MA034, MA036,               Last week of December
Conversion Quarter 2      CTMS monitored studies                                                                                                                    January 1, 2011
                                                                    NY167, BMTCTN , IBCSG, PBTC                                                  2010
(ending December 2010)
                          NCI Intramural/Clinical Center, non-      MD004, NCIMB, NCISB, NCIDER, NCIETI, NCIROB, NCIPOB,
                          CTMS monitored studies                    HIVNCI, NCINAV, NCILMB, NCIMET, NCIMIP
                          CDS Web Submitters                        All CDS Web Submitting protocols
                          CTMS monitored studies                    NONE - Completed July 2010                                                     N/A                   N/A
                          Cooperative Group studies                 Per the Cooperative Group's accepted schedule (~20+% of portfolio)
                                                                    NY016, TX098, IDD, OR014, NC002, TX041, PA075, NC010,                Last week of March 2011     April 1, 2011
                          Non-Cooperative Group/Network, Non-
                                                                    34003, MD015, MD017, IL057, OH007, FL065, WA008, PA110,
Conversion Quarter 3      CTMS monitored studies
                                                                    PA015, NV039, NY011, OR010, UCC
(ending March 2011)
                          CTMS monitored studies                    NONE - Completed July 2010
                          NCI Intramural/Clinical Center, non-
                                                                    NONE - Completed December 2010                                                 N/A                   N/A
                          CTMS monitored studies
                          CDS Web Submitters                        NONE - Completed December 2010
                          Cooperative Group studies                 Per the Cooperative Group's accepted schedule (~20+% of portfolio)
                                                                                                                                         Last week of June 2011      July 1, 2011
                          Non-Cooperative Group/Network, Non-       NY045, TN116, MD114, TN008, CA141,CA221, CA088, CA006,
Conversion Quarter 4      CTMS monitored studies                    CA136, CA043, CA011, MI020, MI213, IN007, OH029, AMC
(ending June 2011)
                          CTMS monitored studies                    NONE - Completed July 2010
                          NCI Intramural/Clinical Center, non-
                                                                    NONE - Completed December 2010                                                 N/A                   N/A
                          CTMS monitored studies
                          CDS Web Submitters                        NONE - Completed December 2010
                                                                                                                                         Last week of September
                          Cooperative Group studies                 Per the Cooperative Group's accepted schedule (~20+% of portfolio)                              October 1, 2011
                                                                                                                                                  2011
                          CTMS monitored studies                    NONE - Completed July 2010
Conversion Quarter 5      NCI Intramural/Clinical Center, non-
                                                                    NONE - Completed December 2010
(ending September 2011)   CTMS monitored studies
                                                                                                                                                   N/A                   N/A
                          CDS Web Submitters                        NONE - Completed December 2010
                          Non-Cooperative Group/Network, Non-
                                                                    NONE - Completed July 2011
                          CTMS monitored studies

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:44
posted:11/11/2011
language:English
pages:39